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ABSTRACT OF THE DISSERTATION
Synthesis, Characterization, and Biological Activity of
Spherical Nucleic Acid (SNA) Constructs
for Cancer Therapy and Imaging
by
Colin Calabrese
Doctor of Philosophy in Chemistry
Washington University in St. Louis, 2017
Professor John-Stephen Taylor, Chair

This dissertation focuses on the development of biocompatible oligonucleotide-based
nanomaterials, known as spherical nucleic acids (SNAs), as therapeutic and diagnostic agents for
intracellular gene regulation and in vivo cancer imaging by positron emission tomography (PET).
SNAs consist of a nanoparticle core functionalized with a dense shell of oligonucleotides such as
deoxyribonucleic acid (DNA). Detailed synthetic procedures and characterization of novel
SNAs with purpose-built biocompatible core materials are described. The SNAs exhibit
comparable chemical, physical and biological properties regardless of core composition. The
functionalities of the SNAs were further tailored by deliberate design and chemical modification
of their oligonucleotide sequences.
The SNA nanostructures studied in this dissertation include those with cores made from
infinite coordination polymers (ICPs), self-assembled block copolymer micelles, 64Cu-alloyed
gold nanoclusters, and commercially-available monodisperse gold nanoparticles. In vitro and in
vivo investigations of each SNA type are described. The first two examples, functionalized on
their surface with DNA, entered a variety of cell lines without the need for transfection agents,
xi

and inhibited the translation of disease-related messenger RNA (mRNA). The 64Cu-alloyed gold
nanoclusters, functionalized on their surface with either DNA or phosphorodiamidate
morpholino (PMO) oligonucleotides, were evaluated in vivo to determine their pharmacokinetics
and biodistribution in mice. The blood circulation time of PMO-modified nanoclusters was far
superior to DNA-modified nanoclusters, enabling their use in tumor pre-targeting studies
wherein a non-radioactive nanocluster was first injected, allowed to accumulate at the tumor site,
and then probed by injection of a complementary oligonucleotide labeled with 64Cu. Studies in
mouse tumor models demonstrated the feasibility of in vivo hybridization-based pre-targeting
using SNA nanomaterials. Furthermore, the basic chemical and biophysical properties of PMOmodified commercial gold nanoparticles were studied. It was determined that PMO-based SNAs
display very similar cellular interactions as compared to their DNA analogues, including the
capability of entering cells in a transfection-free manner and effecting gene knockdown. The
neutral charge of the SNAs based upon PMO oligonucleotides exhibit more rapid capture
kinetics of complementary oligonucleotides compared to DNA SNAs, as well as higher melting
temperatures of hybridized duplexes. Taken together, the chemical versatility of SNAs has led to
significant advances in understanding their basic properties and improving their viability for in
vivo translation for biomedical applications.
Specifically, we uncovered further evidence for the central hypothesis that the unique
properties of SNAs, specifically active cellular uptake and their sharp thermal denaturation
curves, are core-independent and rely on the spherical orientation of DNA around a nanoparticle
core. We also discovered that the cellular interactions of SNAs, mainly active uptake, are
likewise independent of the charge of the nucleic acid shell. However, the chemical composition
of the SNA-bound oligonucleotides strongly influences their in vivo pharmacokinetics, with

xii

neutral oligonucleotides conferring much longer blood circulation times compared to negativelycharged SNAs. We also found that the kinetics and thermodynamics of hybridization of neutral
SNAs to complementary oligonucleotides are superior to those of negatively-charged SNAs,
expanding their potential uses not only as biomedical agents but also as in vivo “click chemistry”
tools capable of the bioorthogonal connection of multiple components under in vivo
physiological conditions. Collectively, the studies presented herein demonstrate that the rational
design of the core material and oligonucleotide shell impart novel properties to SNAs that
expand their capabilities as therapeutic, diagnostic, and bioorthogonal assembly agents.
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Chapter 1
Introduction
Nucleic acids are best known as nature’s universal storage medium for genetic
information. The ability of nucleic acids to encode and transmit data arises from Watson-Crick
base pairing among the five canonical nucleobases found in ribonucleic acid (RNA) and
deoxyribonucleic acid (DNA) oligonucleotides: the purines adenine (A) and guanine (G), and the
pyridmidines cytosine (C), thymine (T), and uracil (U) which pair in the fashion A:T, G:C, and
A:U. (Figure 1.1). Uracil is found exclusively in RNA whereas thymine is found in DNA.

Figure 1.1. Chemical structures of nucleic acids. Left: The five naturally-occurring nucleobases (dotted lines
represent point of attachment to sugar backbone). Right: Structure of RNA and DNA repeating units (5´3´).

An additional feature of the specific hydrogen bond-mediated hybridization between nucleic acid
strands is their capacity to spontaneously form more complex secondary, tertiary and quaternary
three-dimensional structures.1 Perhaps one of the most important biological examples is transfer
RNA (tRNA), whose three-dimensional folded structure serves as a macromolecular adapter to
1

translate the data in messenger RNA (mRNA) into the corresponding amino acids during protein
synthesis in the ribosome.2 Similarly, ribozymes are RNA molecules whose supramolecular,
highly organized structures enable them to catalyze biochemical reactions inside cells just like
traditional protein enzymes.3 Thus, in living organisms, nucleic acids not only store information
but also behave as nanoscale building blocks for precise assembly of functional endogenous
nanomaterials that are crucial to cellular functioning.

Figure 1.2. Comparison of natural and synthetic assembly of functional 3D nucleic acid nanostructures.

Researchers have harnessed the programmable nature of nucleic acid hybridization to
build synthetic nucleic acid nanomaterials with a wide variety of applications ranging from
electronic materials to biomedicine.4-10 With the advent of automated solid-phase nucleic acid
synthesis enabled by advances in phosphoramidite chemistry, chemists can easily generate large
libraries of custom oligonucleotides with high chemical purity on large scales.11-12 One type of
artificial nucleic acid nanomaterial, termed “DNA origami,” relies on computer-aided design to
fold a multicomponent mixture of oligonucleotides into atomically precise and molecularly
identical three-dimensional structures.13 Such structures can be stimuli-responsive, such as a
2

DNA origami “box” which can carry cargo and open in response to a “key” oligonucleotide
(Figure 1.2).14 The naturally-occurring nucleic acids, however, possesses limited chemical
functionality. To design more advanced functional nanomaterials, oligonucleotides can be
conjugated to small organic molecules,15-23 other biomacromolecules,24-27 polymers,28-32 and
nanoparticles.33-38 Such hybrid building blocks can then be assembled into higher-order
structures based on the programmed hybridization of the attached DNA base sequences.39-45

Figure 1.3. Structures of selected synthetic nucleic acid analogues.

In addition, synthetic nucleic acids have been developed that possess artificial backbones
imparting novel chemical attributes. RNA derivatives such as 2´-fluoro-RNA and 2´-OMe-RNA
exhibit enhanced resistance to base-catalyzed decomposition and nuclease degradation.46-47
Locked nucleic acids (LNAs) possess a modified bicyclic sugar backbone that restricts their
conformational flexibility, imparting higher stability to their duplexes with DNA and RNA.48
Fully neutral nucleic acid analogues have also been synthesized, namely peptide nucleic acids
3

(PNA) and phosphorodiamidate morpholino oligonucleotides (PMO) which possess no net
charge, and as a consequence form extremely stable duplexes with complementary nucleic acids
due to the absence of electrostatic repulsion.49-50 Chemists thus have a useful toolbox of
chemically varied nucleic acids to select from when designing nanomaterials (Figure 1.3).
One of the emerging classes of hybrid nucleic acid nanomaterials are spherical nucleic
acids (SNAs), which are comprised of a nanoparticle core decorated with a dense shell of
oligonucleotides (Scheme 1.1).51 The first examples utilized thiolated oligonucleotides which
readily adsorb onto the surface of gold nanoparticles (AuNPs) with a bond dissociation energy of
40-50 kcal/mol, approaching the strength of a covalent bond (80-90 kcal/mol).52 Gradually
increasing the NaCl concentration during the adsorption process, called “salt aging,” screens the
negative charge of the phosphodiester backbone of the DNA molecules as they associate with
Na+ cations, thereby increasing the density of DNA packing on the surface.53

Scheme 1.1. Functionalization of gold nanoparticles to afford spherical nucleic acids (SNAs).

Consequently, the behavior of nucleic acid oligonucleotides changes dramatically when they are
arranged around a spherical core. The binding affinity of SNAs for complementary
oligonucleotides is higher than linear DNA, resulting in higher melting transition temperatures
(Tm) and sharper thermal denaturation curves.54 Initially, AuNP-based SNAs saw great promise
in biodetection schemes due to their ability to detect target oligonucleotides with high specificity,
4

such as in colorimetric sandwich-type assays that rely on the aggregation-dependent color
change of gold nanoparticles in the presence of a complementary strand.55-56 Chemicallyamplified biodetection schemes using SNAs have also been described, where target proteins can
be detected down to attomolar concentrations.57 SNAs have also been employed in the detection
of toxic heavy metal ions.58-59 More broadly, SNAs can be thought of as “programmable atom
equivalents” which self-assemble into extended superlattices of a desired symmetry and
morphology based on the oligonucleotide sequences attached to the nanoparticle core(s).60-62
This approach enables the synthesis of macroscopic nanoparticle “alloys,” for example by
alternating gold and platinum nanoparticles in a well-defined repeating binary lattice structure.63
SNA superlattices have found applications primarily in catalysis, for example in the goldmediated oxidation of alcohols to aldehydes,64 as well as the assembly of bioactive enzymecored SNAs into catalytic superlattices.65
A major discovery was realized when the interaction of SNAs with cell membranes was
first probed. In cell culture, linear oligonucleotides exhibit poor cellular uptake due to their
negative charge, and typically must be transfected with polycations or cationic lipids to deliver
them across the cell membrane via passive diffusion.66-67 Counterintuitively, SNAs were found to
undergo active cell uptake and rapidly cross cell membranes without the need for transfection
agents, despite their higher negative charge density and larger size.68 In fact, higher density of
the oligonucleotide loading on the surface was found to correlate directly with improved cellular
uptake.69 These striking findings prompted efforts to discover the mechanism by which SNAs are
taken up and internalized by cells. The evidence points to an active uptake mechanism triggered
by recognition of SNAs by class A scavenger receptors (SR-As), which were first discovered in
macrophages but are now known to be widely expressed on the surface of mammalian cells.70-71
5

SR-As bind naturally-occurring endogenous and exogenous polyanions, triggering their
endocytosis for eventual destruction in lysosomes.72 SNAs were found to enter cells via SR-Amediated endocytosis, with sufficient escape of nucleic acids from the endosome to engage in
knockdown of target messenger RNA.73
Recognition of SNAs by SR-As is believed to be due to the natural affinity of the
receptor for poly(guanosine) (poly-G) DNA.74 Poly-G spontaneously assembles into threedimensional four-stranded helical structures known as G-quadruplexes, which are stabilized by
Hoogsteen hydrogen bonding and monovalent cations, particularly potassium. It is believed that
the dense, highly oriented packing geometry of oligonucleotides on the SNA surface mimics the
3D structure of the G-quadruplex, leading to recognition by SR-As and subsequent endocytosis.
Supporting this hypothesis, SNAs bearing G-rich oligonucleotides are found to possess superior
uptake to SNAs functionalized with poly-T, poly-A, or poly-C DNA, though SNAs of virtually
any sequence exhibit superior uptake to single-stranded oligonucleotides.71
The cellular uptake of spherical nucleic acids makes them very attractive agents in the
rapidly-evolving toolkit of nanomedicine. Studies have demonstrated excellent biocompatibility
of SNAs, such as minimal immune response as well as enhanced resistance to nucleases which
degrade nucleic acids by cleaving the phosphate backbone.75-76 Once inside cells, SNAs are
capable of behaving as gene regulation agents by binding to and preventing the translation of
messenger RNA into disease-related proteins, independent of SNA core composition.77-78 Other
types of nucleic acids have been employed as well, such as locked nucleic acids (LNA), small
interfering RNAs (siRNA), peptide nucleic acids (PNA) and catalytically active ribozymes.79-82
SNAs can also act as immunomodulatory agents by binding toll-like receptors (TLRs) expressed
on the inner surfaces of endosomal compartments.83
6

Scheme 1.2. Displacement of nanoflares by target messenger RNA restores fluorescence of attached fluorophores. 84

Perhaps the most successful commercial application of SNA technology is the multicomponent nanosystem referred to as the “nano-flare,” which takes advantage of the polyvalent
binding of dye-labelled “reporter” oligonucleotides to SNAs.85-86 The reporter oligonucleotides,
when bound to a AuNP SNA, exhibit low fluorescence due to quenching by the gold core. Once
the SNA binds to target mRNA, the reporter flares are displaced and the fluorescence of the dye
is restored, allowing quantitative detection of virtually any mRNA sequence in live cells by
confocal microcopy and flow cytometry (Scheme 1.2). This elegant technology harnesses both
the active uptake of SNAs along with their high DNA loading and programmable multivalent
interactions with complementary oligonucleotides.
This dissertation is focused on the design, synthesis, and characterization of novel,
rationally-designed SNAs with expanded capabilities arising from either modified core
composition or modified oligonucleotide chemistry compared to the classical DNA-modified
AuNP SNAs. For in vivo translation, SNAs with biocompatible cores are highly desired due to
concerns about the possible long-term chronic toxicity of gold nanoparticles and their tendency
to accumulate in the body.87 Our initial efforts focused on the design of SNAs assembled via

7

metal-ligand coordination bonds, an approach not previously explored for constructing SNA
nanomaterials. The tailorable and reversible nature of metal coordination bonds provides an
opportunity to create programmable DNA nanomaterials that respond to variable physiological
conditions such as pH, ionic strength, and/or presence of endogenous competitive ligands. In
Chapter 2 we report the synthesis and characterization of Fe3+-crosslinked DNA nanoparticles
assembled from 3,4-hydroxypyridinone (HOPO)-modified DNA duplexes. We demonstrate that
Fe3+-HOPO coordination bonds are strong enough to serve as chemically orthogonal cross-links
between DNA strands, and the iron atoms are site-selectively incorporated at the HOPO ligands
rather than chelated by the phosphate backbone or nucleobases of DNA. However, the DNAFe3+ nanoparticles synthesized by this approach did not exhibit appreciable cellular uptake, likely
due to the random orientation of nucleic acids comprising the nanoparticle. Thus, this study
highlighted the importance of the DNA packing geometry in determining cellular uptake and the
same coordination chemistry approach was further adapted to generate bioactive SNAs.
In Chapter 3 the synthesis of Fe3+-HOPO infinite coordination polymer (ICP)
nanoparticles and their subsequent functionalization with DNA is described. Drawing from
previous lessons, the core material was generated first and then modified with a dense shell of
oligonucleotides. A rigid, ditopic HOPO ligand with an azide functional handle was synthesized
and mixed with Fe3+ under dilute aqueous conditions, affording amorphous ICP nanoparticles.
The azide-bearing ICP particles were subsequently mixed with DNA oligonucleotides containing
a strained cyclooctyne, enabling DNA functionalization via copper-free click chemistry under
ambient conditions with no special additives. A particular advantage of the Fe3+-HOPO
coordination bond is its pH sensitivity. At physiological pH, the tris-Fe(HOPO)3 complex is the
predominant species, but at lower pH values, particularly endosomal pH (6.0-6.5), the tris
8

complex dissociates to the bis complex, providing a mechanism for disassembly of the core
material and release of oligonucleotides. The cellular uptake of the DNA-ICP nanoparticles was
probed in several cell lines and found to be comparable to their AuNP-based counterparts. In
addition, the DNA-ICP particles were capable of knocking down a disease-related protein in
ovarian cancer cells in a dose-dependent fashion without the need for transfection agents.
Chapter 4 describes an alternate approach to pH-sensitive SNA core construction by
employing self-assembled DNA-polyester block copolymer micelles. Using poly(caprolactone)
(PCL) as the hydrophobic block and DNA as the hydrophilic block, self-assembled micelles
presenting an outer layer of DNA were obtained. Furthermore, appending several DNA strands
to the terminus of the polycaprolactone block in a brush-like fashion increased the DNA surface
density on the self-assembled micelles. The PCL core material, being a polyester, also exhibits
slow pH-dependent hydrolysis in acidic conditions, providing a release mechanism for the
oligonucleotides. These self-assembled micelle SNAs were capable of cell entry and intracellular
gene knockdown of green fluorescent protein (GFP). Most importantly, comparison of the
biophysical properties of the linear and DNA-brush type micelles showed that the higher DNA
loading on the surface of the micelle led to higher cellular uptake as well as sharper melting
transitions between cross-linked micelles, lending further credence to the hypothesis that DNA
density on the surface of SNAs is inextricably linked to their biological properties.
Transitioning from cell culture to in vivo studies, Chapter 5 describes the development
and evaluation of SNA nanoclusters (NCs) as potential agents for imaging of breast cancer in a
mouse model by positron emission tomography (PET) via a tumor pre-targeting strategy. We
designed the SNA to function as a reverse “nano-flare” which localizes at the tumor site, and
subsequently captures and releases circulating 64Cu-labeled oligonucleotides for sensitive and
9

specific imaging of the tumor tissue with minimal uptake in off-target organs. In vitro, we found
that the nanosystem was extremely efficient at capturing and releasing a target oligonucleotide
under physiologically relevant conditions, with kinetics several orders of magnitude faster than
state-of-the-art covalent pre-targeting nanosystems based on irreversible click chemistry
reactions such as the tetrazine-cyclooctene Diels-Alder cycloaddition. A major advantage of our
design is its programmability based on the particle-bound and tracer oligonucleotide sequence(s)
as well as its reversibility.
Importantly, the core composition of the SNAs was chosen in a way to enable alloying
with 64Cu for studying their biodistribution, as well as rapid fabrication of libraries of SNAs with
varying surface compositions due to the ready availability of thiolated ligands and their simple
surface functionalization chemistry with gold. As opposed to functionalizing pre-fabricated
nanoparticle cores with oligonucleotides, the pre-targeting SNA nanoclusters were synthesized
via a one-pot reaction by mixing thiolated oligonucleotides with Au3+ followed by reduction with
sodium borohydride to afford ultrasmall AuNC SNAs (~2.5 nm diameter). Inclusion of 64CuCl2
in the reaction mixture afforded 64CuAuNCs which could be tracked in vivo to determine their
biodistribution. We discovered that the blood circulation time of DNA-functionalized
64

CuAuNCs was extremely short (<1% remaining in blood after 1 hour) due to their high

negative charge density, leading to protein corona formation and sequestration in the spleen and
liver, rendering them unsuitable for pre-targeting studies.88
Replacement of the DNA oligonucleotide shell with a mixture of PEG and
phosphorodiamidate morpholino (PMO) oligonucleotides afforded colloidally stable SNA NCs
which exhibited greatly improved circulation time (20-30x), enabling in vivo pre-targeting
studies. Our results indicated that the SNA AuNCs accumulate in tumor tissue after injection and
10

are able to capture circulating 64Cu-labeled oligonucleotides, enabling visualization of tumor
tissue by PET via a novel SNA-based pre-targeting strategy. Ongoing studies are focused on
improving the tumor-to-muscle ratio of the PET images, comparing the effectiveness of the pretargeting strategy compared to a single radionuclide injection, and optimizing the overall binding
kinetics of the nanosystem.
The studies outlined in Chapter 6 were prompted by the discovery that neutral PMOmodified SNAs exhibit vastly different pharmacokinetics compared to their charged analogs. The
final chapter focuses on the basic chemical and biophysical properties of PEG/PMO-modified
gold nanoparticles. Monodisperse, commercially-available citrate-capped 10 nm gold
nanoparticles were used as the starting material to generate PMO SNAs, primarily to ensure
batch-to-batch reproducibility and simplify their purification and characterization due to the
well-studied chemical and optical properties of AuNPs. The binding kinetics of PMO SNAs
with complementary oligonucleotides were studied and found to vastly exceed the rates observed
with DNA SNAs. Similarly, the hybridization thermodynamics of PMO SNAs with DNA SNAs
showed much stronger association compared to DNA SNA pairs as measured by thermal
denaturation experiments. The effect of the co-adsorbed PEG length on the colloidal stability and
cellular interactions of the PMO SNAs was also studied. Shorter PEG lengths imparted poorer
colloidal stability but facilitated superior cellular uptake, presumably due to exposure of the
nucleobases to the cell surface and subsequent recognition by scavenger receptors. Longer PEG
lengths did not affect the ability of PMO SNAs to capture complementary oligonucleotides but
negatively affected their cell uptake. Having established the optimal blending ratio of PEG and
PMOs for both colloidal stability and cellular uptake, the ability of PMO SNAs to engage in
intracellular gene regulation was evaluated. Our preliminary results indicated that PMO SNAs
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knocked down disease-related mRNA in ovarian cancer cells without the need for transfection
agents or ancillary targeting moieties, a property not associated with any PMO-modified
nanocarrier to date. Ongoing studies are underway to compare the knockdown effect of PMO
SNAs with previously-validated positive controls such as lipid-transfected DNA.
Taken together, the studies presented in this dissertation contribute both to the
fundamental understanding of SNA behavior in vitro and in vivo as well as the practical synthetic
considerations for their translation into viable therapeutic and diagnostic agents for
nanomedicine. The following chapter will begin the discussion of SNAs for gene regulation by
rational bottom-up design of the SNA core material.
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Chapter 2
Development of a biocompatible Fe3+ coordination strategy for the synthesis of
nucleic acid complexes, nanoparticles, and metallogels
[Portions of this work have been published previously as Chad A. Mirkin, Colin M. Calabrese,
William Morris. Metal-Ligand Coordination Polymer Nanoparticles and Methods for Making.
US Patent No. 9,677,075. 2017.]

Abstract
The synthesis of chemically modified nucleic acids capable of forming 3D networks via metal
coordination bonds is reported. A novel Fe3+-chelating 3-hydroxy-4-pyridinone phosphoramidite
was obtained in 3 steps and incorporated onto oligonucleotides using an automated DNA
synthesizer. The resulting modified oligonucleotides were capable of selectively and
quantitatively binding Fe3+ in aqueous media. Fe(DNA)3 complexes were formed from singlestranded DNA, whereas nanoparticles and coordination polymer metallogels were formed from
double-stranded DNA in aqueous buffer, depending on reaction conditions. This work represents
a general and practical synthetic strategy for the assembly of biocompatible DNA-metal
structures for medicine and materials, and demonstrates that biocompatible metal-ligand
coordination bonds are a selective and stable means for joining nucleic acids together to form
higher-order structures.
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Introduction
Living organisms employ DNA for the storage of genetic information, but its use as a synthetic
building block in the construction of nanomaterials has expanded rapidly in the last thirty years.
Advances in automated oligonucleotide synthesis have afforded researchers a simple and reliable
way to form chemically programmable linkages at the nanoscale via Watson-Crick base pairing
of complementary DNA strands.89 The predictable, reversible, and hence controllable nature of
DNA hybridization makes it an extremely valuable structural design element in the
nanotechnologist’s toolbox.
DNA can spontaneously fold into nanostructures by the rational design of nucleobase
sequences that hybridize into prearranged 2D and 3D shapes.90-91 Native DNA, however,
possesses few modifiable chemical handles for further synthetic elaboration. To design
functional materials, oligonucleotides can be covalently bound to a vast library of organic small
molecules,92-99 polymers,100-105 and nanoparticles.106-107 These nucleic acid conjugates can
subsequently assemble into rationally-designed supramolecular structures based on the sequencespecific hybridization of the attached DNA oligonucleotides.108-111 Due to the biological origin of
DNA, many of these hybrid materials find applications in therapeutics and biosensing. DNA
nanostructures have shown promise as novel drug carriers,112-117 gene regulation agents,68, 118-120
and disease biomarker detectors.85, 121-123 Furthermore, engineered macroscopic DNA hydrogels
have attracted interest for use in tissue engineering,124-125 3D cell culture,126 biomolecule
detection,127 and controlled drug release.128
Consequently, researchers have increasingly sought additional methods for the generation
of DNA nanostructures in a biocompatible and bioorthogonal fashion. Common bioconjugate
14

chemistries include thiol-maleimide, alkyne-azide, and tetrazine-alkene “click” reactions, which
are popular because the functional groups on DNA and other biomolecules do not interfere with
the progress of the reaction. However, these approaches involve irreversible covalent
modifications to DNA, creating unnatural linkages with potentially unknown biological activity.
An alternative approach is to employ metal coordination bonds to assemble oligonucleotides,
which offers the advantage of tunable, reversible, and dynamic linkages that can be formed in
situ from individual DNA components.
The engineering of metal-DNA assemblies is an emerging field of research. Significant
efforts have been dedicated to the synthesis of nucleic acids containing artificial metallo-base
pairs.129-133 Coordination-driven assembly of DNA into larger structures has also been
investigated by several research groups. Discrete structures, such as DNA-Fe2+ triangles,134
DNA-decorated coordination cages,135 and cyclic dimers136 have been described. Extended
coordination polymers of DNA are also known,137-142 though some examples involve DNA
tethered to a pre-fabricated metal complex.143-146 This topic has also been covered in several
reviews.147-150 However, most literature examples of metal-binding oligonucleotides involve
lengthy ligand syntheses on small scales and rely on potentially toxic metal/ligand combinations.
We sought to prepare macroscopic quantities of modified oligonucleotides so their metalcomplexing behavior could be investigated at high concentrations. Furthermore, no DNA-metal
coordination polymer structures have been investigated for biological applications. Since these
materials can be comprised almost entirely of DNA, they are inherently biocompatible if paired
with a nontoxic metal-ligand combination. Employing DNA as a ligand adds a degree of
complexity due to its hydrophilicity, high molecular weight, and intrinsic affinity for transition
metal cations. The system described herein overcomes these challenges, opening the door for a
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new class of metal coordination-based DNA materials and proving that metal coordination bonds
comprise a novel and viable self-assembly technique for biocompatible nucleic acid
nanomaterials.

Experimental Procuedures
Materials and methods. Diphenylcarbamoyl chloride was purchased from TCI America
(Portland, OR). All reagents for oligonucleotide synthesis were purchased from Glen Research
(Sterling, VA) and used according to manufacturer instructions. 10X phosphate-buffered saline
was purchased from Invitrogen (Carlsbad, CA). Deuterated solvents were purchased from
Cambridge Isotope Laboratories Inc. (Andover, MA). All other reagents were purchased from
Sigma-Aldrich (St. Louis, MO) and used without further purification. NMR spectra were
recorded on a Bruker Avance 400 MHz NMR spectrometer. 1H NMR spectra were referenced
internally to residual proton signals in the deuterated solvents.
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P{1H} NMR spectra were

referenced to an external 85% H3PO4 standard. Electrospray ionization (ESI) mass spectra were
recorded on an Agilent 6120 LC-TOF instrument in positive ionization mode. UV-Vis spectra
were collected on an Agilent Cary 5000 UV-Vis spectrometer in quartz cuvettes having a path
length of 1 cm. Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) data
was collected on a Bruker AutoFlex III MALDI-ToF mass spectrometer (Bruker Daltonics,
Billerica, MA).
Crystallography. Single crystals of ligand (1) and two stereoisomers of its iron complex Fe(L)3
were mounted in inert oil (Infineum V8512). All measurements were made on a CCD area
detector with graphite monochromated Cu Kα radiation. Data were collected using a Bruker
APEXII detector and processed using APEX2 from Bruker. Structures were solved using direct
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methods. The non-hydrogen atoms were refined anisotropically. Hydrogen atoms were included
in idealized positions, but not refined. Their positions and isotropic displacement parameters
were restrained relative to their parent atoms using the HFIX command in SHELXL-97.
Oligonucleotide synthesis. Oligonucleotide synthesis was carried out on a BioAutomation
MM48 DNA synthesizer according to the manufacturer standard trityl-on protocol. The ligand
phosphoramidite (3) was coupled for an extended period of time (5 minutes). All
oligonucleotides were synthesized in 1 µmol columns and deprotected by treatment with 30%
aqueous ammonium hydroxide (55ºC, 17h). Ligand-capped oligonucleotides (AL) and (BL) were
then directly purified by reverse-phase HPLC. Dimethoxtyrityl-capped oligonucleotide (A) was
purified by reverse-phase HPLC, then detritylated by treatment with 20% AcOH for 1 hr,
followed by extraction with ethyl acetate (3x) and lyophilization of the aqueous layer.
HPLC purification. Oligonucleotides were purified on a Varian ProStar HPLC system fitted
with a DynaMax Microsorb 300-10 C18 column. The mobile phase consisted of
triethylammonium acetate buffer (pH 7.0) and acetonitrile. Oligonucleotide (A) was purified
employing a gradient of 0-75% acetontrile over 45 minutes, with the desired product eluting after
~25 minutes. Fractions were collected, lyophilized, and detritylation was carried out as described
above. All other oligonucleotides were eluted employing a gradient of 0-35% acetonitrile over 45
minutes, with the desired products eluting after ~20 minutes. Fractions were collected, pooled,
and lyophilized to afford the pure, fully-deprotected oligonucleotides.
Synthesis of 1-(4’-(2-hydroxyethyl)phenyl)-2-methyl-3-hydroxy-4-pyridinone (1). To a 100
mL round-bottomed flask with a magnetic stirrer was added maltol (3.00 g, 23.8 mmol), 4aminophenethyl alcohol (6.53 g, 47.6 mmol), and 25 mL dilute HCl (0.25N). The mixture was
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heated and refluxed for 24 hr with stirring, resulting in the precipitation of the desired product.
Upon cooling to room temperature, the reaction mixture was diluted with H2O and vacuumfiltered to recover the precipitate. The filter cake was washed with H2O followed by methanol
and allowed to dry on the filter, yielding 5.19 g (21.2 mmol, 90%) of (1) as a tan,
microcrystalline powder. Crystals suitable for X-ray diffraction analysis were obtained by
recrystallization from hot DMF. 1H NMR (400 MHz, DMSO-d6) δ 7.48 (d, J = 7.3 Hz, 1H), 7.37
(d, J = 8.5 Hz, 2H), 7.30 (d, J = 8.4 Hz, 2H), 6.16 (d, J = 7.3 Hz, 1H), 3.63 (t, J = 6.8 Hz, 2H),
2.78 (t, J = 6.8 Hz, 2H), 1.93 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 169.98, 145.45, 141.28,
140.03, 138.38, 130.46, 129.13, 127.03, 111.24, 62.13, 38.80, 13.81. HRMS-EI (m/z): [M+H]+
calculated for C14H16NO3 246.1125, found 246.1130.
Synthesis of FeL3 complex from ligand (1). To a 50 mL round-bottomed flask with a magnetic
stirrer was added (1) (0.500 g, 2.04 mmol) and 10 mL absolute EtOH. To the resulting
suspension was added 0.275 g (0.680 mmol) of ferric nitrate nonahydrate, causing the color to
change to dark purple. Concentrated aqueous ammonium hydroxide was added dropwise, with
stirring, until the color of the solution turned red. The mixture was heated overnight at 40° C
with stirring, then poured into ethyl acetate (100 mL), causing precipitation of the complex. The
solids were filtered, washed with additional ethyl acetate, and dried in vacuo to afford 0.480 g
(0.61 mmol, 90%) of complex (1a) as a red powder. Crystals suitable for X-ray diffraction
analysis were grown by slow diffusion of acetonitrile into a methanol solution of the complex.
HRMS-EI (m/z): [M+H]+ calculated for C42H43FeN3O9 787.2390, found 787.2392.
Synthesis of diphenylcarbamoyl-protected pyridinone (2). To a 100 mL round-bottomed flask
with a magnetic stirrer was added (1) (2.00 g, 8.15 mmol) followed by diphenylcarbamoyl
chloride (2.08 g, 8.97 mmol) and dry pyridine (25 mL). The resulting suspension was stirred
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under N2 and N,N-diisopropylethylamine (1.56 mL, 8.97 mmol) was added dropwise via syringe.
After stirring overnight, the reaction mixture was poured into 200 mL dilute HCl (1M) and the
resulting suspension vacuum-filtered and dried in vacuo to afford a brown solid. The crude
product thus obtained was suspended in methylene chloride (10 mL) and shaken vigorously. The
suspension was suction-filtered and washed with additional methylene chloride to afford 2.59 g
of (2) as an off-white powder (5.88 mmol, 72%). 1H NMR (400 MHz, DMSO-d6) δ 7.63 (d, J =
7.6 Hz, 1H), 7.50 – 7.15 (m, 14H), 6.22 (d, J = 7.6 Hz, 1H), 4.67 (s, 1H), 3.62 (t, J = 6.6 Hz,
2H), 2.76 (t, J = 6.8 Hz, 2H), 1.90 (s, 3H).
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C NMR (101 MHz, DMSO-d6) δ 170.48, 151.82,

150.04, 142.94, 141.65, 141.38, 141.12, 140.04, 139.47, 136.54, 130.63, 129.46, 127.47, 127.11,
126.82, 124.33, 115.82, 62.09, 38.80, 14.68. HRMS-EI (m/z): [M+H]+ calculated for C27H25N2O4
441.1809, found 441.1811.
Diphenylcarbamoyl-protected pyridinone phosphoramidite (3). In an oven-dried 50 mL
Schlenk flask with a magnetic stirrer was suspended (2) (0.500 g, 1.14 mmol) in 5 mL dry,
degassed methylene chloride. The mixture was stirred under N2 and N,N-diisopropylethylamine
(0.59

mL,

3.41

mmol)

was

added

via

syringe,

followed

by

O-cyanoethyl-N,N-

diisopropylchlorophosphoramidite (0.51 mL, 2.27 mmol). After 1 hr, methanol (0.1 mL) was
added and the mixture stirred for an additional 30 min. Solvent was removed by rotary
evaporation and the crude product purified by column chromatography on silica gel, eluting with
3:1 acetone/CHCl3 containing 1% triethylamine (v/v). Fractions containing the desired product
(Rf ~ 0.75) were pooled and evaporated to afford 0.53 g phosphoramidite (3) (0.82 mmol, 73%)
as a colorless foam. Prior to DNA synthesis, (3) was dissolved in anhydrous acetonitrile at a
concentration of 0.1M and stored overnight at -20ºC over 3Å molecular sieves. 1H NMR (400
MHz, CD2Cl2) δ 7.61 – 7.03 (m, 14H), 6.38 (d, J = 7.6 Hz, 1H), 3.99 – 3.83 (m, 2H), 3.83 – 3.70
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(m, 2H), 3.57 (dtd, J = 13.6, 6.8, 3.3 Hz, 2H), 2.99 (t, J = 6.5 Hz, 2H), 2.60 (t, J = 6.3 Hz, 2H),
2.00 (s, 3H), 1.14 (dd, J = 16.8, 6.8 Hz, 12H).
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P{1H} NMR (162 MHz, CD2Cl2) δ 147.71.

HRMS-EI (m/z): [M+H]+ calculated for C36H42N4O5P 614.2901, found 641.2897.
AFM imaging. AFM imaging was carried out according to established protocols for DNA
origami structures. Particles were drop-cast onto freshly-cleaved mica sheets pre-treated with 10
mM MgCl2 to promote DNA adhesion to the surface. The droplet was allowed to stand for 10
minutes, then the surface was washed repeatedly with distilled H2O and dried under a stream of
N2. Images were collected by tapping mode in air on a Bruker Dimension Icon atomic force
microscope equipped with a POINTPROBE-PLUS® Silicon-SPM-Sensor.
MTT assay procedure. SKOV-3 cells were seeded in a 96-well plate at a population of 5x103
cells per well. After 24 h, the cells were treated with 0.1 mL of a solution of compound 1
(diluted from DMSO stock solution into Opti-MEM) and incubated at 37oC for 24 h. After
incubation, the compound was removed from the cells and replaced with 0.1 mL of complete
McCoy’s 5A medium (supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin). Cell viability was measured by MTT assay at 48 h and 72 h following
the addition of compound 1 to the cells. Briefly, cells were incubated with 0.1 mL of complete
McCoy’s 5A medium. 10 µL of MTT solution (5 mg/mL MTT in 1x PBS; Molecular Probes)
was added into each well of cells and cells were incubated at 37oC for 2 h. After incubation, 0.1
mL of SDS-HCl solution (0.1 g/mL SDS in 0.01 M HCl) was added to each well to solubilize the
formazan product, and cells were further incubated at 37oC overnight. After overnight
incubation, the absorbance of the cell lysate was measured at 570 nm using a Synergy H4
Multimode Microplate Reader (Biotek). The relative cell viability was calculated compared to
vehicle-treated cells. Reported values represent the mean ± SD of three replicates.
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Cellular uptake experiments. All microscopy was performed using an SP5 laser scanning
confocal microscope exciting at 494 nm. C166 mouse endothelial cells were incubated with 1
mL of cell culture medium containing the particle mixture at a total DNA concentration of 100
nM or 1 µM. After 24 hr, the cells were treated with Hoechst 33258 nuclear stain (Life
Technologies), fixed, washed, and then examined by confocal fluorescence microscopy. Cell
uptake of fluorescein-labeled DNA was observed, and images collected in Z-stack mode verified
that the dye was present in the cytosol rather than the exterior of the cell membrane. The
modified DNA was found to be nontoxic to cells under the conditions tested with no visible loss
of cell viability after 24 hr. Equivalent methods were used for flow cytometry, however cells
were not treated with Hoechst and instead were trypsinized for 3 minutes in 0.5% trypsin-EDTA
(GIBCO), resuspended in Opti-MEM, and analyzed using a Guava Easycyte 8HT (Millipore)
equipped with a 532nm laser.
Gene regulation experiments. The gene knockdown capability of the supramolecular DNAFe3+ nanoparticles was evaluated with skmel-28 human melanoma cells. Cells were cultured in
OptiMEM serum-free buffer, in 48-well plates with a density of 15,000 cells/well. Cells were
then treated with nanoparticles alone or nanoparticles mixed with Lipofectamine® RNAiMAX
(Invitrogen) according to manufacturer instructions to give a total DNA concentration of 30 nM.
The cells were incubated for a total of 48 hours, replacing the media after 16 hours. Cells were
then harvested and the total survivin mRNA expression was quantitated by RT-qPCR.

Results and Discussion
Synthesis of hydroxypyridinone-modified oligonucleotides. We first set out to synthesize a
Fe3+-specific ligand which could be attached to the 5´ hydroxyl group of an oligonucleotide via
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automated DNA synthesis. The ligand chosen for this purpose is structurally related to
deferiprone (Ferriprox®), an FDA-approved iron chelator classified as a 3-hydroxy-4-pyridinone
(3,4-HOPO).151 The coordination chemistry and pharmacological properties of these compounds
have been thoroughly investigated.152 3,4-HOPOs exhibit pH-dependent iron-chelating behavior
in aqueous solution (Figure 2.1), forming the FeL2+ complex at low pH (<4), the FeL2+ complex
at intermediate pH (3-7), and the FeL3 complex at physiological pH (≥7.4). The pH dependence
is due to competition between Fe3+ and H+ at the enolic 3-hydroxy position. The stability

Stability constants (deferiprone)

Figure 2.1. Speciation of deferiprone-Fe3+ complexes.152

log K1

15.10

FeL2+

log K2

11.51

FeL2+

log K3

9.27

FeL3
3+

Table 2.1 Stability constants for Fe /deferiprone.155

constant of the deferiprone tris-iron complex is large (log β3 ≈ 1036), making it an attractive
choice for coordination-driven self-assembly (Table 2.1). Recently, 3,4-HOPO ligands have been
utilized for the formation of PEG metallogels153 as well as crosslinking whole cells in vitro.154
An N-aryl-3-hydroxy-4-pyridinone phosphoramidite was synthesized in 3 steps from
inexpensive, commercially available starting materials (Scheme 2.1). Overnight reflux of maltol
and 4-aminophenethyl alcohol in dilute hydrochloric acid afforded the free ligand (1), which was
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recrystallized from DMF. Selective carbamoylation of the enolic hydroxyl group followed by
phosphitylation of the primary alcohol furnished the phosphoramidite (3), which was coupled to
DNA after purification by column chromatography. To confirm the structure of the iron chelate,
the red tris-Fe3+ complex of the unprotected ligand was obtained by treatment of (1) with 0.33
equiv. ferric nitrate and ammonium hydroxide in ethanol followed by precipitation from ethyl
acetate. Crystals suitable for X-ray diffraction analysis were grown by slow diffusion of
acetonitrile into a methanol solution of the complex. Both Δ-fac and Λ-mer stereoisomers were
obtained as separate single crystals (Figure 2.2 and A2.3). Additionally, the cytotoxicity of (1)
was investigated in C166 mouse endothelial cells using the MTT assay. Over 72 hours,
negligible loss in cell viability was observed at the highest concentration tested (Figure A2.1).

Scheme 2.1. Synthesis of ligand phosphoramidite. Reagents and
conditions: a) 4-aminophenethyl alcohol, dilute HCl, reflux 24h; b)
diphenylcarbamoyl chloride, pyridine, Hünig’s base, RT, 16h; c) 2cyanoethyl-N,N-diisopropylchlorophosphite, Hünig’s base, RT, 1h

Figure 2.2 Crystal structure of a Δ-facFeL3 complex (mer isomer not shown)

The ligand phosphoramidite was coupled to the 5´ terminus of a 20-mer oligonucleotide (AL)
and its complement (BL) sharing a 15-base overlap. Oligonucleotides having a 20-base overlap,
(SV1L) and (SV2L), were also synthesized. SV1L is an antisense oligonucleotide sequence
which targets the mRNA encoding the apoptosis inhibitor protein survivin, which is upregulated
in many cancer cell lines and promotes resistance to chemotherapeutics and more aggressive
disease progression.156 DNA synthesis was carried out in 1 µmol columns according to the
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manufacturer standard trityl-on protocol, followed by cleavage and deprotection in concentrated
NH4OH. The crude oligonucleotides were purified by reverse-phase HPLC and characterized by
MALDI-TOF. The desired ligand-capped oligonucleotides eluted after the truncated failure
sequences due to the slight hydrophobicity of the terminal modification. The control
oligonucleotide (A) lacking any chemical modifications was likewise synthesized and purified
by trityl-on protocol.
Oligo

Sequence (5´3´)

A
AL
BL
SV1L
SV2L
SV1FL

A5-ATC-CTT-ATC-AAT-ATT
Ligand-AAAAA-ATC-CTT-ATC-AAT-ATT
Ligand-AAAAA-AAT-ATT-GAT-AAG-GAT
Ligand-CCC-AGC-CTT-CCA-GCT-CCT-TG
Ligand-CAA-GGA-GCT-GGA-AGG-CTG-GG
Ligand-CCCAGCCTT*CCAGCTCCTTG

FW (calc’d)
6067
6374
6511
6272
6579
6783

[M-H]- (found)
6071
6374
6512
6276
6572
6785

Table 2.2 Oligonucleotides synthesized for this study with the calculated and found masses (MALDI-TOF). T* =
fluorescein-deoxythymidine (Glen Research)

Synthesis and characterization of Fe(DNA)3 complexes. To ensure that iron binds to the
modified DNA in the expected fashion, we first carried out experiments to synthesize the
Fe(DNA)3 complex as a proof-of-concept. The tris-Fe3+ complex of (1) exhibits a ligand-tometal charge transfer (LMCT) band in the visible spectrum, with an associated λmax of 460 nm
and ε460 = 5700 L∙mol/cm-1. The bis and mono complexes absorb at longer wavelengths. Thus,
UV-Vis may be used to monitor the reaction of the ligand-modified DNA with iron, since DNA
does not absorb in this region.i As expected, a 100 µM solution of (AL) in phosphate-buffered
saline (pH 7.4) quantitatively formed the Fe(AL)3 complex after standing overnight in the
presence of stoichiometric Fe(NO3)3∙9H2O, as measured by UV-Vis (Figure 2.3). No LMCT was
observed when the unmodified oligonucleotide A was treated with Fe3+ under the same
conditions (Figure 2.4).
Extinction coefficients of the ligand (ε260 = 3900 L·mol/cm-1) and the FeL3 complex (ε460 = 5700 L·mol/cm-1) were
determined by the Beer-Lambert relationship from serial dilution the compounds in PBS buffer.
i
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Figure 2.3 Top: 100 µM (AL) in 1X PBS. Bottom: 100
µM (AL) in 1X PBS treated with 33 µM Fe3+.

Figure 2.4 Top: 100 µM (A) in 1X PBS. Bottom: 100
µM (A) in 1X PBS treated with 33 µM Fe3+.

Titration of 100 µM (AL) with increasing concentrations of Fe(NO3)3∙9H2O showed a clear 3:1
binding ratio of DNA:Fe3+ (Figure 2.5-6). These results confirm the site-specific complexation of
iron by the DNA macroligand. Furthermore, kinetics experiments indicated that complexation of
iron by the free ligand occurred roughly 10 times faster as compared to the DNA macroligand,
suggesting a diffusion-limited complexation process due to the much larger molecular weight of
the macroligand (Figure A2.4).

25

0.25

Absorbance (AU)

0.24

A460

0.2
0.15
0.1
0.05

0.19
0.14
0.09
0.04
-0.01

0
0

20

[Fe3+]

40

300

60

500

600

700

Wavelength (nm)

(µM)

Figure 2.5. Titration of a 100 µM solution of (AL)
with ferric nitrate in 1X PBS buffer.

400

Figure 2.6. UV-Vis spectra corresponding to the titration
curve shown to the left.

Formation of DNA-Fe3+ metallogel at high concentrations. With the iron-binding DNA in
hand, we set out to determine its ability to self-assemble into higher order structures when
hybridized into a duplex. (Scheme 2.2)

Scheme 2.2. Synthesis of extened DNA-Fe3+ coordination networks by a two-step assembly process.

This could be verified macroscopically by forming duplex DNA (AL·BL) in buffer at
concentrations sufficient for gel formation, followed by addition of Fe3+. A 0.25 mL solution of
(AL·BL) was prepared in 1X PBS containing 2 mM of the duplex and 1.33 mM Fe3+. Control
samples contained either no iron, 2 mM of (AL) alone, or 2 mM of (AL·BL) in the presence of
1.6 mM deferoxamine B (DFO), a hexadentate iron chelator capable of competitively removing
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iron from the HOPO-Fe3+ complex (Table 2.3). Only in the first case was gelation observed, with
the control samples remaining as free-flowing liquids (Figure 2.7). These results indicated that
higher-order DNA coordination polymer structures are indeed formed from the (AL·BL) duplex.
At least 1 mM of duplex was required for gelation to occur. In addition, we found the gelation of
the DNA solution could be reversed by heating above the melting temperature (Tm ≈ 40° C) of
the duplex,ii affording a liquid which solidified upon cooling to room temperature. This opens up
the possibility of novel thermo-responsive DNA metallogels with tunable melting temperatures
depending on the DNA base sequence.
Sample Reagent

Metal

Gel

1

(AL·BL)

None

No

2

(AL)

Fe3+

No

Fe3+

No

Fe3+

Yes

(AL·BL)
3
+ DFO
4

(AL·BL)

3+

Figure 2.7. Gelation of duplex DNA in the presence of Fe at
room temperature (25° C)

Table 2.3. Screening of conditions required for
gelation of DNA/ Fe3+ solutions

A metallogel was also synthesized from the (SV1·SV2) duplex, which possesses a higher
melting temperature (Tm ≈ 70° C) due to its greater number of base pairs and higher GC content.
A 2 mM solution of (SV1·SV2) in 1X PBS, containing
T (ºC)

(AL·BL)

(SV1L·SV2L)
1.33 mM Fe3+, was prepared. At 55° C, the
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gel

gel

55

liquid

gel

75

liquid

liquid

Table 2.4. Temperature-dependent gelation of
DNA/Fe3+ solutions

(AL·BL)/Fe3+ solution flowed freely as a liquid
whereas the (SV1·SV2)/Fe3+ solution remained as a
gel. At 75° C, both solutions melted completely.

ii

Oligonucleotide melting temperatures were calculated using OligoAnalyzer software from Integrated DNA
Technologies (Skokie, IL)
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(Figure 2.8) Furthermore, decreasing the pH of the medium is also expected to decrease the
viscosity of the gel as the metal complexes dissociate to bis and mono species due to competition
with H+. This effect has been demonstrated with similar catechol-based metallogels formed by
complexation of ferric iron.157

Figure 2.8. Temperature-dependent gelation of DNA metallogels heated to 55° C (left) and 75° C (right)

Formation of DNA-Fe3+ nanoparticles at lower concentrations. At concentrations lower than
those required for gelation, the (SV1L·SV2L) duplex forms DNA nanoparticles in the presence
of Fe3+. The following procedure was developed for their synthesis. First, a 1 mL stock solution
was prepared containing 50 µM (SV1L) and 50 µM (SV2L) in PBS, affording the
(SV1L·SV2L) duplex at a total DNA concentration of 100 µM. Stoichiometric Fe(NO3)3∙9H2O
(33 µM) was then added and the mixture allowed to stand overnight at room temperature. The
progress of the reaction was monitored by UV-Vis, in combination with dynamic laser light
scattering (DLS) to verify the formation of higher-order structures. Prior to iron addition, DLS
shows a single monodisperse peak (dH ≈ 6 nm) corresponding to the (SV1L∙SV2L) duplex. After
iron addition, self-aggregation occurs, giving rise to a broad size distribution typically ranging
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from 10-200 nm or higher. Large structures (>10 nm) are not seen when (SV1L) alone is treated
with Fe3+ (Figure A2.2).
Precise control of particle size was an initial roadblock. Precipitation of the DNA-iron mixture
into water-miscible organic solvents (ethanol, THF) yielded very large aggregates (250-1000
nm) which were unstable upon re-immersion in buffer, potentially due to the denaturing effect of
the organic solvent. We also investigated altering the ratio of complementary strands, with the
excess single-stranded DNA acting as a chain stopper, but this approach gave inadequate size
control. In the end, gel-filtration chromatography (GFC) provided the best results. In a typical
synthesis, the crude reaction mixture was passed through a short column (3-5 mL) of Sepharose
CL-4B, a crosslinked agarose matrix. In addition, this technique removes unmetallated DNA and
residual synthesis impurities.

Figure 2.9. (Left) DLS size distribution of particles purified by GFC.
Figure 2.10. (Right) AFM image of particles deposited on mica.

Fractions were collected and analyzed by DLS, showing separation of particles by size. With this
technique, fractions containing particles with a mean diameter of 20-40 nm were obtained,
comparable in size to existing DNA-nanoparticle conjugates. To corroborate the DLS data,
fractions were also imaged by atomic force microscopy (AFM), revealing spherical
nanostructures with a size distribution analogous to that found with DLS (Figure 2.9-10).
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Synthesis of fluorescent DNA-Fe3+ nanoparticles and cellular uptake. DNA and RNA
nanoparticles have attracted interest due to their potential uses as gene regulatory agents. Having
obtained particles of the ideal size for cell entry,158-159 we then examined the level of cell uptake
compared to single-stranded DNA. To visualize internalization, it was necessary to incorporate a
fluorescent dye into the DNA. The sequence of SV1 was modified with a commercially-available
fluorescein-bearing thymidine base (T*), affording SV1FL (Table 2.1). SV1FL was then
duplexed with SV2 and particles were synthesized according to the protocol outlined previously.
Particle size distributions were determined by AFM, due to interference of the fluorescent dye
with DLS size measurements. Sedimentation of heavier fractions occurred upon prolonged
standing, likely due to the hydrophobic nature of the fluorescein modification (Figure 2.11). This
observation suggests that the colloidal stability of the particles is altered by the conjugation of
hydrophobic compounds. C166 mouse endothelial cells were then incubated with three different
size fractions of fluorescein-labeled particles at a total DNA concentration of either 1 µM or 100
nM in Opti-MEM medium, with iron-free SV1FL serving as the control. The treatment period
was 16 hours.

Figure 2.11. (Left) Synthesis of dye-labelled particles and
fractions obtained from GFC showing settling of heavy
particles. Figure 2.12. (Right) Uptake in C166 cells
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Confocal microscopy and flow cytometry indicated that the DNA-iron particles entered cells at
roughly the same rate compared to the iron-free control DNA (Figure A2.5). This result
demonstrates that, with the current design, the DNA-iron coordination polymer particles do not
behave analogously to classical SNAs and are not actively transported into the cell. However,
preliminary RT-qPCR experiments indicated that the particles are indeed capable of survivin
mRNA knockdown if transfected into the cell using a Lipofectamine®, a commercially-available
transfection agent (Figure 2.13). This result suggests that, at the very minimum, the individual
components comprising the DNA-Fe3+ particles are capable of gene regulation once inside the
cell, with the barrier to transfection-free gene regulation being the lack of active transport.

Figure 2.13. Survivin expression in skmel-28 melanoma cells, 30 nM total DNA, quantitated by RT-qPCR.

Conclusions
We have synthesized and characterized complexes and coordination polymers of ligand-modified
DNA with iron. The 3-hydroxy-4-pyridinone ligand has proven effective for assembling iron(III)
complexes of single-stranded DNA and coordination polymers of duplex DNA under
physiological pH and salt concentration. Importantly, we carried out the synthesis of the
modified DNA on large scales (>20 µmol) following simple, user-friendly synthetic methods. At
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high concentrations, metallogels are obtained whose properties can be tuned based on the DNA
base sequence. At lower concentrations, we obtained coordination polymer nanoparticles
possessing a spherical morphology, consistent with literature reports of metal-free DNA
assemblies constructed from similar building blocks.160-163 The cellular uptake of DNA-Fe3+
nanoparticles was examined but their behavior was not analogous to other spherical nucleic acids
(SNAs) previously described, most likely to due to random orientation of the DNA strands
comprising the particle as well as the low density of surface-exposed single-stranded DNA.
Entry of DNA nanostructures into cells is highly dependent on the geometric conformation of the
oligonucleotides.164-165 Furthermore, as evidenced by the concentration-dependent degree of
polymerization of the DNA-Fe3+ polymer, dilution of the nanoparticles for cell culture
experiments can potentially cause the particles to fragment into smaller oligomers. Nevertheless,
we believe this work opens the door to novel DNA-based materials for biological applications.
The DNA metallogels described herein are easy to synthesize, and may be a promising
biocompatible medium for cell transplant therapy and tissue engineering. The DNA
nanoparticles described herein also serve as a proof-of-concept study demonstrating that iron
coordination bonds are an effective means to assemble DNA nanostructures. In Chapter 3 the
same chemistry is applied to generate SNAs capable of spontaneous cellular uptake, applying the
lessons learned from the studies in this chapter.
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Chapter 3
Biocompatible infinite-coordination-polymer nanoparticle-nucleic-acid
conjugates for antisense gene regulation
[Portions of this work have been published previously as Chad A. Mirkin, Colin M. Calabrese,
William E. Briley, Timothy J. Merkel. Biocompatible infinite coordination polymer
nanoparticle-nucleic acid conjugates for antisense gene regulation. US Patent No. 9,617,451.
2017; and Calabrese, C. M.; Merkel, T. J.; Briley, W. E.; Randeria, P. S.; Narayan, S. P.; Rouge,
J. L.; Walker, D. A.; Scott, A. W.; Mirkin, C. A. Biocompatible Infinite Coordination Polymer
Nanoparticle-Nucleic Acid Conjugates For Antisense Gene Regulation. Angew. Chem. Int. Ed.
2015, 54, 476-480.]

Abstract
Herein, we report the synthesis of DNA-functionalized infinite-coordination-polymer (ICP)
nanoparticles as biocompatible gene-regulation agents. ICP nanoparticles were synthesized from
ferric nitrate and a ditopic 3-hydroxy-4-pyridinone (HOPO) ligand bearing a pendant azide.
Addition of Fe(III) to a solution of the ligand produced nanoparticles, which were colloidally
unstable in the presence of salts. Conjugation of DNA to the Fe(III)-HOPO ICP particles by
copper-free click chemistry afforded colloidally stable nucleic-acid nanoconstructs. The DNAICP particles, when cross-linked through sequence-specific hybridization, exhibited narrow,
highly cooperative melting transitions consistent with dense DNA surface loading. The ability of
the DNA-ICP particles to enter cells and alter protein expression was also evaluated. Our results
indicate that these novel particles carry nucleic acids into mammalian cells without the need for
transfection agents and are capable of efficient gene knockdown.
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Introduction
Spherical nucleic acids (SNAs) have emerged as an interesting new class of materials that have
shown promise in programmable materials synthesis,41, 166 bio-detection,121, 167-168 and
intracellular gene regulation.68, 169 Such structures are often comprised of a nanoparticle core
functionalized with a dense layer of oligonucleotides, although hollow, core-free versions have
been developed.78, 170 The earliest example of SNAs involved gold nanoparticles modified with a
dense layer of alkylthiol-functionalized DNA,33 but iron oxide,171-172 silver,173-175 semiconductor
quantum dot,176-177 and organic cores have been explored as well.29, 178-179 Notably, the chemical
and biological properties of SNAs are markedly different from their linear counterparts. SNAs
exhibit cooperative binding and sharp thermal denaturation profiles, enter cells without the need
for cationic transfection agents, and have the ability to bind to receptors in a polyvalent
fashion.51 Consequently, they are powerful new entities for manipulating cellular processes
through gene regulation,80, 180 drug delivery,113, 181 and immunomodulatory pathways.182 The
active uptake of SNAs occurs via caveolin-mediated endocytosis, triggered by their binding to
class A scavenger receptors (SR-As).70, 183 Although SNAs made from gold have shown
commercial promise as medical diagnostic and research tools and have shown no acute toxicity
in vivo,79 there are concerns about the potential long term toxicity of gold nanoparticles and their
metabolic fate.184 Consequently, new forms of SNAs with cores made of biocompatible materials
are highly sought after. Herein, we report a strategy that employs the use of infinite coordination
polymer (ICP) nanoparticles made from ferric ions and a rigid ditopic chelating ligand to
synthesize novel SNA nanoparticle conjugates. These DNA-ICPs are designed from chemical
building blocks approved by the FDA for other pharmaceutical uses, exhibit cooperative binding,
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and can readily cross mammalian cell membranes and inhibit protein expression in a targeted
fashion.
ICP nanoparticles consist of amorphous networks of organic ligands bridged by metal
nodes.185-186 They are promising materials for SNA construction as the ligand/metal combination
that defines the ICP structure can be rationally designed to optimize the toxicological and
pharmacokinetic profiles of the DNA-ICP conjugate. One major limitation of many ICPs
designed for medicinal applications is their instability in aqueous buffers. Some researchers have
circumvented this limitation by encapsulating the particle core in silica187-188 or a shell of
lipids.189 In contrast, we have sought to design ICP particles that could be synthesized, purified,
and stored indefinitely under aqueous conditions and without specialized equipment or reagents.
Furthermore, the use of relatively nontoxic metal ions is a crucial requirement for biological
applications. These goals were accomplished by synthesizing ICP nanoparticles from strongly
chelating 3-hydroxy-4-pyridinone (3,4-HOPO) ligands in combination with Fe3+, the most
abundant transition metal in the body. The coordination chemistry and pharmacology of the 3,4HOPOs have been thoroughly investigated,152 and the 1,2-dimethyl derivative (deferiprone) is
FDA-approved for the treatment of iron overload in humans.151 Furthermore, the Fe(HOPO)3
complex is known to dissociate below physiological pH.190 This provides a potential release
mechanism for delivering DNA into the cytosol following cell entry, a novel property not
typically associated with SNAs prepared to date.
It is known that ditopic HOPO and catechol ligands, being isoelectronic, can form
insoluble coordination polymers with oxophilic metal cations such as Fe3+, Cr3+, Ga3+ and others,
however, such polymers are poorly understood and have not been well-studied in the
literature.191-193 These ligands have mainly been studied for metal sequestration and chelation as
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opposed to materials synthesis. Therefore, we saw an opportunity to construct a novel
biocompatible nanoparticle scaffold for modification with DNA.

Experimental Procuedures
Materials and methods. 3,5-Diaminobenzoic acid was purchased from TCI America (Portland,
OR). 4-Azido-butan-1-amine was purchased from Synthonix, Inc. (Wake Forest, NC). All
reagents for oligonucleotide synthesis were purchased from Glen Research (Sterling, VA) and
used according to manufacturer instructions. Buffer solutions were purchased from Invitrogen
(Carlsbad, CA). Deuterated solvents were purchased from Cambridge Isotope Laboratories Inc.
(Andover, MA). Gold nanoparticles were purchased from Ted Pella (Redding, CA). Amicon®
Ultra centrifugal filter units were purchased from EMD Millipore (Billerica, MA). All other
reagents were purchased from Sigma-Aldrich (St. Louis, MO) and used without further
purification. 1H NMR spectra were recorded on a Bruker Avance 400 MHz NMR spectrometer.
1

H NMR spectra were referenced internally to residual proton signals in the deuterated solvents.

13

C NMR spectra for compounds 3 and 4 were collected on an Agilent DD2 500 MHz NMR

spectrometer operating at an internal temperature of 100° C. Electrospray ionization (ESI) mass
spectra were recorded on an Agilent 6120 LC-TOF instrument in positive ionization mode. UVVis spectra and thermal denaturation curves were collected on an Agilent Cary 5000 UV-Vis
spectrometer in quartz cuvettes having a path length of 1 cm. Matrix-assisted laser
desorption/ionization time-of-flight (MALDI-ToF) data was collected on a Bruker AutoFlex III
MALDI-ToF mass spectrometer employing 2,5-dihydroxyacetophenone (DHAP) as the matrix
material. FTIR spectra were collected on a Perkin-Elmer Spectrum 100 FTIR spectrometer. AFM
images were collected on a Bruker Dimension Icon atomic force microscope in non-contact
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mode equipped with a POINTPROBE-PLUS® Silicon-SPM-Sensor. TEM images were
collected on a Hitachi H8100 transmission electron microscope operating at an accelerating
voltage of 200kV. TEM and EDX data were collected on a Hitachi HD2300 STEM equipped
with two Thermo Scientific X-ray EDX detectors. Dynamic light scattering (DLS) and zeta
potential measurements were collected on a Zetasizer Nano ZS (Malvern Instruments Ltd). ICPMS data were collected on a Thermo X-series II ICP-MS. Elemental analysis was conducted offsite by Intertek Pharmaceutical Services (Whitehouse, NJ).
Synthesis of diaminobenzoic acid mono-hydroxypyridinone (2) To a 100 mL round-bottomed
flask with a magnetic stirrer was added 3,5-diaminobenzoic acid (5.00 g, 32.86 mmol), maltol
(8.70 g, 69.00 mmol) and 30 mL of acidic n-propanol (49:1 propanol/12M HCl). The reaction
vessel was fitted with a water-cooled condenser and the mixture heated to reflux for 16 h. The
resulting suspension was vacuum-filtered while hot and the solids washed with acetone (200 mL)
to yield 4.84 g of (1) as a tan powder (18.60 mmol, 57%). Propanol may be substituted with 5:1
EtOH/H2O affording similar yields. 1H NMR (400 MHz, DMSO-d6) δ 7.52 (d, J = 7.4 Hz, 1H),
7.28 – 7.26 (m, 1H), 6.92 (t, J = 1.7 Hz, 1H), 6.67 (t, J = 2.1 Hz, 1H), 6.16 (d, J = 7.3 Hz, 1H),
5.77 (s, 2H), 1.96 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 169.96, 167.24, 150.62, 145.45,
142.79, 138.07, 133.21, 129.02, 115.64, 115.35, 114.34, 111.30, 13.61. HRMS-ESI (m/z):
[M+H]+ calculated for C13H13N2O4 261.0870, found 261.0875.
Synthesis of diaminobenzoic acid bis-hydroxypyridinone (3) To a 100 mL round-bottomed
flask with a magnetic stirrer was added (2) (5.90 g, 22.67 mmol), maltol (3.57 g, 28.34 mmol),
and 30 mL of acidic 2-ethoxyethanol (49:1 ethoxyethanol/12M HCl). The reaction vessel was
fitted with a water-cooled condenser and the mixture heated to reflux for 64 h. The resulting
suspension was vacuum-filtered while hot and the solids washed with water (50 mL), followed
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by acetone (50 mL), to afford the crude product as a fine brown solid. The bis product was
selectively isolated by precipitation from boiling pyridine (100 mL), filtration, and further
precipitation from hot dimethylformamide (100 mL) and drying in vacuo to afford 0.98 g of (3)
(2.66 mmol, 12%) as a grey powder sparingly soluble in methanol, soluble in hot DMSO and
DMF. 1H NMR (400 MHz, DMSO-d6) δ 8.03 (d, J = 2.0 Hz, 2H), 8.00 (t, J = 2.0 Hz, 1H), 7.64
(d, J = 7.4 Hz, 2H), 6.22 (d, J = 7.4 Hz, 2H), 2.02 (s, 6H). 13C NMR (126 MHz, DMSO-d6) δ
170.43, 165.59, 145.52, 142.92, 138.79, 138.26, 134.82, 130.74, 130.47, 128.55, 111.45, 111.28,
13.79, 13.60. HRMS-ESI (m/z): [M+H]+ calculated for C19H17N2O6 369.1081, found 369.1084.
Synthesis of diiaminobenzoic acid bis-HP azide (4) To a 50 mL round-bottomed flask with a
magnetic stirrer was added (3) (0.400 g, 1.09 mmol) fully dissolved in anhydrous DMSO (30
mL). HATU (0.414 g, 1.09 mmol) and diisopropylethylamine (0.48 mL, 2.73 mmol) were
subsequently added and the reaction vessel was capped with a rubber septum. After 5 minutes, 4azidobutan-1-amine (0.187 g, 1.64 mmol) was injected via syringe and the mixture allowed to
stir for 4 h under N2. The organic phase was diluted with 1 volume of water and allowed to stand
for 1 h. The resulting grey precipitate was collected by vacuum filtration and washed extensively
with water (150 mL), followed by acetonitrile (100 mL), and allowed to dry on the filter. The
obtained azide monomer (4) was used without further purification. (0.283 g, 0.61 mmol, 56%).
1

H NMR (400 MHz, DMSO-d6) δ 8.72 (t, J = 5.7 Hz, 1H), 8.00 (d, J = 2.0 Hz, 2H), 7.91 (t, J =

1.9 Hz, 1H), 7.63 (d, J = 7.3 Hz, 2H), 6.23 (d, J = 7.4 Hz, 2H), 3.41 – 3.19 (m, 4H), 2.03 (s, 6H),
1.60 – 1.53 (m, 4H). 13C NMR (126 MHz, DMSO-d6) δ 170.41, 164.21, 145.55, 142.74, 138.81,
138.27, 137.87, 128.68, 128.54, 126.92, 126.78, 111.39, 111.23, 51.14, 39.56, 26.72, 26.37,
13.81, 13.62. HRMS-ESI (m/z): [M+H]+ calculated for C23H25N6O5 465.1881, found 465.1881.
FTIR (KBr): νmax 2093 cm-1 (N=N=N stretch)
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Synthesis of DABA-bis-HP-N3 ICP particles (ICP-N3 NPs) In a typical experiment, an
aqueous stock solution of DABA-bis-HP-N3 was prepared consisting of 2.28 mM ligand and
24.5 mM NaOH. The ligand is freely soluble in water as its disodium salt. A stock solution of
Fe(NO3)3·9H2O was prepared consisting of 10.80 mM Fe3+ and 4 mM HCl (as stabilizer). To a
glass vial was added 877 µL ligand stock solution, followed by 1 mL Milli-Q H2O, followed by
123 µL Fe(III) stock and the resulting orange-red mixture (2 mL) shaken for 10 minutes. The assynthesized particles have a mean diameter ranging from 10-20 nm (DLS). Particles were
purified by filtration through an Amicon Ultra 15 mL centrifugal filter with a nominal molecular
weight cutoff (MWCO) of 100 kDa, washing with 3 x 3 mL portions of Milli-Q H2O, spinning at
5000 rcf for 10 minutes each. The particles were resuspended in 2 mL of H2O to give an
approximate azide concentration of 1 mM. The particle solution was lyophilized and the
resulting dark red powder characterized by FTIR (KBr), showing the characteristic azide stretch
at 2093 cm-1 is retained after the nanoparticle synthesis.
Characterization of ICP-N3 nanoparticles. To determine the stoichiometry of metal-ligand
binding, we conducted a titration wherein samples each containing a fixed concentration of 200
µM DABA-bis-HP-N3 (4) in 1 mL H2O were prepared with increasing amounts of
Fe(NO3)3·9H2O ranging from 0 to 220 µM. The absorbance at 460 nm was measured for each
sample. The LMCT band at 460 nm is characteristic of the tris-HOPO-Fe3+ coordination
complex._ENREF_117 The equivalence point was reached at 133 µM (0.66 equiv.), consistent
with Fe2L3 stoichiometry (Figure A3.2). Further increase in absorbance is due to the presence of
uncoordinated iron precursor salt. Additionally, we conducted elemental analysis on a
lyophilized sample of the particles to assess their composition. Calc'd for C69H66Fe2N18O15: C
55.28%, H 4.44%, N 16.82%. Found C 49.10%, H 4.18%; N 14.18%. The lower observed
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organic content may be explained by the porous nature of the ICP particles and their ability to
entrap polar solvent molecules, e.g. H2O. Lastly, we studied the bare ICPs by energy dispersive
X-ray spectroscopy (Hitachi H2300-A STEM) (Figure A3.3).
ICP-MS and UV-Vis were used in tandem to determine the extinction coefficient ε460 of the
particles in Milli-Q H2O. Briefly, five samples of ICP-N3 particles in H2O were prepared at
varying dilutions and the absorbance at 460 nm was measured by UV-Vis. Subsequently, the iron
concentration of each sample was determined by ICP-MS. Each sample was prepared in a matrix
consisting of 3% HNO3, 5 ppb indium (internal standard), and deionized water. The iron
concentration was plotted vs. A460, and the data was fit by a simple linear regression model. The
slope of the line corresponds to ε460 ≈ 2870 L·mol-1 cm-1 arising from the LMCT of the ICP-N3
particles, allowing for spectroscopic determination of iron concentration.
The weight of the particles produced by the above procedure is expected to be in the range of 101000 kDa, since a small portion of the as-synthesized particles pass through a 100 kDa cutoff
filter. Supporting this observation, the predicted degree of polymerization for ditopic 3,4-HOPOs
is approximately 1000 repeat units under the reaction conditions given above, when estimated
from literature stability constants of the 3,4-HOPO-Fe(III) complex.155
Oligonucleotide synthesis. All DNA synthesis was carried out on a BioAutomation MM48
DNA synthesizer, according to the standard manufacturer trityl-on protocol with an additional 5
minute coupling time for non-nucleosidic phosphoramidites. Ac-dC and dmf-dG
phosphoramidites were used to enable room-temperature deprotection of the nucleobases.
Oligonucleotides were synthesized on 1 µmol scale and deprotected in concentrated NH4OH
(30%) for 17 hours at room temperature, except for poly(CCT)-Cy5-containing oligonucleotides,
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which were deprotected for 2 hours at room temperature. The resulting crude oligonucleotides
were purified on a Varian Prostar HPLC fitted with a DynaMax Microsorb C18 Column,
employing a gradient of 0-75% acetonitrile in triethylammonium acetate buffer (pH 7.0) over 45
minutes. The optical absorbance of the eluent was monitored at 254/310 nm for DBCOcontaining oligonucleotides, 254/649 nm for Cy5-containing oligonucleotides, and 254/280 nm
for all other oligonucleotides. DBCO-terminated oligonucleotides were lyophilized, resuspended
in H2O, and conjugated immediately to ICP-N3 nanoparticles. Disulfide-terminated
oligonucleotides were lyophilized, reduced to the free thiol and conjugated to AuNPs as
described in previous reports.53
Synthesis of AuNP-DNA conjugates. AuNP-SNAs synthesized in this study were prepared
according to established protocols.3 For AuNP-SNAs employed in cell uptake experiments, the
number of oligonucleotides/AuNP were determined by fluorescence measurements.
Oligonucleotide loading on AuNP-SNAs was quantified using a 5nM solution of Cy5 labeled
AuNP-SNAs. The Au core was dissolved using 100mM KCN diluted in deionized water. The
mixture was then incubated at room temperature for 20 minutes, and the resultant fluorescence
measured against a standard curve. The standard curve consisted of the equivalent
oligonucleotide sequence at a range of concentrations, dissolved in water, treated with KCN and
incubated in the same manner as the SNAs. All fluorescence measurements were made using a
Synergy H4 fluorescent plate reader (BioTek). Loading on the CCT-Cy5-AuNPs used as a
positive control for cell uptake experiments was 113 strands/particle (CCT-Cy5-AuNP).
Loading on the Cy5-T20-AuNPs was 157 strands/particle (Cy5-T20-AuNP). Similar values were
assumed for the non-fluorescent AuNP-SNA (A-AuNP).
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Synthesis of DNA-ICP conjugates. In a typical procedure, a solution was prepared containing
100 µM of the desired cyclooctyne-DNA, 0.5M NaCl, and ICP-N3 particles (500 µM in azide) in
2 mL Milli-Q H2O. The resulting clear, orange solution was shaken for 16 h at 25°C. The
reaction mixture was purified by ultrafiltration through an Amicon® Ultra 15 mL centrifugal
filter (100 kDa MWCO), washing with 4 x 3 mL portions of 0.1M Tris buffer (pH 8.0), spinning
at 5000 rcf for 10 minutes. The particles were resuspended in 1 mL of 0.1M Tris (pH 8.0). DNAICP particles remain colloidally stable at high salt concentrations (up to 1M NaCl), in contrast to
the bare ICP-N3 particles, which sediment within minutes in 1M NaCl. This observation
indicates a stabilizing DNA surface layer has been successfully conjugated to the particle.
Characterization of DNA-ICP conjugates. The size, charge, and DNA-loading of DNA-ICP
particles were analyzed by DLS, zeta potential, and UV-Vis. The DNA concentration of a
particle solution was determined by UV-Vis using the ratio (A260/A460). Bare particles in Milli-Q
H2O possess A260/A460 ≈ 5.4. DNA-decorated particles were synthesized having a ratio A260/A460
varying from 10.9 to 15.5, indicating the presence of DNA attached to the particles. Extensive
washing was conducted to ensure no free DNA remained in solution. Loading of Cy5-containing
DNA was significantly lower, potentially due to the steric bulk of the dye label. Finally, the zeta
potential of the bare and DNA-loaded ICPs was compared, with all samples prepared at identical
dilution in 10 mM Tris buffer (pH 8.0) and 0.1M NaCl. (Table A3.1).
Thermal denaturation studies. DNA-ICP particles bearing complementary sequences with a 17
base-pair overlap (A-ICP and B-ICP) were mixed at varying salt concentrations in 0.1M Tris
buffer (pH 8.0) and heated from 20°C to 80°C at a rate of 0.25°C per minute. At room
temperature, insoluble aggregates formed within 30-60 minutes of mixing the complementary
DNA-ICPs. Upon heating, a sharp melting transition was observed, consistent with high DNA
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surface loading of the ICP particles. The same behavior was not observed for a pair of DNAICPs with mismatched sequences (B-ICP and NonTarget-ICP). The free DNA duplex has a
melting temperature of 54°C in 0.3M NaCl, compared to >60°C for the DNA-ICPs, depending
on the NaCl concentration. The same experiment was repeated using a gold nanoparticle/DNAICP pair (A-AuNP and B-ICP).
MTT toxicity assay of ICP ligands. To ensure the parent ligand comprising the particle core did
not exhibit cellular toxicity, an MTT assay was performed. SKOV-3 cells were seeded in a 96well plate at a population of 5x103 cells per well. After 24 h, the cells were treated with 0.1 mL
of a solution of compound 3 or 4 (diluted from DMSO stock solution into Opti-MEM) and
incubated at 37oC for 24 h. After incubation, the compound was removed from the cells and
replaced with 0.1 mL of complete McCoy’s 5A medium (supplemented with 10% fetal bovine
serum and 1% penicillin/streptomycin). Cell viability was measured by MTT assay at 48 h and
72 h following the addition of compound 3 or 4 to the cells.
Briefly, cells were incubated with 0.1 mL of complete McCoy’s 5A medium. 10 µL of MTT
solution (5 mg/mL MTT in 1x PBS; Molecular Probes) was added into each well of cells and
cells were incubated at 37oC for 2 h. After incubation, 0.1 mL of SDS-HCl solution (0.1 g/mL
SDS in 0.01 M HCl) was added to each well to solubilize the formazan product, and cells were
further incubated at 37oC overnight. After overnight incubation, the absorbance of the cell lysate
was measured at 570 nm using a Synergy H4 Multimode Microplate Reader (Biotek). The
relative cell viability was calculated compared to vehicle-treated cells. Reported values
represent the mean ± SD of three replicates.

43

Cell culture and uptake studies. For visualizing cell uptake by confocal microscopy, ovarian
cancer (SKOV-3), cervical cancer (HeLa) and C166 mouse endothelial cells were cultured in
DMEM supplemented with 10% Fetal Bovine Serum (Atlanta Biologicals) and 1%
Penicillin/streptomycin (Life Technologies).
All microscopy was performed using an SP5 laser scanning confocal microscope. Cellular
images were obtained by culturing HeLa cells in supplemented Dulbecco’s Modified Eagle
Medium (DMEM, Life Technologies) at approximately 30% confluency in Nunc Lab-Tek II
borosilicate-bottom chamber slides (Thermo Scientific). Cells were allowed to attach for 24
hours, after which they were washed once with PBS and resuspended in OptiMEM. Cells were
then treated with either linear DNA, AuNP-SNAs, or DNA-ICPs at a concentration of 100 nM
(DNA basis). After 24 hours the cells were washed once with OptiMEM, and resuspended in
DMEM containing Hoechst 33258 (Life Technologies). All images are of live cells. Equivalent
methods were used for flow cytometry, however cells were not treated with Hoechst and instead
were trypsinized for 3 minutes in 05% trypsin-EDTA (GIBCO), resuspended in Opti-MEM, and
analyzed using a Guava Easycyte 8HT (Millipore) equipped with a 633nm laser.
For naked-eye visualization of cell uptake, MCF-7 and SKOV-3 cells were plated in 6 well
plates (~100,000 cells/well). After incubating the cells for 24 hours in DMEM + 10% FBS
containing medium, the cell media was changed to Opti-MEM and the following concentrations
of DNA-ICPs were added to individual wells (DNA basis): 0.0, 0.1, 0.5, 1.0, 2, and 5 µM. The
particles were incubated in cells for 24 hours, after which the cells were washed thrice in PBS,
cells were replenished with fresh media, and the cells were incubated for an additional 48 hours.
Thereafter, cells were rigorously washed to remove any extracellular ICP particles, trypsinized,
and immediately transferred to 1.5 ml Eppendorf tubes containing PBS. The cells were then
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centrifuged at 1100 RPM for 5 minutes to form cellular pellets. Pictures of the cell pellet were
taken against a white background to show a concentration dependent increase in ICP uptake.
Western blot and gene knockdown analysis. SKOV3 cells were obtained from American
Tissue Culture Collection (ATCC). The cells were incubated in 5% CO2 at 37˚C in McCoy’s 5A
medium supplemented with 10% heat-inactivated FBS. Cells were cultured in 6 well cell culture
plates (BD Biosciences) with 100,000 cells per well seeded 24 hours before treatment with ICPs.
Medium was replaced with Opti-MEM (Life technologies) immediately prior to treatment with
ICPs or Lipofectamine RNAimax (Life technologies) DNA. Lipofectamine transfection was
performed according to manufacturer’s instructions to deliver 25 pmole of DNA. After 12 hours,
the medium was replaced with fresh media (McCoy’s 5A with 10% FBS) and the cells incubated
for another 48 hours. The cells were then washed three times with PBS, trypsinized and the pellet
was resuspended in 100 μL of mammalian cell lysis buffer (Cell Signalling) containing protease
and phosphatase inhibitor (Thermo Scientific). The whole cell lysates were then purified and
collected by centrifugation and frozen at -80 ˚C. Protein concentrations were determined using
the BCA Protein Assay Kit (Pierce). Equal amounts of protein samples (25 μg) were
fractionated by 4-20% precast gradient gel (Bio-Rad) and transferred to nitrocellulose
membranes (Thermo Scientific). Membranes were dried overnight, rehydrated in PBS, then
blocked for 1 hour at room temperature in blocking buffer (LI-COR Biosciences). Proteins were
detected with rabbit primary antibodies against HER2 (1000:1) (Cell Signaling), mouse antibody
against beta-tubulin (1000:1) (Thermo Scientific) and anti-rabbit or anti-mouse IgG-dye
conjugated secondary antibodies (10,000:1) (LI-COR Biosciences). The fluorescence signal was
recorded and quantified using the Odyssey Infrared Imaging System (LI-COR Biosciences) and
quantified using Image Studio software (LI-COR Biosciences).
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Agarose gel analysis of DNA-ICP degradation. To visualize the amount of nucleic acids
released from DNA-ICP particles under acidic conditions, an agarose gel experiment was carried
out. Briefly, five aliquots of DNA-ICPs (B-ICP) containing 12.2 µM total DNA were diluted 1:1
with the following buffer solutions (100 mM each): KHP buffer, pH 4.0; HEPES buffer, pH 5.5;
MES buffer, pH 6.0, PBS buffer, pH 7.4, or Tris buffer, pH 8.0. As a control, a sample was
prepared with the single-stranded oligonucleotide (B-DBCO) containing the same total amount
of DNA in deionized H2O. The solutions were allowed to stand at RT for 48 h, then were
subsequently diluted again 1:1 with 0.5x TAE buffer. The samples were then analyzed in 1%
agarose gel run at 90V for 1 hour in 0.5x TAE buffer. Agarose gels were imaged on a Fujifilm
FLA-5100 gel imager and 1X SYBR® Gold stain was used to visualize oligonucleotides.

Results and Discussion
Synthesis of infinite coordination polymer particles. For the purpose of polymerizing Fe3+ into
coordination polymer nanoparticles, we synthesized a new ditopic ligand DABA-bis-HP-N3 (4),
which deliberately employs the inexpensive building blocks maltol and 3,5-diaminobenzoic acid
(DABA, 1) (Scheme 3.1a). Two sequential acid-catalyzed condensations of maltol with DABA
(1 to 2; 2 to 3) followed by HATU-mediated amidation of the carboxylic acid afforded the azidebearing ditopic ligand 4. Importantly, the carboxylic acid in 3 may be amidated with a wide
variety of amine building blocks, affording ICP particles with tailorable post-synthetic chemistry
dictated by the pendant functional groups.

46

Scheme 3.1. Synthesis and assembly of ICP particles and their cellular uptake. a) Synthetic scheme for bis-3,4HOPO azide (4). b) Assembly of ICP particles from Fe(NO3)3 and compound 4, followed by conjugation with DNA
via a Cu free ‘Click’ reaction. c) Scheme depicting the cellular uptake of ICP-DNA conjugates. Reaction conditions:
i) maltol, n-propanol, reflux, 16 h. ii) maltol, ethoxyethanol, 64 h, reflux. iii) 4-azido-butan-1-amine, HATU,
diisopropylethylamine, DMSO, RT, 4 h. iv) Fe(NO3)3·9H2O, NaOH (aq.), RT, 10 min. v) DibenzocyclooctyneDNA, 0.5M NaCl, RT, 16 h

To synthesize ICP nanoparticles from ligand 4, we prepared a dilute NaOH solution of ligand 4
(1.07 mM ligand, 1877 µL) and injected a solution of ferric nitrate (10.8 mM, 123 µL) into it
(Scheme 3.1b). Particle formation occurs instantaneously and the color of the solution turns from
clear to red due to the ligand-metal charge transfer band (LMCT) of the tris-HOPO-Fe3+
complex (λmax ≈ 460 nm).194 The resulting ICP-N3 nanoparticles were colloidally unstable in the
presence of low concentrations of salts (NaCl, Tris·HCl), leading to gradual precipitation of a
red, insoluble material. (Figure 3.1).

47

Figure 3.1. Bare colloidal ICP-N3 nanoparticles stored overnight at varying concentrations of NaCl. From left to
right: 0 M, 0.1 M, 0.5 M, 1.0 M

The crude ICP-N3 particles were purified by centrifugal filtration (100 kDa molecular weight
cut-off) and re-suspended in H2O. The particles were retained on the filter, as they were too large
to pass through. Minimal loss of material through the filter indicated a colloidal dispersion of
high molecular weight species was obtained. In deionized H2O, the as-synthesized particles were
stable, with a mean hydrodynamic diameter of 10-20 nm, determined by dynamic light scattering
(DLS) (Figure 3.2). TEM and AFM imaging revealed aggregates of small nanoparticles, with
some degree of fusion occurring upon drying (Figure A3.4). Furthermore, the composition of the
ICP-N3 particles was probed spectroscopically. Aliquots containing a fixed concentration of
DABA-bis-HP-N3 ligand in H2O were prepared and treated with increasing amounts of iron
ranging from 0 to 1.1 equivalents. The absorbance at 460 nm increased until 0.66 equivalents of
FeIII were added, consistent with a metal-ligand stoichiometry of Fe2L3 (Figure A3.2).
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Figure 3.2. Characterization of DNA-ICP particles. AFM image of (a) Bare ICP particles drop-cast and dried on
mica. b) DNA-functionalized ICP particles drop-cast and dried on mica. c) DLS histograms comparing size
distributions of bare and DNA-functionalized ICPs. d) Cooperative melting of ICP-DNA aggregates.

Conjugation of oligonucleotides to ICP particles. For conjugation to bare ICP-N3 particles, all
oligonucleotides were made on an automated DNA synthesizer, purified by reverse-phase HPLC,
and characterized by MALDI-ToF. Dibenzocyclooctyne (DBCO) phosphoramidites are
commercially available and easily incorporated onto the 5´ termini of the oligonucleotides. DNA
strands modified with a Cyanine 5 (Cy5) dye were used for intracellular imaging studies. DNA
strands modified with a 5´ alkylthiol were used to construct AuNP-SNAs for comparison with
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DNA-ICP particles (Table 3.1). DBCO-bearing oligonucleotides were conjugated to ICP-N3
particles by simply mixing the two reactants in aqueous NaCl (0.5M) followed by repeated
filtration to remove unreacted DNA. Importantly, gradual addition of salt was not necessary to
prevent aggregation of the nanoparticles, unlike their gold counterparts. The resulting DNA-ICP
particles were suspended in Tris·HCl buffer (100 mM, pH 8.0) and remained colloidally stable
when stored at 5°C or when heated up to 80 °C over the course of a melting analysis.
FW (Calc’d)

Oligo Name

Sequence (5´3´)

A-DBCO
B-DBCO
A-SH
HER2-DBCO
NONT-DBCO
Cy5-DBCO
CCT-Cy5-SH
Cy5-T20-SH*

DBCO-TEG-A4-AATCCTTATCAATATTT
DBCO-TEG-A4-AAATATTGATAAGGATT
HS-(CH2)6-A4-AATCCTTATCAATATTT
DBCO-TEG-CTC-CAT-GGT-GCT-CAC
DBCO-TEG-GAG-CTG-CAC-GCT-GCC-GTC-A
DBCO-TEG-CCTCCTCCT-Cy5-CCTCCTCCT
HS-(CH2)6-CCTCCTCCT-Cy5-CCTCCTCCT
Cy5-TTTTTTTTTTTTTTTTTTTT-(CH2)3-SH

[M-H]- (Found)

6942
7080
6699
5075
6360
6337
6094
7084

6951
7082
6689
5070
6369
6341
6098
7084

Table 3.1. All oligonucleotides synthesized for conjugation to ICP-NPs and AuNPs with mass determined by
MALDI-ToF. *Purchased from TriLink BioTechnologies (San Diego, CA)

Characterization of DNA-ICP SNAs. In addition to increasing colloidal stability, the
conjugation of DNA to the surface of ICP-N3 particles resulted in changes to particle size,
surface charge, and morphology (Figure 3.2). DLS and zeta potential measurements showed a
consistent increase in hydrodynamic diameter and surface charge, respectively. Particles were
imaged by AFM to visualize changes in size and morphology. UV-Vis spectroscopy was used to
calculate the relative contribution of DNA to the absorbance at 260 nm, and hence the DNA
concentration was determined. Inductively-coupled plasma mass spectrometry (ICP-MS) was
used to calculate directly the extinction coefficient ε460 of the ICP particles (Figure 3.4a). Lastly,
incubation of DNA-ICP particles in aqueous buffers ranging from physiological pH (7.4) to low
lysosomal pH (4.0) showed a clear red-shift in the LMCT λmax, indicating partial dissociation of
the tris-coordinated Fe3+ nodes comprising the particle (Figure 3.4b). Likewise, agarose gel
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analysis of DNA-ICP particles incubated in buffers of various pH showed significant shedding of
DNA from the particle core at pH values below physiological pH. (Figure 3.3) Other
coordination polymers based on HOPOs and catechols exhibit similar pH dependence.153, 195-196

Figure 3.3. Agarose gel analysis of ICP degradation after 48 hours. Note that the DNA released from the ICP is
slightly retarded in the gel due to its higher molecular weight after reaction with the ligand (4).

Figure 3.4. UV-Vis analysis of DNA-ICP particles. a) Comparison of bare ICP particles with DNA-ICP particles
showing the DNA absorbance at 260 nm. Inset: determination of LMCT ε 460. b) pH dependence of LMCT
absorbance. The red-shift of λmax with decreasing pH is indicative of complex dissociation (see inset).
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Thermal denaturation studies. In order to probe the surface density of oligonucleotides on the
DNA-ICP particles, thermal denaturation experiments were carried out wherein ICPs with
complementary sequences (A-ICP and B-ICP) were mixed, allowed to hybridize, and then
heated above the melting transition of the duplex. The free double-stranded DNA duplex
possesses a 17 base-pair overlap with Tm = 54.0°C in 0.3M NaCl. In contrast, the same
complementary strands form duplexes with a Tm = 66.9°C when conjugated to ICP-N3 particles,
an increase of nearly 13°C. The melting transition of the DNA-ICP particle aggregates is
extremely narrow, an indication of cooperativity; the full width at half-maximum of the melting
curve is typically <2°C, compared to 10-20°C for free double-stranded DNA (Figure 3.2d). AICP particles alone exhibited no aggregation or melting under the experimental conditions, nor
did A-ICP particles mixed with non-complementary particles (NonTarget-ICP). We also
studied the interaction of DNA-ICP particles with conventional AuNP-SNAs (A-AuNP) that
were prepared and purified according to established protocols. Similar aggregation and melting
behavior was observed between A-AuNP and B-ICP particles mixed in a 1:1 ratio (Figure
A3.5). Overall, these studies suggest high DNA surface loading on the ICP-N3 particles.
Cellular uptake studies. Due to the high apparent oligonucleotide density on the DNA-ICP
surface, we hypothesized that they would function as efficient gene delivery agents, much like
their gold predecessors. To test this assumption, ICP-N3 particles were functionalized with the
poly(CCT) oligonucleotide Cy5-DBCO bearing an internal fluorophore-label to afford Cy5-ICP
particles. Likewise, gold nanoparticles (15 nm) were functionalized with the analogous Cy5-SH
oligonucleotide to afford Cy5-AuNP particles having a loading of approximately 113
strands/AuNP, as determined by fluorescence. To test our hypothesis, uptake was examined in
HeLa cervical cancer cells (Figure 3.5). The DNA-ICP particles were found to cross cell
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Figure 3.5. Cellular uptake and gene knockdown. Confocal microscopy image of HeLa cells treated with (a) Cy5ssDNA and (b) DNA-ICP particles (100 nM DNA in each case). Hoechst stain denotes the nucleus in blue while the
Cy5 dye attached to the DNA is red. c) Fluorescence intensity of Cy5 dye quantified by flow cytometry. d) Nakedeye visualization of DNA-ICPs taken up in pelleted SKOV-3 ovarian cancer cells e) Expression of HER2 protein in
SKOV-3 cells treated with non-targeting DNA-ICPs, HER2 targeting ssDNA + Lipofectamine (25 nM DNA basis),
and HER2 targeting DNA-ICPS. Starred bars (**) indicate knockdown was significant (p<0.05) as determined by
unpaired student's T test.
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membranes more efficiently than the free DNA strands, and exhibited comparable uptake to
AuNP-SNA nanoparticles bearing the same sequence.
These results suggest that DNA-ICP nanoparticles have the potential to transport large
amounts of DNA to the cytosol. A dose-dependent increase in iron concentration was found after
incubation of DNA-ICPs in SKOV-3 ovarian cancer and MCF-7 breast cancer cells for 24 hours.
The color of the iron complex could be seen by the naked eye in pelleted cells treated with DNAICPs. Confocal microscopy experiments with SKOV-3 and C166 cells confirmed that DNA-ICPs
enter such cell lines, demonstrating that these structures exhibit comparable uptake
characteristics to AuNP-SNAs (Figures A3.6-A3.8).
Gene knockdown studies. Having demonstrated the ability of DNA-ICP conjugates to enter
cells in a manner analogous to AuNP-SNAs, we probed their ability to alter protein expression
by targeting a known cancer-related mRNA transcript. SKOV-3 ovarian cancer cells were
chosen as they over-express human epithelial growth factor receptor 2 (HER2), which is
involved in signal transduction pathways leading to malignant cell growth and differentiation.197
We performed a series of gene knockdown experiments utilizing anti-HER2 DNA-ICPS. SKOV3 cells were incubated with different concentrations of antisense DNA-ICPS (HER2-ICP) or
non-targeting DNA-ICPS (NonTarget-ICP), with free anti-HER2 DNA complexed with
Lipofectamine® (Life Technologies) as a positive control. After 3 days, cells were harvested and
HER2 expression was determined by Western blot analysis (Figure 3.5e). Treatment with antiHER2 DNA-ICPs reduced HER2 expression by up to 81%, in a dose dependent fashion. This is
comparable to results achieved with commercial transfection kits, and with no change in HER2
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expression observed with non-targeting DNA-ICPs. Lastly, no toxic effects or cell death resulted
from treatment with DNA-ICPs, as predicted by MTT assays (Figure A2.1 and A3.1).
Conclusions. We have reported a facile method to synthesize biocompatible, DNA-decorated
infinite coordination polymer nanoparticles that are capable of cell entry and gene regulation
without transfection agents. Iron(III)-based ICP nanoparticles, synthesized in water, can be
conjugated directly to oligonucleotides and carry them across cell membranes. By confocal
microscopy, we observed punctate fluorescence when cells were treated with dye-labelled ICP
particles, which is also seen with classical AuNP SNAs, suggesting they share a similar
endocytotic uptake pathway. Furthermore, the core is comprised of benign building blocks that
are not expected to pose significant health hazards. This work represents a major step towards
the construction of clinically viable gene regulation constructs for in vivo applications in the
treatment of cancer and other genetic diseases.
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Chapter 4
Biodegradable DNA-brush block copolymer spherical nucleic acids enable
transfection agent-free intracellular gene regulation
[Portions of this work have been published previously as Zhang, C.*; Hao, L. L.*; Calabrese, C.
M.*; Zhou, Y.; Choi, C. H. J.; Xing, H.; Mirkin, C. A., Biodegradable DNA-Brush Block
Copolymer Spherical Nucleic Acids Enable Transfection Agent-Free Intracellular Gene
Regulation. Small 2015, 11, 5360-5368.]
*These authors contributed equally to this work. C. M. Calabrese carried out the chemical
synthesis and characterization of DNA-block copolymers described herein and was responsible
for conducting the additional experiments requested by peer reviewers prior to publication.

Abstract
A new strategy for synthesizing spherical nucleic acid (SNA) nanostructures from
biodegradable DNA block copolymers is reported. Multiple DNA strands are grafted to one end
of a polyester chain (poly-caprolactone) to generate an amphiphilic DNA brush block copolymer
(DBBC) structure capable of assembling into spherical micelles in aqueous solution. These novel
DBBC-based micelle-SNAs exhibit a higher surface density of nucleic acids compared to micelle
structures assembled from an analogous linear DNA block copolymer (DBC), which endows
them with the ability to more efficiently enter cells without the need for transfection agents.
Importantly, the new SNAs show effective gene regulation without observable cellular toxicity
in mammalian cell culture.
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Introduction
Spherical nucleic acids (SNAs) are an emerging class of nanostructure, typically
consisting of a nanoparticle core densely functionalized with a nucleic acid shell.33, 51 These
structures exhibit a wide variety of novel properties that are substantively different from their
linear nucleic acid counterparts, making them especially attractive for intracellular
applications.68, 79, 169 Specifically, they are recognized by Class A scavenger receptors and
naturally internalized by many cell types via caveolin-mediated endocytosis.70 They have been
used as novel probes for measuring intracellular genetic content and as potent gene regulation
agents.198-199 They are especially attractive as gene regulation materials since they do not need
ancillary transfection agents such as viruses, peptides, lipids or cationic polymers to cross the
cell membrane.73 Thus far, SNAs have been made with a variety of core materials, including
many inorganic compositions63, 171 and several polymer compositions,29, 80, 100, 178, 200-208 and there
are now a few examples of hollow SNA structures that are held together by cross-linked DNA or
silica shells.78, 170 Although the nanoparticle core typically plays little role in determining the
general chemical and biological properties of the corresponding SNAs, it can be a major concern
when such structures are being considered as therapeutic candidates.209-210 Indeed, a significant
synthetic challenge for the chemistry community is to design totally biocompatible and
biodegradable SNAs that exhibit the hallmark properties of conventional SNAs with inorganic
cores. One approach has been to use liposomal architectures as cores,77 but an alternative
approach that may provide even greater tailorability is the use of polymer micelle architectures.
Although a variety of nucleic acid polymer micelle architectures have been reported, 124-133 none
have been developed and optimized with regard to general SNA features and intracellular
biological activity. Indeed, a few studies involving polymer micelle structures for intracellular
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gene regulation have been undertaken, but they either required a cationic transfection agent (e.g.
polyethyleneimine) for transfection or were constructed using non-degradable polymers.80, 211 To
date, there are no biodegradable DNA block copolymer (DBC) based micelle structures that have
been shown to exhibit the natural cellular uptake properties of SNAs, and therefore the use of
such structures with respect to intracellular and therapeutic applications has been limited.
Importantly, SNA-like properties are directly related to the orientation and high density of
nucleic acids on the nanoparticle surface.69

Scheme 4.1. Schematic showing the synthesis of DNA grafted block copolymer-based micelle SNAs. (a) The
synthesis of the linear DNA-b-PEO-b-PCL block copolymer and the corresponding formation of micelle-SNAs
(LDBC-SNAs). (b) The synthesis of the brush DNA-g-PCL-b-PCL block copolymer and the formation of micelle
SNAs (DBBC-SNAs) with a higher surface density of nucleic acids.
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To overcome the problem of low cell internalization associated with DNA block copolymer
micelle structures, we identified the need to synthesize micelle SNAs with a dense layer of
nucleic acids on the polymer core surface. Herein, we describe a strategy for preparing DBC
micelle-SNAs with a biodegradable core and a dense layer of highly oriented oligonucleotides
projecting from the surface of the aforementioned core. Traditionally, approaches to synthesizing
DBC micelle architectures have involved the linear coupling of nucleic acids to hydrophobic
polymer blocks (Scheme 4.1a).100 We have found this approach does not reliably yield structures
with a nucleic acid density high enough and suitable for optimal SNA cellular transfection
capabilities (vide infra). Therefore, our synthetic approach relies on the generation of a DNAbrush block copolymer (DBBC) based micelle structure (Scheme 4.1b), which was pioneered by
Gianneschi et al. in the context of non-degradable constructs for materials assembly purposes.212
In our synthetic approach, the key components of the DBBC micelle structures are prepared by
grafting multiple DNA strands onto the terminal segment of a diblock copolymer consisting of
polycaprolactone (PCL; a component in FDA-approved therapeutics213) and azide-modified PCL
via copper-free click chemistry to form a DBBC macromolecule. Then, when transferred from an
organic solvent mixture consisting of 1:1 DMSO/DMF into an aqueous solution, the assynthesized amphiphilic DNA-brush block copolymers assemble into ~ 40 nm diameter spherical
micelles (Scheme 4.1b). For comparative purposes, we also prepared a similarly sized micelle
structure from a linear DBC component (Scheme 4.1a).

Experimental Procuedures
Materials and Methods. All DNA synthesis was carried out on a BioAutomation MM48 DNA
synthesizer according to the standard manufacturer trityl-on protocol. All reagents for
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oligonucleotide synthesis were purchased from Glen Research (Sterling, VA) and used following
the manufacturer’s instructions. Ac-dC and dmf-dG phosphoramidites were used to enable roomtemperature deprotection of the nucleobases. α-Chlorocyclohexanone, sodium azide, N,Ndimethylformamide (DMF), tin(II) octanoate, caprolactone (CL), and all other solvents were
purchased from Sigma-Aldrich (St. Louis, MO) and used without further purification. Mchloroperoxybenzoic acid (mCPBA) was purchased from Fluka (Buchs, Switzerland).
Oligonucleotide synthesis. Oligonucleotides were synthesized on 1 µmol scale and deprotected
in concentrated NH4OH (30%) for 17 hours at room temperature. The resulting crude
oligonucleotides were purified on a Varian Prostar HPLC fitted with a DynaMax Microsorb C18
Column, employing a gradient of 0-75% acetonitrile in triethylammonium acetate buffer (pH
7.0) over 45 minutes. The optical absorbance of the eluent was monitored at 254/310 nm for
DBCO-containing oligonucleotides, 254/494 nm for fluorescein-containing oligonucleotides, and
254/280 nm for all other oligonucleotides. Fractions were collected, lyophilized, and the DNA
concentration quantified by UV-Vis.
Synthesis of α-chloro-ɛ-caprolactone. To a solution of 10 g (75 mmol) of 2chlorocyclohexanone in 100 mL dichloromethane was added 20 g (81 mmol) of mCPBA (70%).
The reaction mixture was stirred for 3 days at room temperature, then the reaction vessel was
cooled to -20 °C to precipitate mCPBA. After vacuum filtration, the filtrate was washed with
saturated aqueous NaHSO3 (3x), followed by saturated aqueous NaHCO3 (3x), and finally with
H2O. After drying over MgSO4, the organic phase was vacuum-filtered, and the solvent was
removed under reduced pressure to yield the crude product (yield not quantitated) which was
used immediately in the next step.
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Synthesis of Diblock Copolymer Poly(α-N3-εCL-b-εCL). The monomer α-chloro-ɛcaprolactone was prepared by the Baeyer-Villager oxidation of α-chlorocyclohexanone using
excess mCPBA. After isolation, 0.5 g monomer (3.36 mmol) was mixed with 3.0 g commercially
available polycaprolactone (MW = ~ 14 kDa, as macro-initiator) in dry toluene (10 mL). The
mixture was dried by repeated (3×) azeotropic distillation with toluene. Then, the solution was
heated to 130 °C in a preheated oil bath and stirred under N2. The reaction mixture was stirred
for 5 min at 130 °C and then one drop of tin(II) octanoate was added via syringe. The
temperature was maintained at 130 °C for another 3 hours. The resulting viscous mixture was
rapidly cooled, upon which it solidified. The crude polymer was purified by repeated dissolution
in dichloromethane and heptane precipitation (3×), resulting in a white solid after drying. Then
the pendant chlorides of the as-synthesized poly(α-Cl-εCL-b-εCL) were converted into azides by
treatment with sodium azide in DMF overnight at room temperature. After removal of DMF in
vacuo, 15 mL of toluene was added, and the remaining NaN3 was removed by centrifugation
(4000 rpm at 25 °C for 20 min). The diblock copolymer was recovered by precipitation in
heptane. After washing with heptane multiple times, the solid precipitate was collected by
vacuum filtration and dried under reduced pressure to afford 2.2 g (73% yield, PCL basis) of
azide-modified copolymer.
Synthesis

of

Azide-terminated

PEO-PCL

Diblock

Copolymer.

Azide-terminated

oligo(ethylene oxide) with 4 PEG units (C8H16O4N3, 109 mg, 0.5 mmol) was weighed into a dry
flask and ε-caprolactone (8.5 g with M/I ratio of ~ 150:1) was subsequently added. The synthesis
and purification of single azide-terminated PEO-PCL diblock copolymer follow the same
procedures for poly(α-Cl-εCL-b-εCL) as mentioned above with similar isolated yield of the
desired product after precipitation into heptane.
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DNA Conjugation. For each azide-containing polymer, the same procedure was followed. First,
the polymer was dissolved in a 1:1 DMSO/DMF solution, and then a large excess of DBCODNA dissolved in DMSO was added to the polymer solution and incubated at 40 °C overnight.
After conjugation, the resulting linear and brush DBC samples were used immediately for
micelle formation.
Formation and Purification of Micelle-SNAs. Briefly, DBCs dissolved in an organic solvent
(DMSO/DMF, 1:1) were loaded in a dialysis bag with a 50 kDa MW cutoff membrane and the
solution was dialyzed against deionized water for 12 hours. After removal of large aggregates by
filtration through a 0.2 μm syringe filter, the micelle-SNA conjugates were purified using an
Amicon Ultra-15 ultrafiltration device (Millipore, MWCO 50 kDa) to remove excess free DNA.
Characterization. 1H NMR spectra were recorded on a Bruker Avance 400 MHz NMR
spectrometer and referenced internally to residual proton signals in the denatured solvents. FTIR
spectra were collected on a Perkin-Elmer Spectrum 100 FTIR spectrometer using disposable KBr
plates. Gel permeation chromatography (GPC) was carried out in THF at 32 °C at 1 mL/min with
a Viscotek TDAmax liquid chromatograph (Malvern Instruments, UK) equipped with a
programmable autosampler and refractive index detector. AFM images were obtained with a
Bruker Dimension Icon atomic force microscope in a tapping mode under ambient conditions.
DLS hydrodynamic size and zeta potential measurements were collected on a Malvern Zetasizer
Nano-ZS (Malvern Instruments, UK) with a laser wavelength of 633 nm. Cryogenic TEM
images were collected on a JEM 1230 microscope (JEOL) at an accelerating voltage of 80 kV.
NTA measurements were performed with a NanoSight LM10 (NanoSight, Amesbury, UK)
equipped with a sample chamber with a 638 nm laser and a Viton fluoroelastomer O-ring.
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Confocal fluorescence images of the cells treated with micelle-SNAs were collected with a Zeiss
LSM 510 inverted confocal scanning microscope.
Cell Culture, Flow Cytometry, and Western Blotting. Cells were cultured at 37 °C and 5%
CO2 in DMEM supplemented with 10% FBS and 1% streptomycin/penicillin. For cellular uptake
study, HeLa cells were seeded in a 6-well plate 24 h prior to treatment and incubated with
micelle-SNAs derived from linear or brush block copolymer structures, respectively. Right
before flow cytometry analysis, cells were trypsinized, washed, suspended in 0.5 ml 1×
phosphate-buffered saline (PBS) and fixed by addition of 0.5 ml of 3.7% formaldehyde in PBS.
The fluorescence intensity from fluorescein (excitation wavelength at 488 nm, emission
wavelength at 520 nm) of 10,000 cells was collected using a BD LSR II flow cytometer. For
western blotting, C166 cells over-expressing EGFP were transfected with micelle-SNAs (with
0.5, 1, and 2 µM of total DNA in OptiMEM) overnight and further incubate for another 2 days
after medium change. Protein lysate with equal amount of total protein were fractionated by 420% Precast gradient gel (Bio-Rad). The intact gel was then transferred to a nitrocellulose
membrane (Thermo Scientific) and blocked in odyssey blocking buffer (LI-COR Biosciences).
Proteins were detected with primary antibodies against actin (1:500) (Santa Cruz
Biotechnology), EGFP (1:1000) (Clontech Laboratories Inc) followed by IRDye 680 secondary
antibodies (1: 10,000) (LI-COR Biosciences) diluted in PBST containing 5% non-fat milk. The
desired bands were visualized using the Odyssey® CLx Infrared Imaging System (LI-COR
Biosciences).
Thermal denaturation studies. In binary (2-component) nanoparticle systems, two different
sets of SNAs were prepared with different linkers (Type A and Type B) presenting
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complementary sticky ends (5´-TTCCTT-3´ and 5´-AAGGAA-3´). In a typical experiment, the
DNA linkers were first hybridized to the appropriate particles by combining the linkers and
either micelle-SNAs or 15 nm AuNP-SNAs in 0.5 M phosphate buffered saline (PBS) solution,
heating the solution to 40 °C for approximately 30 minutes, then slowly cooling to room
temperature. This was done to ensure that the maximum number of DNA linkers were hybridized
to each particle. The micelle-SNA and AuNP-SNA solutions containing complementary linkers
were then combined in the appropriate ratio, resulting in the formation of visible aggregates
within minutes. To determine the melting temperature of each aggregate, approximately 1 mL of
the suspension was placed into a quartz absorbance cuvette (Hellma) equipped with a magnetic
stirrer and loaded into a Cary 5000 UV/Vis spectrophotometer (Agilent). The melting transitions
were determined by monitoring the absorbance increase at 260 nm, which occurs upon DNA
sticky end dehybridization resulting in aggregate dissociation.
Confocal Microscopy and Immunofluorescence. Cells were seeded in a 35 mm FluoroDish
and incubated with fluorescein-labelled DBBC-SNAs (with total DNA 1 μmol) in complete
DMEM for different time points. Cells were rinsed with PBS, fixed in 3.7% PFA in PBS for 15
min, and imaged under a Zeiss LSM 510 inverted confocal scanning microscope. The excitation
wavelength of fluorescein-labelled DBBC-SNAs was 488 nm, and the corresponding emission
filter was 500-550 nm. To track the colocalization of SNAs with intracellular proteins, after
incubation with fluorescein-labelled DBBC-SNAs (with total [DNA] = 1 μM) for different time
points, cells were rinsed with PBS, fixed with 3.7% PFA in PBS, and permeated with 0.1%
Triton X-100 for 3min. After blocking with 5% BSA in PBS for 1 h, cells were stained with a
primary antibody against the protein marker of interest at 5 μg/mL (1% BSA in PBS) overnight
at 4 °C. After rinses with 0.05% Tween-20 in PBS, cells were stained with an Alexa Fluor 63364

labeled secondary antibody (Invitrogen Alexa Fluor 633 Goat Anti-Rabbit or mouse IgG (H+L)
at 1 μg/mL (1% BSA in PBS) for 1 hour at RT. The excitation wavelength of the secondary
antibody was 633 nm, and the corresponding emission filter was 660 - 710 nm. The primary
antibodies include rabbit against Rab9 (Abcam ab179815), and mouse against LAMP1 (Santa
Cruz sc-20011).
Cytotoxicity analysis. The cytotoxicity of the micelle-SNAs was evaluated with a Vybrant®
MTT Cell Proliferation Kit (Molecular Probes) following the protocol provided by the
manufacturer. Briefly, HeLa cells were seeded in a 96-well plate in 100 μL of media and
incubated for 24 h. The cells were then treated with micelle-SNAs (2 μM, total DNA
concentration) and the same concentration of single-stranded DNA. Cells without any treatment
were used as a control group. At varying lengths of time (1, 2, 3 and 4 days), the media was
removed, the cells were washed with PBS buffer (3×) and then incubated with 100 μL fresh
culture medium and 10 μL of freshly-made 12 mM MTT solution at 37°C in 5% CO2 for 4 h.
After this step, 100 μL lysis buffer (1 g of SDS in 10 mL of 0.01 M HCl) per well was added.
Cells were further incubated overnight and the absorbance was measured at 570 nm using a
Multiskan® Spectrum (Thermo Scientific). Each set of conditions was repeated in three
independent experiments and the results averaged.
Gel electrophoresis. Agarose gel electrophoresis was used to check the formation of micelleSNAs either by linear DBC or DNA grafted DBBC. Gels containing 1% agarose (w/w) were run
on an FB-SB-710 electrophoresis unit (FisherBiotech) at room temperature in 1×Tris-Borate
EDTA (TBE) buffer (50 V, constant voltage). The gels were directly imaged if the DNA was
labeled with fluorescein; otherwise, imaging was carried out by ethidium bromide staining and
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UV illumination (302 nm). Denaturing PAGE analysis for DBBC conjugates was performed in a
gel containing 15% acrylamide (19:1, acrylamide/bisacrylamide), 8 M urea, and 1×TBE buffer.
The sample solutions were heated up to 95 °C for 10 minutes for denaturing. Then, the samples
were loaded into the gel and run on a SE600 cooled vertical electrophoresis unit (Hoefer, 300 V,
constant voltage) with 1×TBE buffer. After electrophoresis, the gels were stained with ethidium
bromide and imaged in a gel reader (Alpha Innotech). Under denaturing conditions, the DBBC
based micelle-SNAs could not run into the gel and remained in the loading well after
electrophoresis (Figure A4.5), indicating that the as-synthesized micelle-SNAs were quite stable
in aqueous solution. To demonstrate the DBBC macromolecules contain multiple DNA strands
on each polycaprolactone chain, we synthesized DBBC macromolecules with only a few DNA
brushes loaded on the polymer chain. By reducing the ratio of DNA/PCL to ~ 3 during the click
conjugation reaction, the as-prepared DNA-brush block copolymer was analyzed by denaturing
PAGE again. In Figure A4.5, a series of bands can be seen on the gel, which can be attributed to
DNA-PCL conjugates with a different number of DNA strands on each polycaprolactone chain.
Again, the major product consisted of large micelle structures that accumulated at the bottom of
the loading well.
Degradation of DBBC-SNAs. To visualize the amount of nucleic acids released from DBBCSNAs under different pH conditions an agarose gel experiment was carried out. Briefly,
fluorescein-labeled DBBC-SNAs containing 10 µM total DNA were diluted 1:1 with the
following buffer solutions (100 mM each): HEPES buffer, pH 5.5; MES buffer, pH 6.0, PBS
buffer, pH 7.4. As a control, a sample was prepared with the AuNP functionalized with the same
oligonucleotides (anti-EGFP antisense DNA) diluted 1:1 with the buffers described above,
respectively. The solutions were allowed to stand at RT for 18, 24, 48, and 72 hours, then
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analyzed by agarose gel electrophoresis (1% agarose). The agarose gels were imaged on a
Fujifilm FLA-5100 gel imager with a 473 nm laser to visualize the fluorescein-labeled DNA.

Results and Discussion
In a typical DBBC micelle-SNA synthesis (Figure A4.1), α-chloro-ε-caprolactone (α-ClεCL) prepared by the Baeyer-Villager oxidation of α-chlorocyclohexanone214 was employed
as a monomer for polymerization. The diblock copolymer poly(α-Cl-εCL-b-εCL) was
synthesized from the monomer, α-Cl-εCL, and commercially available polycaprolactone (MW
= ~ 14 kDa) as the macro-initiator. The pendant chlorides of the as-synthesized poly(α-Cl-ε
CL-b-εCL) were converted into azides by treatment with sodium azide in DMF overnight at
room temperature.215 1H NMR spectroscopy was used to characterize the product, and the
spectrum suggested the as-synthesized diblock copolymer contained on average 15 N3 groups, as
determined by integration (peak A and G in Figure A4.2). In addition, FT-IR spectroscopy of the
azide-containing PCL diblock copolymer showed the characteristic azide band at 2106 cm-1
(N=N=N stretch, Figure A4.3).216 Gel permeation chromatography (GPC) analysis was also
consistent with block copolymer formation as evidenced by an increase in molecular weight
from ~ 14 to ~ 16 kDa (Figure A4.4). When substituted with azide groups, the poly(α-N3-εCLb-εCL) exhibited a slightly shorter retention time than that of poly(α-Cl-εCL-b-εCL) in the
GPC column. Finally, poly(α-N3-εCL-b-εCL) and an excess of cyclooctyne-terminated DNA
strands were added to an organic solvent mixture (1:1 DMSO:DMF) to initiate the copper-free
click reaction of DNA strands with the azide-modified block, resulting in the formation of the
DNA-g-PCL-b-PCL macromolecule. For comparative purposes, a linear DBC was also
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synthesized. Instead of using 14 kDa PCL as the macro-initiator, an azide-terminated
poly(ethylene oxide) with 4 ethylene glycol units was employed to initiate the caprolactone
polymerization to synthesize a PEO-b-PCL block copolymer with a comparable molecular
weight (~18 kDa based on 1H NMR integration). Again, click chemistry was used to conjugate
DNA to the as-synthesized PEO-b-PCL block copolymer and generate the linear DNA-b-PEO-bPCL block copolymer. After the DNA conjugation reaction, both the DNA brush block
copolymer micelle-SNAs (DBBC-SNAs) and the linear DNA block copolymer micelle-SNAs
(LDBC-SNAs) were prepared and purified according to literature protocols used for analogous
linear non-biodegradable structures.29 In this process, excess DNA was removed by an
ultrafiltration device with a MWCO of 50 kDa membrane. The amount of DNA conjugated to
the polymer was determined by measuring the absorbance of the micelle-SNA solutions at 260
nm. Based on the total amount of polymer used for conjugation, it was determined that an
average of 10 DNA strands were successfully conjugated onto each polymer chain. Moreover,
polyacrylamide gel electrophoresis, under denaturing conditions, was used to analyze the
resulting DNA-g-PCL-b-PCL macromolecules. The bands representing DBBC conjugates
containing multiple DNA strands can be clearly identified on the gel when excess DNA was used
for the conjugation (Figure A4.5).

SNA

Sequence (5’  3’)

Micelle-SNA:EGFP

DBCO-(EG)4-(spacer 18)x- CGGACACGCTGAACTTGTGG

Scrambled antisense DNA

DBCO-(EG)4-(spacer 18)x- CGGATACGCTGATCTTGTGG

Fluorescein-SNA

DBCO-(EG)4-(spacer 18)x- CGGACACGCTGAACTTGTGG-Fl

AuNP-SNA

Propylthiol-(spacer 18)5- ACA TCC ACG TAG TCT TAG

Linker Strand-1

AAGGAA T CTA AGA CTA CGT GGA TGT

(hybridized with AuNP-SNA)
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Linker Strand-2

TTCCTT T CCA CAA GTT CAG CGT GTC CG

(hybridized with micelle-SNA)
Table 4.1. Oligonucleotide sequences used in this study. Fl = fluorescein; DBCO = dibenzocyclooctyne; EG =
ethylene glycol. “Spacer 18" denotes a phospodiester followed by 6 ethlyene glycol units in the DNA backbone.
x=0 when the DNA was used in the formation of linear DNA-b-PEO-b-PCL, x=1 when the DNA was used in the
formation of DNA-g-PCL-b-PCL.

Figure 4.1. Characterization of as-synthesized polycaprolactone-based micelle-SNAs. (a) 1% agarose gel
electrophoresis; nucleic acids were stained with ethidium bromide; (b) A typical DLS measurement of micelleSNAs derived from (top) linear and (bottom) brush block copolymer structures; (c) Melting transition behaviour for
micelle-SNAs hybridized to complementary 15 nm AuNP-SNAs; (black trace) micelle-SNAs made from linear
structures and (red trace) micelles made from the brush architecture; (d) Cryogenic TEM images of micelle-SNAs
derived from brush block copolymer. Both DBBC-SNA and LDBC-SNA nanoparticles remain intact under
cryogenic conditions and are relatively uniform in size with diameters ~ 30-50 nm.

With purified samples, multiple techniques were employed to characterize these two
polycaprolactone-based SNAs (Figure 4.1). Gel electrophoresis (1% agarose gel, Figure 1a)
showed a single major band for each sample on the gel image, indicating the micelle-SNAs have
69

a narrow size distribution. Compared to unmodified DNA of the same sequence, the
electrophoretic mobilities of the micelle-SNAs are greatly decreased, consistent with the
significant difference in size and overall charge. Notably, the electrophoretic mobility of SNA
made from the brush architecture is slightly lower than that of one made from the linear
structure, indicating that the former SNA is slightly larger. The size distributions of the micelleSNAs were also probed by dynamic light scattering (DLS), which indicated an average
hydrodynamic diameter of 44 nm for the SNAs derived from the brush architecture and 40 nm
for ones derived from the linear architecture (Figure 4.1b), consistent with the gel analysis.
Meanwhile, zeta potential analysis gave values of -48.5 ± 3.7 mV and -27.9 ± 3.2 mV,
respectively (Figure A4.6), consistent with the micelle derived from the brush architecture
having a higher density of DNA. Furthermore, the micelle-SNAs were cast on mica and imaged
by atomic force microscopy in dry form (Figures A4.7); in both cases, spherical structures were
readily apparent. To visualize the morphology of the micelle-SNAs in an environment closer to
the one in which they are prepared, cryogenic transmission electron microscopy (Cryo-TEM)
was used (Figure 4.1d). In this method, a very thin layer of micelle-SNA-containing solution was
quickly frozen and directly imaged. Cryo-TEM imaging avoids dehydration-induced artifacts,
allowing the fully intact nanoparticles to be visualized. Indeed, round 30-50 nm diameter
particles of both DBBC-SNAs and LDBC-SNAs were observed, which are consistent with the
DLS size data.
Since the density of DNA on the particle surface is a key factor that leads to its SNA-like
properties, it is important to determine nucleic acid surface coverage. In contrast with
conventional AuNP-SNAs, where particle concentration can be easily determined by measuring
the plasmon resonance peak associated with AuNPs, it is difficult to directly determine the
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micelle particle concentration using spectrophotometric methods. Alternatively, we used
nanoparticle tracking analysis (NTA)217-218 to determine the particle concentrations for micelleSNAs (see details in Appendix, Figure A4.8 and Table A4.1). Importantly, the DNA loading for
the brush block copolymer based micelle-SNAs (302 strands/particle; 22.2 pmol/cm2) was
significantly higher than the linear block copolymer based micelle-SNA (190 strands/particle;
15.6 pmol/cm2), which is comparable to AuNP-based SNAs of similar sizes (300 strands/particle
for 30 nm AuNP cores; corresponding to a DNA density of 17.6 pmol/cm2).53 Another important
feature of SNA structures is their cooperative hybridization properties, arising from the
association of multiple DNA strands between each particle. This results in a sharp melting
transition during the thermal denaturation of hybridized complementary particles.29, 51 Generally,
higher DNA loading results in higher melting temperatures and sharper transitions under
comparable conditions. The thermal denaturation of micelle-SNAs was carried out by
hybridizing both brush and linear block copolymer based micelle-SNAs with AuNP-SNAs
containing complementary sticky ends, respectively, and then monitoring the absorbance change
at 260 nm with gradual heating (Figure 4.1c and Figure A4.9). Around the melting temperature,
extinction dramatically increased due to the hyperchromic effect of cooperative DNA
dehybridization. As shown in Figure 1c, the melting curves for both types of micelle-SNAs when
hybridized with AuNP-SNAs were sharp and elevated, with the Tm of the DBBC-based micelleSNA (39.5 ˚C) being almost 3 degrees higher than the linear DBC-based micelle-SNA (36.9 ˚C).
The higher melting temperature for the DBBC-based micelle-SNA is consistent with a structure
with a higher surface density of nucleic acids.219
With well-characterized micelle-SNAs in hand, we evaluated their biological function with in
vitro cell uptake studies. Both micelle-SNAs exhibit the ability to enter cells without the
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assistance of cationic transfection reagents, but with different efficiencies. Confocal microscopy
revealed that fluorescein-labelled micelle-SNAs (1 µM total DNA) enter HeLa cells after 16 h of
incubation. Notably, the green fluorescence from micelle-SNAs consisting of brush block
copolymers was significantly more intense than that of the linear block copolymer based micelleSNAs (Figure 4.2d,e), indicating more efficient uptake of the former as opposed to the latter.
This result was also confirmed by quantifying the fluorescence intensity of the cell population
using flow cytometry.

Figure 4.2. Cellular uptake of micelle-SNAs. (a-e) Fluorescence micrograph of HeLa cells incubated with different
forms of nucleic acids at a total DNA concentration of 1 µM for 16 h. DNA strands were labelled at the 5’-end with
fluorescein and the dye molecules are located at the outside terminus of the micelle-SNA structure. a) negative
control, cells without DNA incubation; b) single stranded fluorescein-labelled DNA (Fluo-DNA); c) positive
control, single stranded Fluo-DNA transfected with Lipofectamine® 2000; d) micelle-SNAs derived from linear
block copolymer structures; e) micelle-SNAs derived from brush block copolymer structures. In the fluorescence
images, micelle-SNAs assembled from the brush block copolymer show significantly higher uptake compared to
those derived from the linear analog or component single stranded DNA; (f) Fluorescence-activated cell sorting
(FACS) analysis of the cells when incubated with different forms of nucleic acids. FACS data also confirm the brush
block copolymer based micelle-SNA has higher cell uptake efficiency than that of the linear block copolymer based
micelle-SNA. Single stranded DNA and DNA transfected by conventional Lipofectamine® 2000 were used as
controls.
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Although incubated with equal amounts of total DNA, the mean fluorescence intensity of
cells treated with brush block copolymer based micelle-SNAs was almost twice that of linear
block copolymer based micelle-SNAs (Figure 2f), presumably due to their higher surface density
of nucleic acids. Compared to the positive control which utilized Lipofectamine® 2000 as the
transfection agent, DBBC-SNAs show slightly lower but comparable transfection efficiency
without any co-carrier. We further studied the intracellular location of DBBC-SNAs as a
function of incubation time under conditions where HeLa cells were continuously incubated with
fluorescein-labelled micelle-SNAs (1 µM total DNA). AuNP SNAs traffic through the endocytic
pathway into late endosomes and reside there without accumulating in lysosomes.210 We
hypothesized that the DBBC-SNAs follow the same route upon cellular entry due to their similar
architecture. In these experiments, the DBBC-SNAs carry a green fluorophore (fluorescein), and
the cells are stained with a complementary Alexa dye-labeled marker of interest (red). As shown
in Figure 4.3, strong colocalization of SNAs with Rab9 (a protein which preferentially localizes
in late endosomes) was observed after 6 h of incubation, and colocalization persisted 24 h postincubation. Importantly, we did not observe appreciable colocalization between the fluorescent
signals of DBBC-SNAs and markers for lysosomes (LAMP-1) over a 24 h period of time. From
these data, we conclude that SNAs primarily remain inside late endosomes and do not migrate
beyond this point to the lysosome. These observations confirm that within a typical cell doubling
time (23-24 h for HeLa cells), the micelle-SNAs likely employ the same intracellular trafficking
pathway as AuNP-based SNAs.
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Figure 4.3. Confocal microscopy of fluorescein-labelled DBBC-SNA and immunofluorescence staining of organelle
markers (red, labelled by Alexa Fluor 663). Biomarkers are Rab9 (for late endosomes) and LAMP-1 (for
lysosomes). Note that most DBBC-SNAs colocalize with late endosomes during the incubation in HeLa cells. There
is no significant colocalization of DBBC-SNAs with lysosomes, which is consistent with the behaviour of AuNPSNAs.

We further tested the intracellular gene regulation capacity of the DBBC-based micelleSNAs in specialty C166 mouse endothelial cells over-expressing enhanced Green Fluorescent
Protein (eGFP). The DNA strands on the micelle-SNAs were synthesized with an antisense
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sequence against the eGFP mRNA. After transfection and further incubation for 48 h, eGFP
knockdown was readily apparent by fluorescence microscopy (Figure 4.4a,b). Importantly, the
quantification of eGFP protein expression via western blot shows a concomitant ~ 52% reduction
in eGFP expression (Figure 4.4c), demonstrating that the micelle-SNA can effectively bind the
cytosolic mRNA target and alter the expression of its associated protein. Compared to LDBCSNAs under the same conditions, DBBC-SNAs are more effective at regulating gene expression
via the antisense mechanism (Figure 4.4d).

Figure 4.4. Gene regulation by DBBC-based micelle-SNAs. (a) Fluorescence micrograph of C166 mouse
endothelial cells that highly express the EGFP protein before DBBC-based micelle-SNA treatment. (b) Fluorescence
micrograph of C166 mouse endothelial cells after DBBC-SNA treatment. The green fluorescence was significantly
suppressed due to the EGFP gene knockdown. The micelle-SNAs were equipped with anti-EGFP sequence and the
cells were cultured for another 2 days after SNA transfection. (c) Western blotting of EGFP expression in C166 cells
after treatment with anti-EGFP DBBC-based micelle-SNAs and single stranded DNA samples under various total
DNA concentrations. (d) Western blotting of EGFP expression in C166 cells after treatment with anti-EGFP DBBCSNAs and control samples under total DNA concentrations of 2 μM. The positive control sample was antisense
DNA transfected by conventional Lipofectamine® 2000. Actin was used as an internal reference.
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When the DBBC-based micelle-SNAs are modified with a scrambled DNA sequence, EGFP
expression does not change at all concentrations tested (0.5-2 µM of total DNA), indicating the
gene knockdown effect is sequence-specific (Figure A4.10). To further validate that our new
constructs may have significant potential for biomedical applications, we tested the
biodegradation and cellular toxicity of DBBC-SNAs. During the transfection and intracellular
trafficking process, SNAs will encounter quite different chemical environments, such as varied
pH values and ionic strength in serum, endosomes, and lysosomes. This may cause the PCL core
of the micelle particles to degrade at a different rate depending on their location.

Figure 4.5. The pH-dependent degradation of DBBC-based micelle-SNAs. Samples were incubated in 50 mM
MES buffer (pH 5.5), 50 mM HEPES buffer (pH 6.0), or 1X PBS (pH 7.4). Agarose gel electrophoresis was used to
monitor the degradation process. a) Degradation of DBBC-based micelle-SNAs after 24 hour incubation under
different pH buffer conditions. Note that a significant amount of single stranded DNA can be observed in the gel
image; b) the mobility and shape of the DBBC-based SNA bands over incubation time under different buffer
conditions. In the first 24 hours, the SNA bands look relatively sharp. However, as the incubation time increases,
the bands become smeared and diffuse, indicating the gradual degradation of the entire micellar structures. Note that
the micelles held at lower pH (5.5) suffer considerably more degradation after 72 hours.
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To evaluate their biodegradability, we incubated the DBBC-SNAs in buffers of varied pH values
to mimic different intracellular environments. As shown by agarose gel electrophoresis,
component single-stranded DNA appeared after 24 h incubation, indicating the degradation of
micelle-SNAs and shedding of DNA oligonucleotides (Figure 4.5a). Meanwhile, gel bands
representing the DBBC-SNAs became smeared and diffused with increased incubation time
(Figure 4.5b). Notably, micelle-SNAs degraded faster in lower pH buffer conditions, pointing to
the possibility of their faster degradation when trafficking through intracellular vesicles with low
pH, such as the endosomes.210 The cellular toxicity of DBBC-based micelle-SNAs was analyzed
using the standard MTT assay (Figure 4.6).220

Figure 4.6. Cellular toxicity of DBBC-based micelle-SNAs analyzed by a standard MTT assay. Cells treated with
DBBC-SNAs (red), LDBC-SNAs (blue), and single stranded DNA (black) at the same total DNA concentration (2
μM). Viable cells with active metabolism convert MTT into a purple colored formazan product with an absorbance
maximum near 570 nm, and cell viability was quantified by normalization of the absorbance at 570 nm to nontreated cells. Error bars represent the standard deviation of absorbance at 570 nm from 3 independent wells of cells
in a 96-well plate.
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Even with an incubation time of up to 4 days, we found that cell viability remained essentially
unchanged. This confirms that the as-synthesized micelle-SNAs with biocompatible and
biodegradable polycaprolactone cores do not have measurable cellular toxicity under these
conditions.
Conclusions. We have developed a novel strategy to construct a DNA-brush block copolymer
based micelle-SNA with increased DNA surface density, which endows the new construct with
properties similar to existing AuNP SNAs. Compared to the micelle-SNAs constructed from
linear block copolymers, the DBBC-based micelle-SNAs exhibit a higher surface density of
nucleic acids, a more negatively charged surface, a higher melting temperature, a more
cooperative thermal denaturation profile, and more effective transfection agent-free cellular
uptake. Importantly, the micelle-SNAs derived from the DNA-brush block copolymer show
effective target gene knockdown in vitro.
It is worthwhile to note that since the polymer core can gradually degrade under
physiological conditions due to acid-catalyzed or esterase-catalyzed cleavage of the ester
backbone bonds,221 these constructs open new avenues towards the controllable, continuous
release of nucleic acids as regulatory agents for intracellular biological processes. Generally, in
addition to PCL, a wide variety of polyesters, such as PLA222 and PLGA223 can be employed to
initiate polymerization and then form DBBC-based SNAs consisting of different types of
polyester cores. As such, the rate of particle degradation and nucleic acid release may be tuned
by judicious monomer selection. We anticipate that this synthetic approach can be extended to a
wide variety of polyesters to generate a new class of nanostructured materials with highly
tailorable properties for various nucleic-acid based therapeutic approaches. In addition, this study
further demonstrates that high surface density of nucleic acids on SNAs is directly correlated
78

with their cooperative binding behavior and cellular uptake, and that the self-assembled micelle
SNAs undergo the same endocytotic intracellular trafficking pathway as classical AuNP SNAs.
These results point to a shared recognition and uptake mechanism among all SNAs regardless of
core composition.
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Chapter 5
CCR5 pre-targeted nanosystem for breast cancer imaging and therapy based
on in vivo nucleic acid hybridization of spherical nucleic acid nanoclusters
Abstract
Positron emission tomography (PET) probes for the sensitive and specific imaging of
tumor tissue, relying on nucleic acid hybridization-based pre-targeting, were synthesized and
evaluated in a mouse breast cancer model. Ultrasmall gold nanoclusters (< 3 nm) functionalized
with a dense shell of phosphorodiamidate morpholino (PMO) oligonucleotides and targeting
peptides were fabricated and their biodistribution was studied by alloying the gold core with
64

Cu. We hypothesized that the polyvalent nature of the spherical nucleic acid nanoclusters

(AuNC SNAs) would enable faster and more specific pre-targeting than linear nucleic acid
hybridization. The ability of these nanoclusters to capture and release a target oligonucleotide
was evaluated in vitro and the kinetics of the target capture were determined. Injection of rodents
with the AuNC SNAs followed by a complementary 64Cu-radiolabeled target oligonucleotide
demonstrated specific localization of the probe at the tumor site after accumulation of the
nanoclusters. The sequence-specificity of the capture process was also investigated. Studies are
ongoing to assess the relative tumor accumulation of hybridized 64Cu-oligo compared to directtargeted 64CuAuNC SNAs and their targeting efficiency.
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Introduction
Imaging probes for sensitive and specific detection of biomarkers specifically expressed
during breast cancer (BC) progression to determine the tumor burden, rate of progression, and
metastatic sites are extremely important in clinical oncology.224-226 More importantly, the
accurate determination of these biomarkers may help to design targeted therapeutic intervention
to improve the treatment outcome of patients. Of the probes developed for BC imaging, positron
emission tomography (PET) probes, especially PET radionuclide-labeled nanoparticles have
been widely used for both pre-clinical and clinical investigations due to their enhanced targeting
specificity, imaging sensitivity, and optimal target-to-background (T/B) contrast ratio.227-231
However, non-specific tumor retention of nanoprobes may interfere with accurate quantitative
measurements of the targets for precise diagnosis and specific treatment, especially for early
stage tumors and metastases.
Recently, the Liu laboratory developed an ultra-small gold nanocluster alloyed with 64Cu
(64CuAuNC) for PET imaging of BC that shows low non-specific tumor retention and significant
clearance from non-target tissues in vivo.232 This is a critical advance given the capability of
these 64CuAuNCs to afford extended blood retention, radiolabel stability, and multivalency for
improved targeting efficiency. Of the targets assessed as prognostic markers for BC, the
chemokine receptor CCR5, is of interest due to the important role of CCL5/CCR5 axis in
promoting tumor progression and metastases and the overexpression of CCR5 in tumors
compared to normal breast tissue.233-241 For accurate detection of biomarkers expressed in
tumors, the pre-targeting strategy is a promising method to improve detection efficiency and T/B
contrast ratio compared to the direct targeting strategy. Pre-targeting involves the delivery of two
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components: a non-radioactive tumor-seeking antibody, peptide, or particle, and subsequent late
binding radiolabeled molecules that specifically interact with the pre-targeting moiety associated
with the tumor.242-244 Of the pre-targeted systems, the nucleic acid hybridization strategy is
attractive due to the fast hybridization kinetics, duplex stability, programmability, and
reversibility.245 Gold was chosen as the core material for the initial development of this system
due to the ease of rapidly prototyping different nanocluster designs using commercially-available
thiolated oligonucleotides, polymers, and heterobifunctional linkers.
Numerous pre-targeting systems for in vivo PET imaging have been described based on
both irreversible bioorthogonal “click” reactions as well as hybridization of nucleic acids.
Irreversible pre-targeting reactions demonstrated to work in vivo include strained cyclooctyneazide cycloaddition and inverse electron-demand Diels-Alder cycloaddition.246-247 Nucleic acid
hybridization strategies have been investigated employing linear DNA, locked nucleic acid
(LNA), peptide nucleic acid (PNA), PMOs, and PMO dendrimers.248-252 We hypothesized the
efficiency and specificity of the pre-targeting approach could be increased by introducing the
pre-targeted oligonucleotides in the form of polyvalent spherical nucleic acid (SNA)
nanoclusters. SNAs hybridize with target oligonucleotides much more rapidly than their linear
counterparts and form more thermodynamically stable duplexes.253-254 In addition, presentation
of a tumor-targeting ligand on the SNA surface allows for multivalent interaction with the
disease-related receptor.255
Herein, we report a CCR5 pre-targeted nanosystem using nonradioactive spherical
nucleic acid nanoclusters (AuNC SNAs) with multiple copies of PEG-DAPTA and
phosphorodiamidate morpholino (PMO) oligonucleotides conjugated to the surface (DAPTAPMO SNAs). PMO oligonucleotides were found to be far superior to conventional DNA
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oligonucleotides for surface functionalization of the SNAs due to their enhanced blood
circulation time. After the clearance of non-specifically retained AuNC SNAs, the SNAs bound
on the surface of tumor cells can be illuminated following the administration of a complementary
oligo radiolabeled with 64Cu through in vivo nucleic acid hybridization. We investigate the in
vitro capture and release kinetics of this nanosystem and demonstrate the feasibility of this
approach under physiological conditions. Further, we report the imaging of tumor tissue in a
mouse breast cancer model with this pre-targeted nanosystem. While the focus of this research is
on BC, this strategy potentially has wide applicability across a variety of diseases and will enable
not only imaging, but tumor treatment with either cytotoxic drugs or therapeutic radionuclides.
We further demonstrate the sequence-specificity of in vivo nucleic acid hybridization.

Experimental Procuedures
Materials and methods. DBCO-Cy5 was purchased from AAT Bioquest (Sunnyvale, CA). All
reagents for oligonucleotide synthesis were purchased from Glen Research (Sterling, VA) or
ChemGenes (Wilmington, MA) and used according to manufacturer instructions. Custom
phosphorodiamidate morpholino oligonucleotides were synthesized by Gene Tools (Philomath,
OR). 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-NHS ester was
purchased from Macrocyclics (Plano, TX). 64CuCl2 was produced on-site at the the Mallinckrodt
Institute of Radiology (MIR) cyclotron facility and received as a stock solution in 0.1N HCl.
Thiolated poly(ethylene glycol) derivatives were purchased from Creative PEGWorks (Chapel
Hill, NC). Thiol-PEG5K-NHS ester was purchased from Nanocs (Boston, MA). Buffer solutions
and cell culture media were purchased from Gibco (Gaithersburg, MD). D-Ala-Peptide-T-amide
was custom-synthesized by CPC Scientific (Sunnyvale, CA). All other reagents were purchased
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from Sigma-Aldrich (St. Louis, MO) and used as received. UV-Vis spectra were collected on a
Cary 60 spectrometer in quartz cuvettes with a path length of 1 cm. TEM images were collected
on a JEOL JEM-1400Plus transmission electron microscope. Dynamic light scattering (DLS) and
zeta potential measurements were collected on a Zetasizer Nano ZS (Malvern Instruments Ltd).
MALDI spectra were collected on an Applied Biosystems Voyager-DE STR MALDI-TOF
spectrometer.
Synthesis of DNA and RNA conjugates. DNA and 2´-OMe-RNA oligonucleotides were
synthesized on a MerMade MM12 automated oligonucleotide synthesizer according to standard
manufacturer protocols. OMe-RNA oligonucleotides were modified at the 5´ terminus with
commercial monomethoxytrityl (MMT)-protected alkylamino, cyanine dye (Cy5), and PEG
modifiers from Glen Research following manufacturer instructions. The OMe-RNA
oligonucleotides were purified by reverse-phase HPLC on C18-coated silica with
triethylammonium acetate buffer (0.03M, pH 7.0) and acetonitrile as the mobile phase ramping
from 0-75% acetonitrile over 45 minutes. Fractions were pooled, lyophilized, and deprotected by
treatment with 20% acetic acid for 1 hour at room temperature. The aqueous layer was washed
3x with ethyl acetate, lyophilized again, and the resulting dried RNA characterized by UV-Vis
and MALDI-TOF. Amino-modified OMe-RNA was reacted with an excess of DOTA-NHS ester
in a mixture of 9:1 DMSO/4-methylmorpholine for 16 hours at room temperature. The reaction
mixture was diluted with water and the crude product purified by ultrafiltration (3 kDa MWCO
Amicon Ultra-4, Millipore) spinning at 7500 x g for 30 minutes. The retained OMe-RNA was
suspended in 0.5 mL PBS buffer and purified once more by eluting through a NAP-5 desalting
column (GE Life Sciences). Fractions were collected and pooled and the resulting DOTAmodified OMe-RNA characterized by MALDI-TOF spectroscopy.
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Synthesis of Cy5-PMO-OPSS. 5´-azide and 3´-ortho-pyridyl disulfide (OPSS) modified PMO
oligonucleotide was purchased from Gene Tools. A stock solution of 1 mg DBCO-Cy5 in 1 mL
anhydrous DMSO was prepared (~825 nmole/mL), and 80 µL of DBCO-Cy5 stock solution was
mixed with 50 µL of PMO stock solution (1 mM in H2O). The mixture was shaken at 37° C
overnight and diluted to 0.5 mL with 1X PBS. The crude reaction mixture was purified by size
exclusion chromatography (NAP-5 column equilibrated in 1X PBS) to remove excess Cy5 and
fractions collected and analyzed for purity by UV-Vis and MALDI-TOF.
Radiolabeling of OMe-RNA-DOTA conjugates. In a typical experiment, 1 nanomole of OMeRNA-DOTA conjugate was mixed with 0.5-1 mCi of 64CuCl2 buffered with 0.1M NH4OAc (pH
5.5) for 45 minutes at 45° C. The mixture was purified by repeated ultrafiltration (3 kDa
MWCO) to remove unbound 64CuCl2 and a small portion of the retentate (3 µL) analyzed by
radio-iTLC on silica gel with 1:1 10% NH4OAc buffer (pH 5.5) and methanol as the mobile
phase. Radiochemical purity was assessed by integration of the TLC trace and the radiochemical
yield and specific activity determined by the relative activity in the retentate vs the filtrate postpurification.
Synthesis of Thiol-PEG5K-DAPTA. To a 1.5 mL centrifuge tube was added 0.1 mL anhydrous
DMSO, 19.3 mg of thiol-PEG5K-NHS (.004 mmol, 1 equiv.) and 10 mg of D-Ala-Peptide-Tamide (DAPTA) (0.006 mmol, 1.5 equiv.) and the mixture shaken overnight at 37° C.
Afterwards, the reaction mixture was diluted to 0.5 mL in 1X PBS and purified by gel filtration
through a NAP-5 column (GE Healthcare Life Sciences) equilibrated with 1X PBS to remove
excess DAPTA. Fractions were collected and pooled and the presence of conjugated DAPTA
was established by UV-Vis (λmax ≈ 280 nm). The starting material and product were both
analyzed by MALDI-TOF to confirm conjugation of DAPTA. The molecular weight distribution
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of the starting material showed a maximum at 4830 Da, whereas the MW distribution of the
product showed a maximum at 5776 Da, an overall shift consistent with the molecular weight of
DAPTA appended to the polymer (MW = 856.9 g/mol).
Synthesis of 64CuAuNC PMO SNAs. To a 20 mL glass vial with a magnetic stirrer was added 2
mL of Milli-Q H2O, 8.6 µL of HAuCl4 stock solution (58 mM), 20 µL of IGEPAL CA-630
solution (1% w/v in H2O), 50 µL PMO- OPSS stock solution (1 mM in H2O) and an equal
amount of PEG5K-thiol stock solution (1 mM in H2O). Finally, 1 mCi of 64CuCl buffered in
0.1M NH4OAc (pH 5.5, 10 µCi/µL) was added and the reactants equilibrated with stirring for 30
min at room temperature. For the synthesis of non-radioactive SNAs, the 64CuCl addition step
was omitted. Next, 0.4 mL of sodium borohydride solution (40 mM in H2O) was added, causing
the reaction mixture to turn a deep maroon color. The reaction mixture was stirred overnight
followed by the addition of a second portion of sodium borohydride after 16 hours to ensure
complete incorporation of 64Cu. The particles were purified by ultrafiltration (Amicon Ultra-15
30 kDa MWCO) with 3 x 4 mL washes of Milli-Q H2O spinning at 5000 x g. The retained
particles were suspended in 1 mL H2O and radiochemical purity was assessed by radio-iTLC on
silica gel with 1:1 10% NH4OAc (pH 5.5) and methanol as eluent and subsequent integration of
the region(s) of interest. (Figure A5.2) For synthesis of 64CuAuNC DNA SNAs, the same
procedure was followed as described for PMO SNAs, but instead, 3´-thiolated DNA was
employed and the reaction mixture treated with 10 × 20 µL portions of 5M NaCl over ~ 12 h.
Oligonucleotide capture studies. Non-radioactive PMO AuNC SNAs were synthesized as
described above with a 1:1 ratio of PMO/PEG5K. For each batch of SNA, the extinction
coefficient of the clusters at 520 nm was determined by UV-Vis and ICP-MS (Figure A5.3).
Estimation of cluster core size by TEM was used to calculate the average number of Au atoms
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per cluster according to the equation: atoms/cluster = (rcluster/ratom)3. The calculated gold
concentration in a sample of AuNCs was divided by the calculated number of gold atoms per
cluster to give the concentration of clusters. In a typical synthesis, the number of gold atoms per
cluster was approximately 700-800. Binding rates were determined using fluorescence
measurements collected on an ISS K2 spectrometer with an excitation wavelength of 633 nm and
an emission wavelength of 670 nm. For each binding curve, a solution of 500 pM Cy5-labeled
antisense 2´-OMe-RNA in 1 mL 1X PBS was prepared in a polymethacrylate cuvette and
allowed to warm to 37° C using the internal temperature controller. Then, the OMe-RNA
solution was mixed with AuNCs and the change in fluorescence over time was measured in 2
second increments. Bimolecular rate constants were derived by curve-fitting the acquired data
for each nanocluster concentration tested (1, 2.5, 5, 10 and 25 nM) in triplicate.
Cellular uptake and surface association studies. 4T1-Luc breast cancer cells (ATCC,
Manassas, VA) were suspended in 1.5 mL microcentrifuge tubes containing Gibco DMEM
phenol red-free media supplemented with 10% fetal bovine serum at a density of 5.0·105
cells/tube. Cells were treated in triplicate with Cy5-labeled AuNC s at a total AuNC
concentration of 4 nM per group and incubated for 24 hours. The media was removed and the
cell pellets were washed with 3 × 1 mL portions of 1X PBS, resuspended in PBS by vigorous
pipetting, then transferred to polystyrene tubes cooled in an ice bath for flow cytometry analysis.
The relative fluorescence intensity of each group of cells was measured exciting at a wavelength
of 633 nm on a BD FACSCalibur flow cytometer and the mean fluorescence intensity was
calculated in triplicate. For cellular surface association studies, the same treatment protocol was
followed, but the washed cell pellets were instead incubated with NaCN (10 mM in 1 mL PBS)
for 30 minutes to allow dissolution of surface-associated AuNCs and subsequent release of
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fluorophore labels. The fluorescence of the supernatants was measured on an ISS K2
spectrometer with an excitation wavelength of 633 nm and an emission wavelength of670 nm.
The relative fluorescence intensity was calculated in triplicate for each group of cells.
Animal biodistribution studies. All animal studies were performed in compliance with
guidelines set forth by the NIH Office of Laboratory Animal Welfare and approved by the
Washington University Animal Studies Committee. Normal female C57BL/6 mice (Charles
River Laboratory, Wilmington, MA) were used for the biodistribution studies. About 10 µCi of
Cu radiotracer in 100 μL saline (APP Pharmaceuticals, Schaumburg, IL) was injected via the
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tail vein. The mice were anesthetized with inhaled isoflurane and re-anesthetized before
euthanizing them by cervical dislocation at each time point (1 h, 4 h, and 24 h post injection, n =
3 per group). Organs of interest were collected, weighed, and counted in a well Beckman 8000
gamma counter (Beckman, Fullerton, CA). Standards were prepared and measured along with
the samples to calculate the percentage of the injected dose per gram of tissue (%ID/gram) and
the and the percentage of injected dose per organ (%ID/organ).
Micro-PET/CT imaging. The human breast cancer 4T1 cell line (ATCC, Manassas, VA) was
cultured in RPMI 1640 medium supplemented with 10% FCS, 50 units mL−1 sodium penicillin,
50 units mL−1 streptomycin sulfate, and 2 mM L-glutamine at 37 °C with 5% CO2. Female
Balb/c mice at 6 weeks age (Charles River Laboratory, Wilmington, MA) were subcutaneously
implanted with 3 × 106 4T1 cells into the right flank. The tumors were allowed to grow for 1
week to reach a size of approximately 0.5–0.8 g before the mice were used for the PET/CT
imaging studies. Mice were anesthetized with isoflurane and injected with 60-70 µCi of 64Cu
radiotracer in 100 μL of saline via the tail vein. MicroPET scans were performed on either
microPET Focus 220 (Siemens, Malvern, PA) or the Inveon PET/CT system (Siemens, Malvern,
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PA) at 1 hour (20 min frame), 4 hours (30 min frame), and 24 hours post-injection (60 min
frame). The microPET images were corrected for attenuation, scatter, normalization, and camera
dead time and co-registered with microCT images. All of the PET scanners were cross-calibrated
periodically. The microPET images were reconstructed with the maximum a posteriori (MAP)
algorithm and analyzed using Inveon Research Workplace. The tumor uptake of 64Cu radiotracer
was calculated in terms of the percent injected dose per gram (%ID g−1) of tumor tissue in threedimensional regions of interest (ROI) without the correction for partial volume effect.

Results and Discussion
Design of pre-targeting system. Our initial design for the catch-and-release pre-targeting
nanosystem relied on SNA nanoclusters functionalized on their surface with a “sense” DNA
sequence, and complementary 2´-OMe-RNA “antisense” and “comptetitor” strands to deliver the
radionuclide cargo and subsequently release it, respectively. (Table 5.1).
Oligo

Sequence (5´3´)

FW
[M-H](calc’d) (found)

Sense*
CCC AGC CTT CCA GCT CCT TGA-OPSS
7328
7329
DOTA Antisense‡
DOTA-C12-UCA AGG AGC UGG AAG
5738
5764
Cy5 Antisense‡
Cy5-UCA AGG AGC UGG AAG
5622
5607
DOTA Scr Antisense‡
DOTA-C6-GGC GAA UAU GAC GGA
5654
5661
Competitor‡
UCA AGG AGC UGG AAG GCU GGG
7165
7143
Competitor*
TCA AGG AGC TGG AAG GCT GGG
7274
7277
Sense-Cy5*
Cy5-CCC AGC CTT CCA GCT CCT TGA-OPSS
8641
8642
Sense-PEG6†
PEG6-CCC AGC CTT CCA GCT CCT TGA-PEG6-SH
7211
7201
Sense-PEG2000†
PEG2K-CCC AGC CTT CCA GCT CCT TGA-PEG6-SH
8867
8831
Sense-DAPTA†
DAPTA-C12-CCC AGC CTT CCA GCT CCT TGA-PEG6-SH
7956
8012
Table 5.1. Oligonucleotide sequences employed in this study with molecular weights determined by MALDI-TOF
in negative ionization mode. Oligos denoted with a (*) = PMO, (†) = DNA, (‡) = 2´-OMe-RNA

The sequence design was based on previously-reported studies with SNAs probing the kinetics
of complementary strand displacement from duplexes bound to the SNA surface.256 We
anticipated this approach would offer kinetics suitable for in vivo for pre-targeting experiments,
as well as synthetic modularity, allowing the attachment of targeting moieties to the 5´ terminus
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of the sense strand as well as varied cargoes to the 5´ terminus of the antisense strand. (Scheme
5.1). 2´OMe-RNA was chosen for antisense and competitor oligonucleotides due to its enhanced
nuclease resistance and the higher thermodynamic stability of DNA-RNA duplexes relative to
DNA-DNA duplexes.257 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was
selected as the chelating moiety for 64Cu due to its high association constant with Cu2+ ions,258
commercial availability of functionalized derivatives (e.g. DOTA-NHS ester), and FDA approval
for in vivo use in human clinical trials of radiopharmaceuticals.259

Scheme 5.1. Proposed pre-targeting nanosystem based on in vivo SNA hybridization.

Synthesis, characterization and biodistribution of SNAs. Radiosynthesis of 64Cu-alloyed
AuNC SNAs was carried out via a one-pot sodium borohydride reduction of HAuCl4 in the
presence of thiolated oligonucleotides adapted from previously reported methods (see
Experimental Procedures).232 In vivo biodistribution experiments revealed that 64Cu-labeled
90

DNA-SNA nanoclusters exhibited very short circulation time in mice, with less than 1% of the
injected dose remaining in the blood after one hour. Various lengths of PEG modification as well
as the hydrophobic CCR5-targeting peptide (D-Ala-peptide T-amide) were presented on the
surface of the SNA nanoclusters but none achieved blood circulation greater than 1% ID/gram
after one hour. Our findings were consistent with the previously-reported in vivo biodistribution
of 13 nm AuNP siRNA SNAs as determined by ICP-MS in non-tumor-bearing mice.79
25

%ID/gram
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2:1
PMO:PEG5K
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PMO:PEG5K
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PMO:PEG5K

DNA-PEG6

DNA-PEG2K

DNA-DAPTA

Figure 5.1. Blood circulation of AuNC SNAs 1 hour post-injection in female C57 mice. Inset: structural
comparison of PMO (left) and DNA oligos is shown (right)

None of the terminal DNA modifications tested ameliorated the rapid sequestration of the
SNAs in the liver and spleen, suggesting that the negative charge of DNA is not effectively
screened by conjugation of neutral molecules (PEG, peptides) to the 5´ DNA terminus. These
results demonstrated that a DNA SNA-based pre-targeting strategy is hampered by the
pharmacokinetics of the DNA-SNA nanoconstruct, including virtually any other in vivo
application requiring delivery to specific tissues. We saw this as an opportunity to expand the
versatility of the SNA platform for in vivo biomedical use, and our findings prompted us to alter
the chemical composition of the oligonucleotides on the surface of the SNA nanoclusters.
Switching the particle-bound nucleic acids from DNA to PMO oligonucleotides
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dramatically improved the blood circulation time, but also required the inclusion of thiol-PEG in
the reaction mixture to coadsorb on the surface of the nanoclusters, rendering them colloidally
stable. PMO-only nanoclusters irreversibly aggregated upon attempted purification. A ratio of
1:1 PEG (average Mn = 5000) to PMO oligonucleotide was found to provide the longest blood
circulation time, sufficient for in vivo pre-targeting studies (Figure 5.1 and Figure A5.1).
Blood circulation of the 1:1 PEG5K/PMO SNAs was 19.0 ± 1.9 %ID/gram at 1 hour
post-injection, compared to 0.62 ± 0.05% ID/gram for PEG6-capped DNA SNAs. The blood
circulation of the PMO SNA remained high at 4 hours (12.0 ± 0.22% ID/gram) and 24 hours (5.5
± 1.2% ID/gram). After one hour, the majority of the DNA SNA ended up in the liver (38.3 ±
1.2% ID/gram) and spleen (29.5 ± 4.1% ID/gram), compared to the PMO SNA which exhibited
much lower liver and spleen accumulation (17.0 ± 1.8 and 4.7 ± 0.3% ID/gram, respectively).

Figure 5.2. Core size, hydrodynamic diameter, and zeta potential characterization of AuNC PMO SNAs.
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The PEG/PMO-decorated AuNC SNAs were characterized by DLS, TEM, and zeta
potential measurements (Figure 5.2). The loading of PMO oligonucleotides and PEG on the
surface of the clusters was determined to be 22 ± 2 PMOs/cluster and 19 ± 1 PEG/cluster. The
gold core was dissolved with sodium cyanide, and the released ligands were isolated by sizeexclusion chromatography and quantified by UV-Vis spectroscopy. The loading is higher than
the reported values for DNA SNAs of similar size (~5 oligonucleotides per 2 nm cluster),
presumably due to the absence of electrostatic repulsion between the surface ligands.260

Figure 5.3. Biodistribution of 64Cu-OMe-RNA radiotracer (top) and PMO SNA nanocluster (bottom) in female C57
mice 1 hour post-injection. Biodistribution of nanoclusters at longer time points is shown in Figure A5.1.

The biodistribution of the antisense 64Cu-DOTA-2´-OMe-RNA strand was also studied. In a
typical experiment, the free DOTA-RNA was incubated with 64CuCl2 for 45 minutes at 45° C
and purified by ultrafiltration, with a radiochemical yield of 87-88% and radiochemical purity
>99%. On average, the measured specific activity of 64Cu-DOTA-RNA was between 0.5-1
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mCi/nmol depending on the amount of 64Cu added to the reaction mixture, consistent with
literature reports.261 The pharmacokinetics of the 64Cu-DOTA-2´-OMe-RNA were consistent
with the behavior of similar short 2´-modified oligonucleotides, exhibiting rapid excretion with
most of the tracer residing in the kidneys (21.1 ± 2.6 %ID/gram) after one hour (Figure 5.3).262
Binding kinetics measurements. With both the pre-targeting SNAs and the cargo in hand, we
then set out to determine the kinetics of the antisense strand capture in vitro at physiologically
relevant concentrations via fluorescence quenching experiments. AuNC SNA concentrations
ranging from 1 to 25 nM were examined for their ability to capture 500 pM of antisense Cy52´OMe-RNA in 1X PBS at 37° C, relying on the quenching of the dye label upon hybridization
to the nanocluster to monitor the rate of the reaction. The change in fluorescence over time was
measured and kobs for each binding curve was determined by fitting the data to the simple
association kinetics equation:
([𝐓𝐚𝐫𝐠𝐞𝐭 𝐁𝐨𝐮𝐧𝐝] = [𝐓𝐚𝐫𝐠𝐞𝐭 𝐁𝐨𝐮𝐧𝐝]𝐦𝐚𝐱 · 𝒆𝒌𝒐𝒃𝒔 · 𝐭𝐢𝐦𝐞)
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Figure 5.4. Binding kinetics measurements. Left: Representative linear fit to determine kon (slope) and koff
(intercept). Right: Binding curves of antisense Cy5-OMe-RNA to AuNCs at different AuNC concentrations.
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Both kon and koff were determined using a linear fit (kon = (kobs - koff) / [SNAs]). From our
measurements, the bimolecular rate constant for capture of the antisense strand kon by the PMO
SNA nanoclusters was 3,360,000 ± 234,000 M-1 s-1, several orders of magnitude faster than
previously described DNA-SNA systems as well as commercially-available bioorthogonal click
reaction pairs such as the tetrazine-cyclooctene Diels-Alder cycloaddition (Figure 5.4).263 The
dissociation constant Kd of the hybridized OMe-RNA was 1.70 ± 0.12 nM, indicating that
hybridization would indeed be achievable under physiological conditions.
Further, the ability of the competitor to release the hybridized antisense strand was
studied. While introduction of an excess (10 µM) of 2´-OMe-RNA competitor strand resulted in
the displacement of ~50% of the bound antisense strand from the SNA surface, addition of the
same amount of PMO competitor strand possessing an identical sequence released 100% of the
bound antisense strand, likely due to the lack of charge repulsion experienced by the incoming
competitor strands. (Figure 5.5).

Fraction Unbound
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Figure 5.5. Representative capture-and-release curves of PMO AuNC SNAs. At t=0 s, 10 nM of nanocluster is
added to a solution of 500 pM antisense Cy5-OMe-RNA. At t=300 s, various concentrations of competitor
oligonucleotide are added and the fluorescence is restored as the OMe-RNA is displaced from the nanocluster.
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Taken together, our results indicated that the pre-targeting nanosystem would be effective
under in vivo conditions due to both the favorable biodistribution of the key components (SNA
and tracer) as well as their rapid binding kinetics under dilute conditions.
Cellular uptake experiments. Internalization of the SNAs into the tumor cells poses a potential
issue as they would be rendered unavailable to bind the circulating antisense strand in vivo. DNA
SNAs are well-known for their ability to rapidly cross cell membranes without transfection
agents, thus, this phenomenon would have to be avoided in the case of PMO SNAs, since linear

Mean Fluorescence Intensity

oligonucleotides do not cross cell membranes readily.68
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Figure 5.6. Uptake of PMO and DNA AuNCs with varying surface ligand coating in 4T1 breast cancer cells.

To test whether internalization would prohibit effective in vivo hybridization, 4T1 breast cancer
cells were treated in suspension with several variants of fluorescent cyanine dye-labeled
nanoclusters to deconvolute the relative contribution of the oligonucleotides as well as the
targeting ligand DAPTA to their degree of internalization. Nanoclusters were prepared with
surfaces bearing the sense sequence DNA-Cy5, PMO-Cy5/PEG5K (1:1), or PMO-Cy5/PEG5K96

DAPTA (1:1) and incubated for 24 hours with 4T1 cells at a nanocluster concentration of 4 nM.
The cells were subsequently washed and then analyzed by flow cytometry. The DNA SNAs, as
expected, exhibited the highest degree of internalization followed by PMO SNAs (Figure 5.6). In
addition, to probe the surface association of the various nanocluster types with 4T1 cells, the
same experiment was repeated, but after 24 hours, the cells were gently washed with PBS and
the suspended cell pellet treated with 10 mM NaCN for 30 minutes to dissolve any surfaceassociated gold nanoclusters, releasing the Cy5 label into solution. The results of this experiment
indicated that the DAPTA-functionalized nanoclusters had the highest surface association with
the cells (Figure 5.7), as expected due to the role of DAPTA as an antagonist of the CCR5
receptor.264 These results suggested that the majority of PMO SNAs would not be trapped inside

Fluorescence Intensity (AU)

cellular compartments and would be available for hybridization at the tumor site.
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Figure 5.7. 4T1 cell surface association of DNA and PMO AuNCs with varying surface ligand coating after NaCN
treatment of cell pellet.
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Optimization of pre-targeting schedule. Successful PET imaging of tumor tissue by in vivo
pre-targeting is highly dependent on the wait time (pretargeting interval) between the injection of
the non-radioactive targeting capture moiety and the radioactive cargo. Our initial in vivo pretargeting experiment was designed to determine the optimal time between introduction of the
SNA and the radioactive cargo to allow hybridization of 64Cu-OMe-RNA at the tumor site. 4T1
tumors were implanted in the mammary fat pads of female BALB/c mice and SNA nanoclusters
functionalized with 1:1 PMO/PEG5K-DAPTA were injected one week post-implant. The total
dosage of SNA delivered per animal was 11.4 µg (Au basis) or roughly 72.5 pmol (SNA basis).
Then, mice were injected with 60-70 µCi of 64Cu-OMe-RNA tracer (specific activity = 577
µCi/nmol) either 4 hours, 24 hours, or 48 hours post-injection of SNA (n=3 mice in each group).
Mice were imaged by PET/CT 4 hours post-injection of the 64Cu-OMe-RNA tracer and the
tumor uptake quantitated for each injection delay timepoint. Activity of the 64Cu-OMe-RNA
tracer in the tumor increased from 0.39 ± .05% ID/gram at 4 hours to 1.85 ± 0.32% ID/gram at
24 hours and remained constant at 1.98 ± 0.45% ID/gram after 48 hours (Figure 5.7). This initial
result was promising as it suggested that tumor accumulation of the 64Cu-OMe-RNA tracer was
indeed dependent on presence of SNA at the tumor site. The rapid elimination of 64Cu-OMeRNA would preclude its nonspecific tumor accumulation in the absence of SNA pre-treatment.
Likewise, the tumor-to-muscle ratio more than doubled from approximately 2.5 in the 4
hour group to ~6.6 in the 48 hour group, demonstrating increased tumor imaging sensitivity with
an increased pre-targeting interval. Consistent with previous studies with 64CuAuNCs in a
different tumor model, we observed low non-specific tumor retention of the tracer by the
enhanced permeability and retention (EPR) effect (<3% ID/gram).232
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Figure 5.8. Left: Representative axial PET images of tumor-bearing mice at different pretargeting intervals. Right:
coronal image of mouse in 4-hour group showing tumor localization.
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Figure 5.9. Accumulation of 64Cu-OMe-RNA tracer in tumor tissue at different pretargeting intervals.

99

To expand on this preliminary study, we conducted a repeat experiment to confirm the sequencespecificity of the tumor accumulation of the tracer. Two groups of 4T1 tumor-bearing mice (n=3
each) were pre-treated with injections of SNA nanoclusters functionalized with 1:1
PMO/PEG5K-DAPTA (52.6 µg injected per animal, Au basis).
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Figure 5.10. Tumor uptake of active vs. scrambled 64Cu-OMe-RNA tracer in 4T1 tumor mice. Top: Representative
PET images of mice receiving either scrambled or active tracer. Left: Quantification via PET/CT imaging. Right:
Quantification via post-PET biodistribution. Starred bars (**) indicate statistical significance (p < 0.05).
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24 hours later, the mice were injected with 60-70 µCi of 64Cu-OMe-RNA tracer, with 3 mice
receiving the complementary antisense OMe-RNA sequence and 3 mice receiving the scrambled
sequence. Mice were imaged by PET/CT 4 hours post-injection of the 64Cu-OMe-RNA tracer
and the tumor uptake quantitated for each animal. Subsequently, the animals were sacrificed,
tumors were excised, and the activity of 64Cu-OMe-RNA in the tumors and other organs of
interest was determined by gamma counting (Figure 5.10-5.11). Finally, the tumors were
sectioned and imaged by autoradiography to visualize the relative tumor uptake of the antisense
and scrambled tracers (Figure 5.12).

**

0.6

T/M Ratio

%ID/organ

0.8

0.4
0.2
0

Complementary

Scrambled

6
5.8
5.6
5.4
5.2
5
4.8
4.6

Complementary

Scrambled

64

Figure 5.11. Post-PET biodistribution quantification of Cu-OMe-RNA tumor uptake. Left: Percent injected dose
per organ (tumor). Right: Tumor-to-muscle ratio calculated by post-PET biodistribution. Starred bars (**) indicate
statistical significance (p < 0.05).

The results of this study indicated that the complementary 64Cu-OMe-RNA tracer exhibits
increased tumor uptake relative to the scrambled tracer, confirming that the pre-targeting effect is
sequence-specific. The PET image quantification, post-PET biodistribution, and autoradiography
results suggest a 1.5 to 2-fold increase in tumor accumulation of the complementary tracer
compared to the scrambled tracer. Post-PET biodistribution indicated that the complementary
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tracer exhibited %ID/tumor nearly double than that of the scrambled tracer. The tumor-to-muscle
ratio was slightly higher for the complementary tracer, but not significant. (Figure 5.11).

Figure 5.12. Representative images of tumor sections and their activity visualized by autoradiography.

Due to the stability of the PMO/OMe-RNA duplex, we believe the tumor-to-muscle ratio
can increased by extending the imaging time post-injection of the 64Cu-OMe-RNA, permitting
further clearance of non-specifically bound oligonucleotides.
Studies are ongoing to evaluate direct-targeted PMO SNAs alloyed with 64Cu (and no
subsequent oligonucleotide tracer) co-functionalized with PEG5K or PEG5K-DAPTA in
comparison to the pre-targeting system. An additional control group consists of 64Cu-OMe-RNA
tracer with no prior SNA injection. We hypothesized that the PET signal arising from directtargeted 64CuAuNC SNAs would be less intense than that of pre-targeted SNAs hybridized with
the radiotracer OMe-RNA, since the alloying of 64Cu in the core of the nanocluster typically only
results in trace 64Cu incorporation (roughly one 64Cu atom per 105 atoms of gold, with a typical
cluster comprising fewer than 1000 atoms).232 In contrast, each PMO-functionalized SNA has
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over 20 potential binding sites for a complementary radiolabeled oligonucleotide. Therefore, the
pre-targeting strategy has the potential to deliver significantly more 64Cu atoms per nanoparticle
to the tumor site. At the time of writing. these experiments are ongoing in tumor-bearing mice
using the 4T1 BC model.
Conclusions. We have developed a novel nanocluster SNA-based pre-targeting nanosystem
aimed at sensitive and specific imaging of tumor tissue via in vivo nucleic acid hybridization in a
mouse breast cancer model. Ultrasmall nanoclusters bearing neutral PMO oligonucleotides were
synthesized and characterized, and their pharmacokinetics far outperformed analogous
nanoclusters with conventional charged DNA oligonucleotides. To our knowledge, this is the
first example of SNAs exhibiting extended blood retention time in vivo, enabling a variety of
new applications not limited to PET imaging. The in vitro kinetics of the capture process
between the pre-targeted AuNC SNAs and the complementary 2´-OMe-RNA oligonucleotide
were investigated. The rate constant for the hybridization between the SNA and the target RNA
was superior to existing covalent pretargeting reactions, with single-digit nanomolar binding
affinity between the SNA and its complementary oligonucleotide. Effective release of the cargo
was also demonstrated by introduction of a longer competitor oligonucleotide. Cell culture
studies indicated that the AuNC PMO SNAs did not exhibit significant internalization in the
targeted cancer cell line and the presence of the targeting peptide DAPTA on the nanocluster
increased cell surface association, suggesting the nanoclusters would be available to capture
complementary oligonucleotides circulating in the blood. Lastly, preliminary in vivo PET
imaging studies indicated that injection of AuNC SNAs followed by complementary 64Culabeled OMe-RNA resulted in increased PET signal in the tumor tissue as the time interval
between SNA injection and radiolabel injection was increased, and this effect was sequence103

specific, though the tumor-to-muscle ratios were not statistically different. Studies are ongoing to
confirm that the pre-targeting system results in a stronger PET signal and higher tumor-tobackground ratio relative to direct-targeted 64CuAuNC SNAs, and that DAPTA-functionalized
SNAs exhibit superior tumor localization compared to non-targeting SNAs. Future directions
will focus on further improving the kinetics of hybridization by employing an all-PMO
nanosystem (nanocluster, tracer, and competitor) as well as studying PEGylation of the tracer to
improve circulation time and subsequent tumor accumulation. In addition, the tracer cargo may
be altered to instead deliver treatment in the form of a cytotoxic drug or a therapeutic
radionuclide.
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Chapter 6
Synthesis, characterization, and biological properties of neutral
phosphorodiamidate morpholino (PMO) spherical nucleic acids
Abstract
Herein, we describe the synthesis, characterization, and biological properties of spherical
nucleic acids (SNAs) constructed from neutral phosphorodiamidate morpholino (PMO)
oligonucleotides and Au nanoparticles (AuNPs). Commercially available, monodisperse AuNPs
were chosen as the core material to ensure reproducibility and uniformity of the synthesized
nanoconstructs. The surfaces of AuNPs (10 nm diameter) were densely modified with a mixture
of thiolated PMOs and poly(ethylene glycol), resulting in colloidally stable SNAs resistant to
aggregation at high salt concentrations (up to 0.5M NaCl). The PMO SNAs, as compared with
conventional SNAs, exhibit the ability to more rapidly capture complementary RNA
oligonucleotides, a consequence of their neutral charge. PMO SNAs, when hybridized with
complementary SNAs, exhibit cooperative thermal denaturation transitions, consistent with
dense PMO loading. Finally, PMO SNAs were found to undergo cell uptake without transfection
agents in a manner analogous to their DNA counterparts, affording a novel nanosystem for PMO
delivery without the use of potentially toxic cationic polymers or cell penetrating peptides. Their
ability to engage in intracellular gene regulation is also examined.

105

Introduction
Spherical nucleic acids (SNAs) have emerged as a powerful new class of functional
nanomaterials that have shown promise in supramolecular assembly,265-267 disease biomarker
detection, 268-269 and antisense gene regulation.270 The classical SNA structure is comprised of a
gold nanoparticle core functionalized with a dense layer of deoxyribonucleic acid (DNA)
oligonucleotides.51 A wide range of core materials have been explored including transition
metals,174-175, 271 metal oxides,272-275 organic materials,276-277 metal-organic frameworks,278 and
self-assembling micellar structures.279 The high negative surface charge arising from the
phosphate backbone of the nucleic acid shell imparts colloidal stability due to electrostatic
repulsion between particles. In solution, SNAs behave much differently from linear nucleic
acids. SNAs exhibit cooperative binding and narrow thermal melting transitions when hybridized
with complementary particles or oligonucleotides. They are also able to cross cell membranes
without the need for ancillary transfection agents despite their high negative charge density.
Consequently, they are valuable tools for manipulating cellular processes through gene
regulation,280 drug delivery,281 and immunomodulation.282 For the cell types studied thus far, the
active uptake of SNAs occurs via endocytosis, triggered by their binding to class A scavenger
receptors (SR-As) expressed on the surface of mammalian cells.183, 283 Although SNAs made
from naturally-occurring oligonucleotides (DNA, RNA) have shown commercial promise as
diagnostic, therapeutic, and research tools, their biodistribution in vivo suffers from low blood
circulation due to their high surface charge, resultant protein corona accumulation, and
susceptibility to nuclease degradation.284-285 Therefore, for therapeutic purposes, SNA research
has focused heavily on topical or local uses (e.g. the skin, immunomodulation)286-287 and on the
development of new strategies for improving blood circulation and nuclease resistance.288-289
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Consequently, we decided to explore and develop a new form of SNA, based upon neutral PMO
oligonucleotides. PMOs have shown promise as intracellular gene regulation agents due to their
extremely high binding affinity for target mRNA.290 They can be synthesized using
straightforward phosphoramidite chemistry.291 The higher binding affinity of morpholino
oligonucleotides for complementary oligonucleotides, which is reflected in a higher duplex
melting temperature, is due to the lower charge repulsion between the hybridized strands.292
However, linear PMOs, like linear DNA and RNA oligonucleotides, do not readily enter cells
without the aid of cationic transfection agents,293-294 electroporation,295 or cell-penetrating
peptides296-297 and therefore alone are not suitable for regulating intracellular processes,
including gene knockdown. Gold nanoparticle-PMO conjugates have been described, with one
example requiring both a targeting protein for cellular uptake and subsequent localized
photocleavage to release PMOs into the cytosol.298 Other examples of AuNP-PMO conjugates
have been described for the purpose of detecting target oligonucleotides in colorimetric assays,
but such particles are not stable in solutions of high ionic strength and require a potentially toxic
fluorosurfactant during the synthesis procedure.299-300 Herein we describe methods for the onestep synthesis of the first PMO SNAs stable under physiological conditions, their hybridization
behavior with complementary oligonucleotides and SNAs, their unusual ability to cross cell
membranes without the need for ancillary transfection agents, and their intracellular gene
regulation behavior.

Experimental Procedures
Materials and methods. Citrate-capped gold nanoparticles were purchased from Ted Pella
(Redding, CA). PMO oligonucleotides were purchased from Gene Tools (Philomath, OR).
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Uranyl acetate solution was purchased from Electron Microscopy Sciences (Hatfield, PA). DNA
and RNA synthesis reagents were purchased from ChemGenes (Wilmington, MA) and Glen
Research (Sterling, VA). Buffer solutions and cell culture media were purchased from Gibco
(Gaithersburg, MD). Thiolated poly(ethylene glycol) derivatives were purchased from Creative
PEGWorks (Chapel Hill, NC) and Nanocs (Boston, MA). DBCO-Cy5 was purchased from AAT
Bioquest (Sunnyvale, CA). All other reagents were purchased from Sigma-Aldrich (St. Louis,
MO) and used as received. UV-Vis spectra and thermal denaturation curves were collected on an
Agilent Cary 5000 UV-Vis spectrometer in quartz cuvettes having a path length of 1 cm.
Dynamic light scattering (DLS) and zeta potential measurements were collected on a Zetasizer
Nano ZS (Malvern Instruments Ltd). TEM images were collected on a JEOL JEM-1400Plus
transmission electron microscope and samples were negative-stained with 2% uranyl acetate
solution for 30 seconds prior to imaging.
Synthesis of PMO SNAs. To a 15 mL centrifuge tube was added 20 µL 1 mM PMO-orthopyridyl disulfide (OPSS) solution, 2.0 mL Ted Pella 10 nm gold colloid (~9 nM stock solution),
20 µL IGEPAL CA-630 1% solution,100 µL 0.1M phosphate buffer (pH 7.4), and the mixture
shaken for 30 minutes at room temperature to allow adsorption of the PMO oligonucleotides by
spontaneous dissociation of the ortho-pyridyl disulfide bond to release 2-thiopyridone. Then, 20
µL of 1 mM thiolated PEG solution (Mn = 1000, 3000 or 5000 Da) was added and shaking
continued overnight at room temperature. The particles were purified by ultrafiltration using an
Amicon Ultra-15 100kDa MWCO filter with 3 x 4 mL washes of Milli-Q H2O spinning at 5000
x g. The particles were resuspended in 1.0 mL Milli-Q H2O and the concentration was calculated
by UV-Vis by measuring the absorbance at 520 nm and dividing by the known extinction
coefficient for 10 nm AuNPs (9.6·107 L·mol-1·cm-1). DNA-functionalized SNAs were
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synthesized according to established protocols employing gradual NaCl addition to increase the
loading density of oligonucleotides.53
Synthesis of Cy5-PMO-OPSS. 5´-azide and 3´-ortho-pyridyl disulfide (OPSS) modified PMO
oligonucleotide was purchased from Gene Tools. A stock solution of 1 mg DBCO-Cy5 in 1 mL
anhydrous DMSO was prepared (~825 nmole/mL), and 80 µL of DBCO-Cy5 stock solution was
mixed with 50 µL of PMO stock solution (1 mM in H2O). The mixture was shaken at 37° C
overnight and diluted to 0.5 mL with 1X PBS. The crude reaction mixture was purified by size
exclusion chromatography (NAP-5 column equilibrated in 1X PBS) and fractions collected and
analyzed for purity by UV-Vis and MALDI-TOF.
Synthesis of DNA and 2´-OMe-RNA oligonucleotides. DNA and 2´-OMe-RNA
oligonucleotides were synthesized on a MerMade MM12 automated oligonucleotide synthesizer
according to standard manufacturer protocols. OMe-RNA oligonucleotides were modified at the
5´ terminus with a commercial cyanine dye (Cy5) modifier from Glen Research following
manufacturer instructions. DNA oligonucleotides were prepared using a 3´ disulfide-bearing
linker attached to the solid support and modified at the 5´ terminus with a single hexaethylene
glycol (Spacer 18) linker from Glen Research. The oligonucleotides were purified by reversephase HPLC on C18-coated silica with triethylammonium acetate buffer (0.03M, pH 7.0) and
acetonitrile as the mobile phase ramping from 0-75% acetonitrile over 45 minutes. Fractions
were pooled, lyophilized, and deprotected by treatment with 20% acetic acid for 1 hour at room
temperature. The aqueous layer was washed 3x with ethyl acetate, lyophilized again, and the
resulting dried nucleic acids resuspended in Milli-Q H2O and the oligonucleotide concentration
quantified by UV-Vis.
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Oligonucleotide capture studies. Binding rates were determined using fluorescence
measurements collected on an ISS K2 spectrometer with an excitation wavelength of 633 nm and
an emission wavelength of670 nm. For each binding curve, a solution of 100 pM Cy5-labeled
antisense 2´OMe-RNA in 1 mL 1X PBS was prepared in a polymethacrylate cuvette and allowed
to warm to 37° C using the internal temperature controller. Then, the RNA solution was mixed
with PMO SNAs and the change in fluorescence over time was measured in 1 second
increments. Bimolecular rate constants were derived by curve-fitting the acquired data for each
SNA concentration tested (50, 100, 200, 400 and 800 pM) in triplicate. For comparison purposes,
DNA SNAs were likewise tested at concentrations of 100, 200, 400, and 800 pM.
Cellular uptake studies. All microscopy was performed using an Nikon A1Rsi laser scanning
confocal microscope exciting at 640 nm. KB human carcinoma cells were plated on glass bottom
dishes coated with polylysine (MatTek Corporation, glass no. 1.5), and allowed to grow
overnight. Attached cells were treated with 300 µL of cell culture medium containing either Cy5PMO labeled SNAs at a total concentration of 2.5 nM or single-stranded PMO oligonucleotides
at 250 nM. After 2 and 24 hr intervals, Hoechst 33258 nuclear stain (10 µM, Life Technologies)
was added and further incubated for 15 min, washed, and then imaged by confocal fluorescence
microscopy (exciting at 405 and 640 nm). Images were collected in both normal and Z-stack
mode to verify that particles were present in the cytosol rather than the exterior of the cell
membrane. Images were analyzed using Nikon NIS-Elements software. For flow cytometry,
SKOV3 ovarian cancer cells (ATCC) were plated in a 24-well plate at 20,000 cells per well in
DMEM media (Gibco) containing 10% fetal bovine serum (Hyclone) and 1% penicillinsteptomycin (ThermoFisher). Twelve-hours later, cells were treated in triplicate with either Cy5labeled SNAs at a total SNA concentration of 2.5 nM or Cy5-labeled single-stranded PMO
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oligonucleotide at a concentration of 250 nM and incubated for 24 hours. The media was then
removed, the cells were washed with 3 × 1 mL portions of 1X PBS, trypsinized to remove from
the plate, and pelleted by centrifugation at 350 x g for 5 minutes. The cells were then fixed in
4% paraformaldehyde for 30 minutes at 4 degrees Celsius, washed with 1X PBS, then transferred
to polypropylene tubes for flow cytometry analysis. The relative fluorescence intensity of each
group of cells was measured exciting at a wavelength of 633 nm on a BD LSR II flow cytometer
and the mean fluorescence intensity was calculated in triplicate.
Gene knockdown studies. SKOV3 ovarian cancer cells (ATCC) were plated in a 24-well
plate at 100,000 cells per well in DMEM media (Gibco) containing 10% fetal bovine serum
(Hyclone) and 1% penicillin-steptomycin (ThermoFisher). Twelve-hours later, cells were
washed and treated in triplicate with SNAs (SNA1, SNA2, or non-targeting SNA) at a total SNA
concentration of 2.5 nM in Optimem. A positive control of an antisense DNA targeting
HER2 was used by treating cells with 250 nM DNA in lipofectamine 2000. Twenty-four hours
later, Optimem was removed and fresh growth media (DMEM, 10% FBS, 1% PenStrep) was
added for another 48 hours. The total treatment time was 72 hours from the initial
transfection. The media was then removed, the cells were washed with 3 × 1 mL portions of ice
cold 1X PBS, then the cells were lysed with 100 uL of RIPA lysing buffer. Lysates were
collected and total protein concentration was measured with the BCA Protein Assay Kit. Equal
amounts of protein (10 ug) were fractionated by a 4-20% precast SDS-polyacrylamide gel (Bio
Rad) and transferred to a nitrocellulose membrane (Thermo Fisher). The membranes were then
immediately blocked with 1%BSA in PBST for 1 hour at room temperature. Primary rabbit
antibodies against HER2 and GAPDH (1000:1, Cell Signaling) and flourescently tagged antirabbit IgG secondary antibodies (20000:1, LI-CORE) were used to detect proteins. The
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membranes were imaged using a 800 nm laser on the Odyssey Infrared Imaging System (LICore) and quantified using ImageJ.

Results and Discussion
DNA SNAs remain colloidally stable without the need for co-adsorption of poly(ethylene
glycol) (PEG) or other stabilizing polymers on the gold surface. The charge density of the DNA
alone is sufficient to render the DNA SNAs colloidally stable due to their strong interparticle
repulsion in solution.53 In contrast, we found that SNAs synthesized with a surface layer
consisting of 100% PMO oligonucleotides led to irreversible aggregation upon purification,
irrespective of the oligonucleotide sequence or length. Thus, we experimented with coadsorption of thiolated PEGs along with ortho-pyridyl disulfide (OPSS)-modified PMOs. We
discovered that PEG-thiol (Mn = 5000), mixed 1:1 with 21-mer PMO oligonucleotides in the
presence of citrate-capped gold nanoparticles, afforded colloidally-stable PEG/PMO SNAs
capable of hybridizing with complementary oligonucleotides and SNAs. (Table 6.1)
Oligo

Sequence (5´3´)

Sense (PMO)
Sense (DNA)
Sense-Cy5 (PMO, DNA)
Antisense (2´-OMe-RNA)
MeltA (PMO, DNA)
MeltB (PMO, DNA)
HER2-Target1 (PMO)
HER2-Target2 (PMO)
NonTarget (PMO)
HER2-Target (DNA)

CCC AGC CTT CCA GCT CCT TGA-OPSS
PEG6-CCC AGC CTT CCA GCT CCT TGA-PEG6-Thiol
Cy5-CCC AGC CTT CCA GCT CCT TGA-Thiol
Cy5-UCA AGG AGC UGG AAG
TTA TAA CTA TTC CTA AAAAA-Thiol
TAG GAA TAG TTA TAA AAAAA-Thiol
CAT GGT GCT CAC TGC GGC TCC GGC-OPSS
AGG GAG CCG CAG CTT CAT GTC TGT G-OPSS
CCT CTT ACC TCA GTT ACA ATT TAT A-OPSS
CTC CAT GGT GCT CAC

Table 6.1. Oligonucleotide sequences employed in this study. PEG6 = 6 ethylene glycol unit spacer

The as-synthesized PEG/PMO SNAs had a mean hydrodynamic radius of 25.0 ± 6.0 nm
(compared to 8.6 ± 2.3 nm for citrate-capped AuNPs) and a surface zeta potential of -6.9 ± 4.9
mV (compared to -22 ± 5.6 mV for citrate-capped AuNPs), consistent with their neutral overall
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charge. To test their colloidal stability, the PEG/PMO SNAs were stored at increasing salt
concentrations (up to 0.5M NaCl) and examined for signs of aggregation by dynamic light
scattering (DLS). After three months, no aggregation or sedimentation was observed (Figure 6.1,
A6.1). The observed hydrodynamic radii of the SNAs was consistent with TEM images
produced by negative staining with 2% uranyl acetate (Figure 6.2).
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Figure 6.1. Hydrodynamic radius of PMO SNAs vs NaCl concentration. No statistically significant change in d H
was observed, indicating a lack of salt-induced aggregation.

Figure 6.2. TEM image of PEG5K/PMO SNAs stained with uranyl acetate.
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PEGs of lower molecular weights (3000 and 1000 Da) were also examined for their ability to
stabilize PMO SNAs. The PEG/PMO SNAs exhibited similar stability with 3 kDa PEG-thiol
mixed in a 1:1 ratio, but a 1:1 ratio of 1 kDa PEG-thiol was insufficient to stabilize PMO SNAs
against aggregation when centrifuged at 20,000 x g for 90 minutes (Figure 6.3). This issue was
remedied by increasing the molar ratio of PEG to PMO to 2:1. Most importantly, we found that 1
kDa-PEG modified PMO SNAs were capable of spontaneous cell uptake, whereas 5 kDa-PEG
modified PMO SNAs showed no apparent uptake by confocal microscopy (vide supra).
Therefore, both the colloidal stability and cellular interaction of PMO SNAs is dependent on the
length and quantity of co-adsorbed PEG molecules.

Figure 6.3. 1:1 PEG/PMO SNAs after centrifugation and resuspension in water. PEG molecular weight from left to
right: 1000 Da, 3000 Da, 5000 Da

For the 1:1 PEG5K/PMO SNAs employed for biophysical studies, the average loading of PMO
oligonucleotides and PEG molecules was determined by co-adsorbing PEG5K-fluorescein and
21-mer morpholino oligonucleotides on 10 nm citrate-capped AuNPs. Three separate batches
were prepared by the same protocol and 0.5 mL aliquots of each were subsequently dissolved by
sodium cyanide, the gold salts removed by gel filtration, and the relative amounts of each surface
ligand determined by UV-Vis spectroscopy. The average loading of PMOs per 10 nm AuNP was
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103 ± 7 molecules, whereas the average loading of PEG5K per AuNP was 72 ± 15 molecules,
indicating a roughly equal surface absorption ratio.
Kinetics experiments to determine the rate of capture of complementary charged
olignucleotide (15-mer 2´-OMe-RNA) by uncharged PMO SNAs under physiologically relevant
conditions were carried out. Briefly, a solution of 100 pM target oligonucleotide (OMe-RNA
labeled with Cy5 at the 5´ terminus) was prepared in 1X PBS and allowed to equilibrate to 37°
C. The fluorescence intensity of the solution was monitored after an aliquot of 21-mer
PEG5K/PMO SNAs was added to the solution, resulting in quenching of the Cy5 fluorescence
by the AuNP core as the OMe-RNA molecules hybridized to the particles. The experiment was
repeated at varying concentrations of SNAs (from 50 pM to 800 pM) to determine the rate
constant kon for the capture process. (Figure 6.4). In all cases, the number of morpholino strands
was in excess relative to the concentration of the target OMe-RNA, since each AuNP bears
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Figure 6.4. Binding kinetics measurements. Left: Dependence of kobs on concentration of SNAs. Slope of line = kon,
intercept = koff. Each data point represents the average of three kinetics experiments. Right: Representative binding
curves of Cy5-antisense OMe-RNA to PMO SNAs at different SNA concentrations.
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We determined that PMO SNA captures the target with a bimolecular rate constant kon of
approximately 78,300,000 ± 1,040,000 M-1s-1, with a dissociation constant (Kd) of 52.6 ± 5.6 pM,
which is many orders of magnitude higher than state-of-the-art in vivo click reactions such as the
tetrazine-cyclooctene Diels-Alder cycloaddition and potentially one of the most rapid
bioorthogonal conjugation methods discovered to date.301 PMO SNAs also capture target
oligonucleotides far more rapidly than DNA SNAs at similar concentrations, on the order of
seconds rather than minutes.254 A DNA SNA loaded with the same oligonucleotide sequence
(113 ± 17 DNA/AuNP) captured the complementary OMe-RNA at a rate of 2,250,000 ± 230,000
M-1s-1, over 30 times slower under identical conditions (Figure A6.2). The associated Kd for the
OMe-RNA hybridized to the DNA SNA was 61.3 ± 2.3 nM.

SNA

Kd

kon (M-1 s-1)

Surface
Area

Oligo density

PEG density

AuNP PMO
SNA (10 nm)

52.6 pM

78,300,000

1257 nm2

13.6 pmol/cm2

9.5 pmol/cm2

AuNC PMO
SNA (2.5 nm)

1.7 nM

3,360,000

79 nm2

46.3 pmol/cm2

40.0 pmol/cm2

DNA SNA
(10 nm)

61.3 nM

2,250,000

1257 nm2

14.9 pmol/cm2

-

Table 6.2. Rate constants, dissociation constants, and surface coverage of SNAs discussed in Chapters 5 & 6.

Comparison of the rate constants and association constants for the SNAs discussed in this
chapter and the previous chapter reveals that the Kd value for the smaller (<3 nm) PMO-based
nanocluster falls in the middle ground between the 10 nm PMO SNA and the 10 nm DNA SNA
(Table 6.2). There is less correlation in terms of the bimolecular rate constant kon. Due to the
higher radius of curvature of the smaller nanoclusters, their surface coverage of oligonucleotides
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is significantly higher than that of the 10 nm particles.302 Other authors investigating the
hybridization kinetics of surface-bound PMOs found that lower surface coverage led to faster
hybridization rates, which implies that the steric crowding on the smaller nanoclusters inhibits
the capture of incoming antisense strands.303
It is worth noting that the calculated rate constant for the 10 nm PMO SNA system
approaches the maximum experimentally observed rates associated with diffusion-limited
reactions (109 M-1 s-1) and the capture of oligonucleotides seemingly occurs faster than the rate at
which the nanoparticle can diffuse through solution.304 Pinhiero et. al. describe a similar
oligonucleotide capture system with DNA nanoparticles.305 The authors describe nucleation as
"the rate-limiting step of hybridization at low DNA concentrations (nano- to micromolar range),
relying on efficient collisions between the interacting strands. The subsequent strand realignment
and fully complementary base-pairing are expected to proceed at a much faster rate." In our
system, the fluorescence quenching of the reporter dye occurs only after the antisense strand has
fully hybridized to the SNA. Consequently, hybridization of the antisense strand to the
nanoparticle can be simplified to a bimolecular process with an overall rate constant of kon. A
large excess of capture strands on the gold nanoparticles further simplifies the kinetics and
allows application of a pseudo-first-order kinetic model. Consistent with pseudo-first-order
behavior, the reaction was carried out at several different SNA concentrations with a constant
antisense strand concentration. The linear dependence of the rate constant as a function of the
SNA concentration confirms that a pseudo-first order kinetic model is valid.
Typical bimolecular rate constants for hybridization of unmodified DNA duplexes are on
the order of 106 M-1 s-1.306 We observed a similar kon rate for a corresponding DNA SNA. In
contrast, the hybridization of neutral oligos such as PNA with complementary DNA have been
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shown to be accelerated by as much as 500-fold compared to DNA-DNA duplexes.307-308
Therefore, our observation that a PMO SNA captures a complementary oligonucleotide with
kinetics over 1 order of magnitude higher than a DNA SNA agrees with literature reports of
hybridization rates between DNA and neutral oligonucleotides in solution. An additional factor
to consider is the polyvalent nature of the PMO SNAs. From the perspective of the incoming
antisense oligonucleotide, it encounters an extremely high local concentration of its
complementary strand when colliding with a PMO SNA, leading to enhanced kinetics due to the
increased likelihood of a successful hybridization event. The same rate enhancement effect is
often observed when nanoparticles are functionalized with multiple copies of enzymes, despite
the slower diffusion of the NP-enzyme nanoconstruct.309 Therefore, we believe the dramatic
enhancement in kinetics calculated for the PMO SNA target capture are consistent with
phenomena already observed by other authors.
Since DNA hybridization typically exhibits anti-Arrhenius behavior resulting in small or
negative activation energies,310-311 we calculated the activation energy of capture of a
complementary 2´OMe-RNA strand by a PMO SNA. The bimolecular rate constant for OMeRNA hybridization was measured at 10°C and the activation energy (Ea) for hybridization was
estimated using the Arrhenius equation. We calculated Ea to be roughly 3.7 kcal/mol, which is
below the activation energy for the diffusion of liquid water (~4.2 kcal/mol),312 indicating that
the hybridization process on the SNA is indeed diffusion-controlled (See Chapter 6 Supporting
Information).
Having compared the kinetics of PMO SNA hybridization with complementary
oligonucleotides to DNA SNAs, we then examined their hybridization behavior with
complementary SNAs. DNA SNAs and PMO SNAs were synthesized bearing 20-mer sequences
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with a complementary 15-base-pair overlap. The thermal denaturation behavior of the DNADNA SNA pairs and PMO-DNA SNA pairs were compared. Briefly, the SNAs were mixed in
the presence of salt (0.5M NaCl) and allowed to aggregate. Then, the mixture was gradually
heated and monitored by UV-Vis to determine the melting temperature (Tm) of the nanoparticle
aggregates. As a control, DNA and PMO SNAs with identical sequences were also mixed to
eliminate the possibility of non-specific aggregation. The resulting thermal denaturation curves
demonstrate that the morpholino SNA and DNA SNA pair, compared to DNA-DNA SNA pair,
exhibits a dramatically increased melting temperature (>20° C) as well as a sharper melting
transition. In contrast, the non-complementary pairs did not interact (Figure 6.5). At the same salt
concentration (0.5M NaCl), the single-stranded DNA-DNA and DNA-PMO duplexes exhibited
broad melting transitions. Interestingly, the melting temperature of the free DNA-DNA duplex
exceeded that of the DNA-PMO duplex at 0.5M NaCl, since the Tm of DNA-PMO duplexes
remains constant irrespective of salt concentration, whereas the Tm of DNA-DNA duplexes
increases nearly linearly with salt concentration. In comparison, the DNA-DNA duplex had a
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lower Tm than the DNA-PMO duplex in 1X PBS. (Figure 6.6).313
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Figure 6.5. Melting behavior of DNA and PMO SNAs bearing complementary or non-complementary sequences.
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Figure 6.6. Melting behavior of single-stranded DNA-DNA and DNA-PMO pairs at either physiological salt
concentration (1X PBS) or elevated salt concentration (0.5M NaCl)

Cellular uptake experiments by flow cytometry and confocal microscopy in ovarian
cancer cells (SKOV-3) and human cervix carcinoma (KB) cells demonstrated high uptake of
PEG1K/PMO SNAs compared to single-stranded PMOs. The SNAs for cellular uptake were
prepared with a 2:1 ratio of PEG1K to PMO oligonucleotides, and consequently their colloidal
stability was enhanced. Typically, cationic peptides or polyamines must be appended to
morpholinos to aid their passage across the cell membrane. Here, we demonstrate that their dense
loading onto a gold nanoparticle is sufficient for transfection to occur. In SKOV-3 cells, uptake
of Cy5-labeled PEG/PMO SNAs (2.5 nM) was approximately two orders of magnitude higher
than the free Cy5-labeled single-stranded morpholino (250 nM) (Figure 6.7). This same trend is
observed when comparing the cellular uptake of single-stranded DNA to DNA-SNAs. Cellular
uptake in KB cells was monitored by confocal microscopy at 2 hours and 24 hours, showing low
uptake of PMO SNAs at the 2-hour time point but significant punctate perinuclear fluorescence
at the 24-hour time point, suggesting their uptake occurs via an endocytotic pathway (Figure
6.8).314 We hypothesize that the shorter PEG is necessary to expose the nucleobases so that they
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can be recognized by cell surface receptor(s), as the outer nucleobase presentation on analogous
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Figure 6.7. Uptake of PMO SNAs in SKOV-3 ovarian cancer cells after 24 h compared to single-stranded PMO
oligonucleotides. Note that the y-axis is represented on a logarithmic scale for clarity.

Figure 6.8. Confocal microscope images of cellular uptake in KB cells. Treatments: 250 nM single-stranded Cy5PMO after a) 2 hours and b) 24 hours, or PMO SNA (2. nM) after c) 2 hours and d) 24 hours, or DNA SNA after e)
2 hours and f) 24 hours. Bright-field images are omitted for clarity.
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Figure 6.9. Comparison of uptake of PEG5K/PMO and PEG1K/PMO SNAs. a) Uptake in KB cells of
PEG5K/PMO SNA after 24 hours. b) Uptake in KB cells of PEG1K/PMO SNA after 24 hours.

Having demonstrated the ability of morpholino-SNAs to enter cells without the need for special
transfection agents or chemical modification of the oligonucleotides, we then turned our
attention to the ability of the SNA to deliver antisense morpholinos to the cytosol to knock down
disease-related mRNA. In contrast to other commonly employed antisense oligonucleotides such
as siRNA, which trigger mRNA degradation by RNAse H, morpholino oligonucleotides exert
their gene knockdown effect by tightly binding to the target mRNA and physically blocking
movement of the ribosome to prevent transcription. For this purpose, we chose two previouslyvalidated morpholino sequences targeting human epithelial growth factor 2 (HER2).315 HER2 is
upregulated in a variety of cancer cell lines and is involved in signal transduction pathways
leading to malignant cell growth.197
PMO SNAs were synthesized by modifying citrate-capped gold nanoparticles with a 2:1
ratio of 1000 Da PEG-thiol and PMO-OPSS oligonucleotides. Active HER2-targeting SNAs
(Target1-SNA, Target2-SNA) along with SNAs bearing an inactive PMO sequence (NonTarget122

SNA) were synthesized and purified (Table 6.1). As a positive control, a validated DNA
sequence for antisense HER2 knockdown was also synthesized for delivery with the commercial
transfection agent Lipofectamine®. SKOV-3 cells were treated for 24 hours with 2.5 nM of
either Target1-SNA, Target2-SNA, or NonTarget-SNA. The cells treated with Lipofectamine
and DNA were dosed according to manufacturer instructions (25 nM DNA).
Analysis of HER2 protein expression by Western blot revealed high knockdown efficiency
(>50%) for both targeted PMO SNAs (Figure 6.10), with some non-specific knockdown by the
non-targeting SNA. However, the positive control failed to produce any knockdown effect. At
the time of this writing, studies are currently underway to test other positive controls such as
cationic morpholinos or morpholinos co-delivered with Endo-Porter, a novel peptide developed
by Gene Tools that facilitates endosomal escape of PMOs and other bioactive macromolecules.

Figure 6.10. Analysis of HER2 expression in SKOV-3 cells by Western Blot. Lighter bands correspond to higher
knockdown. Numerical values represent % inhibition of gene expression.
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Conclusions. In conclusion, we have described a method for the synthesis of stable
phosphorodiamidate morpholino oligonucleotide (PMO)-functionalized gold nanoparticles that
exhibit the hallmark properties of spherical nucleic acids traditionally made from charged
oligonucleotides (DNA, RNA) as opposed to neutral oligonucleotides. Co-functionalization of
the gold surface with PEG enhances the colloidal stability of the nanoparticles and renders them
resistant to salt-induced aggregation. Crucially, the PEG does not interfere with the ability of the
PMO SNAs to capture target oligonucleotides or hybridize with complementary SNAs. We
discovered that the cellular uptake of the PMO SNAs depends on the length of the co-adsorbed
PEG, with shorter PEG lengths permitting cellular uptake. The uptake of PMO SNAs was nearly
two orders of magnitude higher than their single-stranded PMO counterparts, an effect also
observed with DNA SNAs compared to their corresponding linear DNA oligonucleotides. The
cellular internalization of PMO SNAs could be visualized by flow cytometry and confocal
microscopy in two different mammalian cell lines. Lastly, we examined the ability of the PMO
SNAs to engage in gene knockdown without the use of any ancillary transfection agents. Our
preliminary data suggests that PMO SNAs, once internalized, can interact with cytosolic mRNA
to engage in intracellular gene regulation. Studies are ongoing to validate useful positive controls
for quantitative comparison of knockdown efficiency with previously-described antisense
therapies, and further improve the knockdown effect with more careful tailoring of the PMO
SNA surface composition and the mRNA targeting sequences.

124

Chapter 7
Conclusions
This dissertation has focused on the development of nucleic acid-based nanoconstructs
for cancer therapy and imaging, specifically those fabricated with a dense shell of
oligonucleotides arranged around a spherical core (SNAs). The first part of the dissertation
(Chapters 2 and 3) emphasizes the use of metal coordination bonds as a chemically orthogonal
strategy to assemble oligonucleotides into nanoparticles, and the behavior of coordination
polymer-DNA based nanoconstructs in cell culture, specifically their cellular uptake and gene
knockdown capability. A metal-ligand pair based on FDA-approved materials was identified
comprising Fe3+ and 3,4-hydroxypyridinones (3,4-HOPOs) with excellent stability and
biocompatibility. Direct crosslinking of DNA strands via Fe3+-mediated assembly afforded
nanoparticles and/or metallogels depending on the reaction conditions. The nanoparticles
assembled in this fashion did not exhibit spontaneous cellular uptake, demonstrating the
importance of controlled oligonucleotide geometric orientation in the nanoparticle fabrication
process. However, direct cationic lipid transfection of the particles indicated they were capable
of intracellular gene regulation, indicating that the metal-ligand modification of DNA did not
affect its binding with mRNA. Thus, a new bioorthogonal assembly strategy for DNA
nanomaterials was discovered for further elaboration.
The coordination chemistry developed in Chapter 2 was further adapted to create Fe3+
infinite coordination polymer (ICP) nanoparticles which could be subsequently functionalized
with oligonucleotides. In Chapter 3, synthesis of colloidal nanoscale ICPs was achieved by
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mixing a rigid azide-modified bis-hydroxypyridinone ligand with Fe3+ under dilute aqueous
conditions, leading to the spontaneous formation of “clickable” azide-bearing nanoparticles. The
N3-ICP particles were converted into SNAs in a single step by the addition of NaCl and
cyclooctyne-functionalized DNA. The resulting DNA-ICP particles exhibited all the typical
properties of conventional AuNP-based SNAs, including cooperative thermal denaturation
curves with complementary particles, active cellular uptake, and intracellular gene knockdown.
Furthermore, the pH-sensitive nature of the Fe3+ coordination bonds employed in the particle
core afforded a novel means for biodegradation of the nanoparticles once internalized into cells.
In summary, the studies in Chapters 2 and 3 established a new bioorthogonal and biocompatible
metal-mediated assembly method for nucleic acids. We also expect this research to lead to
development of other therapeutic and diagnostic agents; for example, the Fe3+ ICPs described in
Chapter 3 could also function as magnetic resonance imaging (MRI) contrast agents.316 Due to
the propensity of the ditopic HOPO ligand to precipitate metal ions out of solution, such
molecules may also find applications in heavy metal sequestration and waste remediation.317-318
Chapter 4 also explores the fabrication of biocompatible cores for SNAs, this time relying
on self-assembly of micelle-type structures to present a dense orientation of oligonucleotides on
the particle surface. A rational design approach was also employed in this case, relying on FDAapproved polycaprolactone (PCL) as the core material due to its biocompatibility and pHdependent hydrolysis in aqueous media. Two separate versions of the micelle SNA were
synthesized to study the effect of DNA density on the particle surface: a linear block copolymer
of PCL and DNA as well as a brush-type block copolymer comprising PCL bearing multiple
DNA strands at the terminus. In agreement with the previous studies, it was found that the DNAbrush block copolymer (DBBC) had enhanced polyvalent behavior compared to the linear DNA
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block copolymer (DBC) owing to the higher DNA surface density. Specifically, the Tm of the
DBBC SNA with complementary SNAs was enhanced compared to its linear counterpart, as well
as the degree of cellular internalization and target mRNA knockdown. The studies in Chapters 3
and 4 add further evidence to the central hypothesis that the properties of SNAs are largely coreindependent and instead rely on the spherical orientation of nucleic acids on the surface as well
as the density of their packing. Visualization of the cellular uptake of coordination polymer and
micelle-cored SNAs by confocal microscopy strongly suggested that they are recognized and
endocytosed in the same manner as traditional AuNP SNAs. Although recognition by a receptor
other than SR-A cannot be ruled out, the polyvalent nature of the particles and their 3D
geometric orientation of DNA is clearly responsible for their cellular uptake.
Chapters 5 and 6 see a return to the use of gold as the core material for SNAs, as the
primary interest was in the functionality of their attached oligonucleotides and the need for rapid
prototyping and synthesis of modified particles using established gold-thiol chemistry. The work
in Chapter 5 was motivated by an idea to develop an in vivo pretargeting system for PET
imaging based on SNAs, because of their polyvalency and rapid hybridization kinetics. This
work led to the serendipitous discovery that replacement of charged nucleic acids (RNA, DNA)
on the SNA surface with neutral phosphorodiamidate morpholino oligonucleotides (PMOs)
markedly affects their biophysical properties while still retaining the key behaviors normally
associated with SNAs such as cooperative hybridization and spontaneous cell entry, as further
investigated in Chapter 6. Chapter 5 focuses on the use of ultrasmall (<3 nm) SNA gold
nanoclusters (AuNCs) as in vivo PET imaging agents via a pre-targeting strategy. Gold was
chosen since it can be alloyed with radionuclides for PET imaging and biodistribution studies, as
well as the ease of surface functionalization with a variety of commercially available thiolated
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ligands. Our initial design of the system relied on tumor-targeted sub-3 nm DNA SNA AuNCs
designed to capture and release a radiolabeled oligonucleotide in vivo, allowing for sensitive and
specific detection of tumor tissue. Specifically, our interest was in targeting the CCR5 receptor
which is over-expressed in triple-negative breast cancer. Alloying of the gold core with 64Cu
enabled tracking of the biodistribution of the SNAs by PET. Though the DNA AuNC SNAs
demonstrated acceptable capture kinetics in vitro, their pharmacokinetic behavior was hampered
by extremely short blood circulation time and high accumulation in the liver and spleen. Trialand-error led to the replacement of DNA with PMO oligonucleotides, dramatically enhancing the
blood circulation time of the 64CuAuNCs. This discovery alone could have a major impact on the
use of SNAs as therapeutic agents, as current human and animal trials rely on charged SNAs of
which only a small fraction may end up in the desired organ(s).
With PMO AuNCs in hand, we carried out kinetics experiments to determine the rate of
capture of a complementary RNA strand. Under physiological conditions, the bimolecular rate
constant for hybridization of the target RNA far exceeded our expectations, outperforming
covalent bioorthogonal click reactions employed in other pretargeting systems. We also studied
the cellular interactions of PMO AuNCs, specifically to determine whether they would be
internalized like their DNA counterparts or remain on the cell surface to facilitate hybridization
with a circulating radiotracer. We found that the PMO AuNCs were internalized to a lower
degree than DNA AuNCs, and additionally, inclusion of a CCR5-targeting ligand on the particle
surface enhanced cell suface association. Our positive in vitro data prompted us to examine the
pretargeting system in vivo with tumor-bearing mice.
We first tested the ability of PMO AuNCs to localize in tumor tissue and capture a
complementary radiolabeled RNA strand. Our initial studies focused on optimizing the
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pretargeting interval of the nanosystem, also known as the “wait time” between injection of the
non-radioactive capture component and the radioactive cargo. In tumor-bearing mice, our results
indicated that little 64Cu-RNA accumulated in the tumor tissue four hours after injection of the
PMO AuNC, with a significant increase in tumor accumulation observed after a 24 or 48 hour
delay. Using this information, we designed a study to determine the specificity of the
pretargeting effect by comparing the tumor uptake of a scrambled radiolabeled RNA to a
complementary radiolabeled RNA, demonstrating that the complementary sequence exhibits
superior tumor accumulation. In addition, we also sought to compare the pretargeting system
against a direct-targeted 64CuAuNC SNA, to evaluate whether the pretargeting strategy improves
tumor uptake of 64Cu and reduces background in off-target organs relative to delivering the
radiotracer directly in nanocluster form. In addition, their targeting efficiency against CCR5positive tissue must be compared to particles without the CCR5-targeting peptide. This study is
currently underway. Future directions for this work include improving the kinetics of
hybridization by employing an all-PMO nanosystem (nanocluster, tracer, and competitor) as well
as studying PEGylation of the tracer to improve circulation time and subsequent tumor
accumulation. The nanosystem is not limited to PET imaging either; the tracer or competitor
cargo can also deliver treatment in the form of a cytotoxic drug or a therapeutic radionuclide.
Lastly, we expect that the biocompatibility of the pre-targeting nanoclusters can be further
enhanced by switching to copper cores, which do not accumulate in the body like gold, yet can
still be alloyed with 64Cu for biodistribution and imaging studies.319
In Chapter 6, we decided to look more in depth at the chemical and biological properties
of PMO-based SNAs using the typical array of experiments used to study SNA behavior.
Commercially-available 10 nanometer gold nanoparticles were used as the core material to
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generate monodisperse and easy-to-characterize PMO SNAs as a proof of concept, though as
discussed in previous chapters, virtually any core material could be utilized for clinical
translation of these nanoconstructs. Optimization of synthetic conditions gave colloidally stable
PMO SNAs which resisted salt-induced aggregation and exhibited neutral surface charge as
evidenced by zeta potential measurements. Loading studies indicated that approximately 100
PMO oligonucleotides could be adsorbed on the surface of a 10 nanometer particle along with
PEG to impart colloidal stability. The binding kinetics of the resulting PMO SNAs were studied,
demonstrating exceptionally fast bimolecular rate constants for hybridization with
complementary oligonucleotides and picomolar binding affinity. The kinetics of the 10 nm PMO
SNAs were compared with analogous DNA SNAs as well as the AuNC-based SNAs.
Oligonucleotide charge and surface density were found to play a major role in the rate constants
for complementary strand capture, in agreement with previously published studies on DNA
hybridization kinetics with charged and neutral oligonucleotides both in solution and on surfaces.
The PMO SNAs also exhibited cooperative melting behavior and enhanced melting transition
temperatures when hybridized with complementary SNAs. These results prompted us to
investigate whether PMO SNAs interact with cells in the same way as DNA SNAs.
Optimization of synthetic conditions (namely the molar ratio and length of coadsorbed
PEG) afforded PMO SNAs capable of spontaneous cellular entry. By flow cytometry and
confocal microscopy, PMO SNAs were found to enter mammalian cells at a greater rate than
single-stranded PMOs, in an analogous fashion to DNA SNAs. Compared to DNA SNAs,
however, PMO SNAs showed lower cellular uptake. Despite this difference, we decided to test
the antisense gene regulation capability of PMO SNAs due to the differing mechanisms of gene
knockdown between DNA and PMOs. DNA binding to mRNA triggers degradation of the
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mRNA by RNAse-H, preventing ribosomal translation. In contrast, PMO binding to mRNA
prevents movement of the ribosome along the mRNA, effectively blocking transcription. Due to
the much higher affinity of PMOs for complementary mRNA, we theorized that PMO SNAs
could engage in gene regulation despite their modest uptake relative to DNA SNAs. Preliminary
results suggest the PMO SNAs are capable of knockdown and further studies are underway to
compare against a panel of validated positive controls targeting the same messenger RNA.
Hopefully, this dissertation has conveyed the importance of nucleic acids in
nanomedicine, as both chemically programmable structural components and bioactive
therapeutic agents. Specifically, the discovery of spherical nucleic acids has advanced the field
of biomedicine and enabled new clinically-relevant technologies in gene regulation and
biodetection. The work presented herein demonstrates a multi-faceted approach to further
increase the clinical viability of SNAs as therapeutic, diagnostic, and bioorthogonal conjugation
agents. Detailed studies of SNA core composition as well as oligonucleotide composition have
led to a better understanding of the basic chemical properties of SNAs, their cellular interactions,
and their in vivo pharmacokinetics. Ideally, these advances will have major implications in the
treatment and detection of diseases, especially those with poor prognoses, such as cancers of the
brain, lung and breast, as well as other afflictions associated with significant mortality such as
cardiovascular disease, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy.
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Appendix
Chapter 2 Supporting Information

Figure A2.1. MTT toxicity assay of 3,4-HOPO chelating ligands.

Figure A2.2. Change in hydrodynamic radius upon formation of Fe(DNA)3 complex.
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Figure A2.3. Crystal structures of Λ-mer-FeL3 (left) and Δ-fac-FeL3 (right)

Figure A2.4. Diffusion-limited binding kinetics of free ligand with Fe3+ compared to DNA-ligand conjugate.
Conditions: 100 µM ligand, 33 µM Fe(NO3)3·9H2O, 1X PBS, RT
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Figure A2.4. Uptake of different fractions of fluorescein labeled DNA-Fe3+ nanoparticles in C166 cells compared to
the free DNA.
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Chapter 3 Supporting Information

Figure A3.1. MTT toxicity assay of DABA-bis-HP-azide ligand.
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Figure A3.2. Left: titration of ligand 4 with iron(III). Right: determination of ε460 of ICP-N3 particles
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Figure A3.3. Left: EDX spectrum of background (copper TEM grid and aluminum holder) and ICP-N3 particle.
Right: TEM image of the same ICP-N3 particle sample. Scale bar = 100 nm.
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Figure A3.4. AFM and TEM images of ICP particles. Top left: Bare N3-ICPs. Top right: DNA-ICPs. Bottom left:
Bare N3-ICPs. Bottom right: DNA-ICPs.
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Figure A3.5. Thermal denaturation of complementary (left) and non-complementary (right) ICP/AuNP-DNA
conjugates.

ICP Particle Type
Bare
A-ICP
B-ICP
Her2-ICP
NonTarget-ICP
Cy5-ICP

ζavg (mV)
-18.9
-35.2
-33.7
-31.1
-33.4
-23.7

dH (nm)
14 ± 2
31 ± 10
32 ± 8
31 ± 13
31 ± 11
n/a*

%A260 DNA
53%
60%
61%
65%
14%

Table A3.1. Characterization of DNA-ICP conjugates. *DLS was not suitable for analysis of Cy5-containing
particles. AFM imaging revealed particles with a similar size distribution. (37 ± 11 nm, NanoScope Analysis
software)
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Figure A3.6. Top left: SKOV-3 ovarian cancer cells cells treated with fluorescent ssDNA. Top right: cells treated
with DNA-ICPs bearing the same sequence. Bottom: flow cytometry analysis comparing untreated SKOV-3 cells
with Cy5-labeled ssDNA, AuNP-SNAs, and DNA-ICPs. All treatments 100 nM total (DNA basis).
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Figure A3.7. Cell uptake (C166 mouse endothelial) of Cy5-labeled AuNP-SNAs (top left) compared to free DNA
(top middle), unreated cells (top right), and CCT-Cy5-DNA ICPs (bottom). All treatments 100 nM total (DNA
basis).

Figure A3.8. Cell uptake (HeLa cells) of Cy5-labeled AuNP-SNAs (top left) compared to free DNA (top middle),
unreated cells (top right), and CCT-Cy5-DNA ICPs (bottom). All treatments 100 nM total (DNA basis).
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Chapter 4 Supporting Information

Figure A4.1. Synthetic scheme depicting (a) brush DNA-g-PCL-b-PCL and (b) linear DNA-b-PEO-b-PCL and their
self-assembly into micelle-SNAs.
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Figure A4.2. The 1H NMR spectra of (a) poly(α-N3-ɛCL-b-ɛCL) and (b) N3-PEO-b-PCL.

Figure A4.3. FT-IR spectra of as-synthesized azide modified diblock copolymer poly(α-N3-g-ɛCL-b-ɛCL).
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Figure A4.4. GPC analysis of as-synthesized poly(α-N3-ɛCL-b-ɛCL) and poly(α-Cl-ɛCL-b-ɛCL).

Figure A4.5. Poly acrylamide gel electrophoresis (PAGE) analysis of the DNA-brush block copolymer under
denaturing condition (1×TBE buffer with 8 M urea, heated at 95 ºC for 10 min before running the gel). (a) Excess
DNA strands were used to conjugate on the poly(α-N3-ɛCL-b-ɛCL), the as-synthesized DBBC based micelle-SNAs
could not run into the gel, indicating the high stability of the micelle-SNA structure; (b) With lower ratio of
DNA/PCL (~ 3) for DNA conjugation, a series of DNA-PCL conjugate strands can be observed on the gel,
demonstrating multiple DNA strands can really grafted on a PCL chain. The majority of the DNA-polymer
conjugates still remain as micelles which migrate extremely slowly on the gel.
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Figure A4.6. Zeta Potential of linear DBC micelle-SNA (upper panel) and DBBC micelle-SNA (lower panel).

Figure A4.7. AFM images of linear DBC based micelle-SNA and DBBC micelle-SNA samples deposited on mica.
(a) AFM image of linear DBC based micelle-SNA samples; (b) AFM image of DBBC micelle-SNA samples.
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Figure A4.8. Cryo-EM image of linear DBC based micelle-SNA nanoparticles frozen in vitreous ice.

Figure A4.9. Particle concentrations of micelle-SNAs determined by Nanoparticle Tracking Analysis (NTA) using
the Nanosight Instrument. (a) Screenshot of scattering pattern for 20 nm AuNP-SNA particles tracked by NTA, the
standard sample concentration is 10 nM; (b) Screenshot of scattering pattern for DBBC micelle-SNA nanoparticles
tracked by NTA instrument, the total DNA concentration for both linear DBC based micelle-SNA and DBBC
micelle-SNA is 20 µM.
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Sample

NTA
Experiments

NTA Counts
(particle/mL)

20 nm AuNPSNA

1st run
2nd run
3rd run
1st run
2nd run
3rd run

0.64×108
0.85×108
0.82×108
8.60×108
8.12×108
7.56×108

1st run
2nd run
3rd run

5.16×108
5.09×108
5.10×108

Linear DBC
based micelleSNA w/ total
DNA of 20 μM
DBBC based
micelle-SNA w/
total DNA of 20
μM

Average
Counts
(particle/mL)

Concentration

0.77×108

10 nM

8.09×108

105 nM

5.12×108

67 nM

Table A4.1. List of nanoparticle concentrations determined by Nanoparticle Tracking Analysis using Nanosight.

Figure A4.10. Melting transition of binary (2-component) SNA mixture composed of micelle-SNAs and 15 nm
AuNP-SNAs. (a) Scheme depicting binary SNA system in which two different types of SNAs can associate together
via DNA linker strategy; (b) After addition of the DNA linker, it hybridizes with the complementary strands on
either micelle-SNAs or AuNP-SNAs. When the SNAs are mixed, the complementary sticky ends crosslink the
particles to form aggregates within minutes; (c) The first derivative of the melting curves reveals the melting
temperature for DBBC micelle-SNA /AuNP-SNA and linear DBC based micelle-SNA /AuNP-SNA to be 39.5 °C
and 36.9 °C, respectively. Similar to pure AuNP-SNA binary systems, sharp, elevated melting transitions were
observed for the aggregates composed of both DBBC micelle-SNA /AuNP-SNA and linear DBC based micelleSNA /AuNP-SNA.
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Figure A4.11. Control experiment of gene regulation by DBBC-based micelle-SNAs with scrambled sequence.
Western blotting of EGFP expression in C166 cells after treatment with DBBC micelle-SNAs and single-stranded
DNA with scrambled sequence. Actin is used as an internal reference. Both DBBC micelle-SNAs and singlestranded scrambled DNA with various total DNA concentrations were incubated with C166 cells overnight. After 72
h, the cells were collected for western blotting. The effect of gene knockdown can be observed with scrabled
sequence.
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Chapter 5 Supporting Information
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Figure A5.1. Biodistribution of 64Cu-labeled PMO/PEG5K SNA nanoclusters at 1, 4 and 24 hours.
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Figure A5.2. Representative radio-iTLC trace of purified 64CuAuNCs.
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Figure A5.3. Representative calculation of AuNC extinction coefficient ε520 by ICP-MS. Slope of linear fit = ε520.
For a sample of AuNCs of known core size (TEM average), ε520 can be used to calculate [AuNCs].
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Chapter 6 Supporting Information

Figure A6.1. Colloidal stability of DNA SNAs and morpholino/PEG5K SNAs bearing the same oligonucleotide
sequence at varying salt concentrations (left standing 3 months).
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Figure A6.2. Representative linear fit of concentration of DNA SNAs vs. observed rate constant upon hybridization
with 100 pM complementary OMe-RNA at 37° C. Each data point represents the mean of 3 experiments.
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Figure A6.3. Representative linear fit of concentration of PMO SNAs vs. observed rate constant upon hybridization
with 100 pM complementary OMe-RNA at 10° C.

T (°C)
10
37

kon (M-1 s-1)
43,900,000 ± 95,000
78,300,000 ± 1,040,000

E𝑎 =

R∗T1 ∗T2
(T1 −T2 )

𝑘

ln(𝑘1 )
2

Ea = 15.6 kJ/mol (3.7 kcal/mol)

Table A6.1. Estimation of Ea for capture of complementary OMe-RNA by PMO SNAs.
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